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ABSTRACT OF THE DISSERTATION 
 
Mycobacterium tuberculosis tRNA triggers TLR8  
to induce a pathway for Th1 cell instruction 
 
by 
 
Caroline Keegan 
Doctor of Philosophy in Microbiology, Immunology and Molecular Genetics 
University of California, Los Angeles, 2016 
Professor Robert L. Modlin, Chair 
 
Mycobacterium tuberculosis, the etiologic agent of tuberculosis, has infected one third 
of the world’s population and is one of the leading global infectious disease threats.  
Treatment is challenging, lasting upwards of six months even for drug sensitive 
infections, and the proliferation of multi and extensively drug resistant forms of 
tuberculosis underscore the urgent need for knowledge of the mechanisms driving 
pathogenesis of this disease.  The ability of the innate immune system to combat 
infection involves activation of pattern recognition receptors (PRRs) that detect 
evolutionarily conserved pathogen-associated molecular patterns, including nucleic 
acids and lipoproteins.  Activation of PRRs, including Toll-like receptors (TLRs), induces 
secretion of inflammatory and immunomodulatory cytokines that instruct adaptive 
	 iii	
immune pathways for T cell differentiation.  For intracellular pathogens like M. 
tuberculosis, a Th1 response is required, whereas a Th2 response is beneficial for the 
control of extracellular parasites, but is associated with active tuberculosis disease.  
This dissertation seeks to understand modulators of the initial immune response to 
M.	tuberculosis through characterization of innate immune pathways induced by distinct 
bacterial ligands.  The first study explores a mechanism by which Th1 or Th2 cytokines 
alter the vitamin D-dependent antimicrobial pathway in response to M. tuberculosis 
19kD lipoprotein, and illustrates the importance of the Th1 cytokine IFN-g in guiding an 
antimicrobial response.  Next, is a comparison of the immune response induced by the 
M. tuberculosis-derived ligands: 19kD lipoprotein and purified tRNA.  M. tuberculosis 
tRNA was found to induce a gene network inducing secretion of key Th1 cytokines 
including IL-12p70 and IFNg, which are necessary for host defense against TB.  
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CHAPTER 1 
 
 
 
Introduction 
Innate and adaptive immune response to  
Mycobacterium tuberculosis 
 
 
	 2	
 
Tuberculosis  
Mycobacterium tuberculosis, the etiologic agent of tuberculosis, has been a 
plague on humanity since ancient times.  The genomes of ancestral strains of 
M. tuberculosis have been identified and sequenced from Neolithic human 
remains (Hershkovitz et al., 2008), and the disease was common in the 5th century BCE 
where Hippocrates reported, “Consumption was the most considerable of the diseases 
which then prevailed, and the only one which proved fatal to many persons” 
(Hippocrates and Adams, 1938).  Currently, one third of the world’s population is 
infected, and tuberculosis remains one of the leading global infectious disease threats 
(WHO, 2015).   
The most common form of disease is pulmonary tuberculosis, an affliction of the 
lungs characterized by fever, chest pain, persistent cough, coughing up blood and 
weight loss.  Extrapulmonary tuberculosis, disease occurring outside of the lungs, may 
take several forms including Pott’s disease (infection of the spine), scrofula (infection of 
the lymph nodes), and miliary tuberculosis (extensive disseminated infection) (Frith, 
2014).  For much of history, tuberculosis was thought to be an inherited condition.  
However, in 1882, Robert Koch presented definitive proof that tuberculosis was a 
transmissible bacterial infection.  He demonstrated the presence of bacilli in infected 
tissues which he isolated and grew in culture, then used the cultured bacteria to infect 
guinea pigs and reconstitute disease.  For this discovery, he was awarded the Nobel 
Prize in 1905.  Still, there was no effective treatment for tuberculosis until the 1940’s 
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when treatment with the antibiotic streptomycin was found to be successful (Zumla et 
al., 2013), although antibiotic resistance swiftly developed.   
At this time, the treatment regimen for susceptible strains involves a six month 
course of a combination of antibiotics, isoniazid and rifampicin, which have toxic side 
effects.  Premature discontinuation of treatment has fueled the rise of resistant strains 
(Cohen et al., 2015).  The emergence of multi- and extensively-drug resistant 
tuberculosis is especially pronounced in developing regions where populations are 
crowded and lack reliable access to health care.  The primary preventative measure 
against tuberculosis has been in use since 1921: inoculation with live Bacillus 
Calmette–Guérin (BCG), an attenuated strain of Mycobacterium bovis.  However, this 
vaccine confers only modest protection.  A recent meta-analysis determined that 
infection was reduced by 27%, and progression from latent to active disease was 
reduced by 58% (Roy et al., 2014).  Clearly, there is a need for new methods of 
tuberculosis prevention and treatment, and for that a thorough understanding of the 
interaction between host and pathogen is required.  
 
Pathogenesis of tuberculosis 
Tuberculosis is transmitted by small droplets containing bacilli which are 
aerosolized when a person with active pulmonary infection coughs, sneezes or spits.   
If these particles are inhaled, bacteria are delivered deep into the lungs of the new host.  
The infectious dose is very low; less than ten bacilli are required to establish infection. 
In the lungs, M. tuberculosis first encounters resident alveolar macrophages which 
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phagocytose the invading bacteria; engulfing the pathogen and sequestering it in an 
internal compartment called a phagosome.  Neutrophils are rapidly recruited to the site 
of infection, where they may assist in killing the pathogen as well as secreting 
chemoattractants to recruit T cells and dendritic cells.  Usually, phagocytosed 
pathogens are destroyed as the phagosome fuses with lysosomes, which contain 
antimicrobial peptides reactive oxygen species, reactive nitrogen intermediates, and an 
acidic pH to degrade the contents of the phagolysosome.  The degraded products may 
then be displayed by antigen presenting cells, which thereby instructs the adaptive 
response.  However, M. tuberculosis is able to subvert this process, preventing 
lysosomal fusion and creating a comfortable environment where it may grow (Pethe et 
al., 2004; Romagnoli et al., 2012).  There are also reports that M. tuberculosis can 
escape from the phagosome and replicate within the cytosol (Rahman et al., 2014; 
Simeone et al., 2012; Srinivasan et al., 2016; van der Wel et al., 2007).  It can further 
attenuate the host immune response through secretion of virulence factors (Houben et 
al., 2012; Lee et al., 2013; Master et al., 2008; Romagnoli et al., 2012; Sun et al., 
2013). 
Despite the many strategies employed by M. tuberculosis to undermine the host 
immune response, the majority of humans infected with M. tuberculosis are able to 
control the pathogen and develop a latent infection in which the bacteria is contained 
within granulomas in the lungs and becomes dormant.  However, 5-10% of these latent 
infections will progress to active disease within the host’s lifetime.  Individuals with 
weakened immune systems are especially at risk; 25% of tuberculosis deaths are 
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associated with HIV co-infection.  Considering the staggeringly high number of latently 
infected individuals, it is important to understand the differences in immune response 
between those that maintain latent infection and those that suffer disease progression.  
 
Th1 vs. Th2 polarization during M. tuberculosis infection  
Although it is not fully clear which immune mechanisms are required for 
protective immunity against tuberculosis in humans, there is strong correlative evidence 
to suggest that induction of an appropriate adaptive T cell response contributes to host 
defense.  For control of intracellular pathogens like M. tuberculosis, a T helper 1 (Th1) 
response is required, whereas a T helper 2 (Th2) response is beneficial for the control 
of extracellular parasites, but is associated with active tuberculosis (Geffner et al., 
2009).  The Th1 response, associated with containment of M. tuberculosis infection, is 
dominated by the cytokines IFN-g, IL-12p70. and TNF-a (da Silva et al., 2015).  The 
defining cytokine of Th1-mediated immunity, IFN-g, is produced by NK and activated T 
cells, and drives many pathways for defense against M. tuberculosis.  In mice, IFN-g is 
required for induction of nitric oxide (NO) and control of tuberculosis infection.  In 
humans, IFN-g is critical for phagosome maturation and production of the antimicrobial 
peptides cathelicidin and beta defensin 2 as part of the vitamin D-dependent 
antimicrobial pathway (Fabri et al., 2011; Klug-Micu et al., 2013).  In both mouse and 
human systems, IFN-g can also help overcome the M. tuberculosis-induced arrest of 
phagosome maturation by inducing autophagy, “self-eating”, a process in which the 
infected cell induces its own destruction, killing invading pathogens in the process 
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(Alonso et al., 2007; Deretic et al., 2006; Gutierrez et al., 2004).  Defects in IFN-g 
production and signaling pathways lead to susceptibility to mycobacterial disease 
(Boisson-Dupuis et al., 2015).  
In contrast, a Th2 response is associated with disease progression (Harris et al., 
2007) and is associated with production of IL-4, IL-10 and type I IFN.  IL-10 is an anti-
inflammatory cytokine, known to suppress secretion of IL-12, a Th1 cytokine critical for 
control of M. tuberculosis infection.  IL-10 has also been demonstrated to suppress 
phagosome maturation, a key method employed by phagocytes to destroy pathogens, 
in M. tuberculosis-infected macrophages (O'Leary et al., 2011).  Studies have linked 
abundance of type I interferon with active tuberculosis (Berry et al., 2010; Teles et al., 
2013), and hypervirulent strains induce more type I interferon (Manca et al., 2005).  The 
T helper response can be skewed to Th1 or Th2 by cytokines produced as part of the 
innate response, so it is important to identify how the immune system initially 
recognizes and responds to M. tuberculosis and how this regulates T cell polarizing 
cytokine response patterns. 
 
Modulation of adaptive immunity by the IL-12 cytokine family 
The bioactive form of IL-12, IL-12p70 is one of four members of the IL-12 family 
of heterodimeric cytokines, two proinflammatory, and two inhibitory.  Each member is 
made from a combination of two independently regulated subunits which are sometimes 
shared between cytokines, and signal through dimeric receptors which are similarly 
shared.  Despite their similarities in composition, each cytokine induces distinct 
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responses.  Bioactive IL-12 is a combination of IL-12p35 and IL-12p40 and is produced 
by monocytes, macrophages, dendritic cells and B cells (Gubler et al., 1991).  It is 
known to synergize with IL-18 to induce IFN-g from natural killer cells and T cells, and is 
the canonical impetus for Th1 polarization (Micallef et al., 1996).  IL-23, a combination 
of IL-12p19 and IL-12p40, indirectly supports the formation of T helper 17 (Th17) cells 
by enhancing transcription of IL17 (Hunter, 2005).  IL-27 is composed of Epstein-Barr 
virus-induced gene 3 (EBI3) protein, and IL-27p28.  In mice, IL-27 aids Th1 polarization; 
acting in synergy with IL-2 and IL-12 to enhance IFN-g secretion by NK cells (Pflanz et 
al., 2002), and suppressing the differentiation of naïve T cells into Th17 or inducible T 
regulatory (iTreg) populations (Neufert et al., 2007).  The most recently discovered 
member of the IL-12 family is IL-35, a combination of EBI3 protein and IL-12p35.  In a 
mouse model, IL-35 suppresses proliferation of both Th1 and Th2 cells, instead 
converting naïve T cells into a regulatory population designated iTr35 cells (Collison et 
al., 2012; Collison et al., 2007).   
 
IL-12 mediated response during bacterial infection 
IL-12 plays an essential role in the immune response of M. tuberculosis by 
inducing secretion of IFN-g and promoting Th1 polarization.  Diminished IL-12p70 
signaling is associated with active tuberculosis, as illustrated by (Song et al., 2000) who 
found reduced IL-12p70 response to M. tuberculosis 30kDa protein in blood from 
patients with active tuberculosis vs PPD-reactive donors.  Deficiencies in members of 
the IFN-g and IL-12 signaling pathways, specifically mutations in their receptors 
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IL12RB1 and IFNGR1, account for the majority of known etiologies for the genetic 
disorder Mendelian susceptibility to mycobacterial disease (MSMD) (Figure 1-1), which 
renders the affected susceptible to infection from typically nonpathogenic mycobacteria 
such as the vaccine strain M. bovis BCG (Bustamante et al., 2014).  The known causes 
center around IFN-g-mediated immunity; ultimately resulting in impaired IFN-g 
production or inability to respond to IFN-g, but defects in IL-12 signaling are among the 
most common causes of MSMD.  For example, a loss of function mutation in IL-12RB1, 
a component of the IL-12 receptor, produces cells that are unable to respond to IL-12 
or IL-23; ultimately resulting in very low IFN-g production.  Other genetic causes of 
decreased IL-12 signaling are loss of function mutations in IL-12p40 or in NF-kB 
essential modulator (NEMO), a kinase which, as its name implies, is required for NF-kb 
activation (Ben-Mustapha et al., 2014; Braue et al., 2015).  IL12B knockout mice were 
susceptible to death from tuberculosis infection, and exhibited low IFN-g production.  
IL12A knockout mice survived longer than the IL12B knockouts, and produced a little 
more IFN-g, however still died early.  IL-23 was able to compensate for lack of IL-12p35 
for a short time early in the infection; however, the mice eventually succumbed to 
infection (Cooper et al., 2002; Khader et al., 2005).  
 
IL-12p70 protein regulation  
Although IL-12 induces Th1 cells that produce IFN-g, there is also evidence that 
IFN-g signaling can augment IL-12 induction, mediated through an interferon-stimulated 
response element (ISRE) in the promoter of both IL12A and IL12B.  Priming by IFN-g 
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can lead to IL-12 induction through both IRF1 which induces IL12A transcription (Kollet 
and Petro, 2006), and IRF8 which induces both IL12A and IL12B.  IRF3, which is 
activated downstream of signaling through the TLR3 and TLR4 adaptor protein TRIF, 
also binds to the p35 promoter (Goriely et al., 2006), and may explain why synergistic 
activation of Toll-like receptors induces high IL-12p70 secretion (Bekeredjian-Ding et al., 
2006).  
 
IL12B transcriptional regulation 
Regulation of the IL-12p40 subunit has been more extensively studied.  IL12B is 
transcribed only in immune cells (D'Andrea et al., 1992) following recognition of 
microbial stimuli.  TLR engagement results in freeing of the NF-kB transcription factor 
complex from an inhibitory protein, allowing the transcription factor to translocate from 
the cytosol to the nucleus, binding to IL12B promoter (Plevy et al., 1997; Sanjabi et al., 
2000; Sanjabi et al., 2005).  Nucleosome remodeling is also critical for exposing a 
transcription enhancer element in the IL12B promoter (Zhou et al., 2007).  IFN-g further 
enhances production of IL-12p40 (Murphy et al., 1995; Wang et al., 2000).  The 
IL-12p40 subunit may also be secreted as a monomer or homodimer which can 
antagonize bioactive IL-12p70 by competitively binding to the IL-12 receptor, but not 
strongly enough to trigger signaling (Ling et al., 1995).  
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IL12A transcriptional regulation 
The IL-12p35 subunit is encoded by IL12A, and, in contrast to IL12B, is 
constitutively expressed at low levels in many cell types, including ones that would not 
produce bioactive IL-12.  The IL-12p35 subunit is not secreted unless as part of the 
IL-12p70 or IL-35 heterodimer.  There are several mechanisms by which IL12A 
transcription is enhanced in immune cells.  Similar to IL12B, NF-kB activation is 
required for transcription of IL12A (Grumont et al., 2001), and is enhanced by IFN-g 
(Hayes et al., 1995) through binding of IRF1 to an ISRE in the IL12A promoter (Liu et 
al., 2003; Liu et al., 2004).  IFN-g signaling further enhances IL12A transcription by 
driving nucleosome remodeling and exposing G/C rich regions that are binding sites for 
transcription factor sp1 (SP1) (Goriely et al., 2003).  Gene expression is often used as 
an indicator for eventual protein production, but assessment of IL-12p70 production is 
not so straightforward, especially in a mixed cell population.  In addition to IL12A 
transcription in non-immune cells, the mRNA product produced by unstimulated cells 
contains additional ATG sites in the 5’ untranslated region, which interfere with 
translation.  Following perturbation by microbial stimuli, translation begins from an 
alternate start codon, allowing protein production (Babik et al., 1999). 
 
Human interferons 
Interferons are a class of small signaling molecules that trigger the production of 
a broad range of effector molecules associated with interfering with viral replication and 
triggering an immune state to combat viral infection.  Of the three interferon families, the 
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type I interferon family is the most diverse, comprising thirteen isoforms of IFN-a, and 
IFN-b which are the basis for most studies on the effects of type I interferon, as well as 
lesser known members IFN-e, IFN-k and IFN-w which are still under investigation.  All 
type I interferons signal through the interferon-a/b receptor (IFNAR), a heterodimeric 
protein composed of the subunits IFNAR1 and IFNAR2.   
Type II interferon consists solely of IFN-g, which signals through the interferon-
gamma receptor (IFNGR), a heterodimer formed by IFNGR1 and IFNGR2.  Type I and 
type II interferon signaling pathways are self-reinforcing and antagonistic to the other.  
Type III interferon contains three isoforms of IFN-l which signal through a receptor 
composed of IFN-l-R1 and IL-10RB, a subunit which is shared with the IL-10 receptor.  
While it has not yet been thoroughly studied, modulation of the immune response by 
type III interferon appears nearest in effect to type I interferon (Jordan et al., 2007).  
Type II interferon is critical for immune control of M. tuberculosis infection (Flynn et al., 
1993), but both positive and negative effects have been attributed to type I interferon. 
 
Divergent effects of type I interferon during bacterial infection 
Though essential for control of many viral infections, type I interferons are 
generally detrimental in cases of bacterial infection, including infection by mycobacteria.  
A type I interferon signature was found in the blood of patients with active tuberculosis 
(Berry et al., 2010; Maertzdorf et al., 2011; Ottenhoff et al., 2012), and type I interferons 
were shown to suppress production of immune-protective cytokines in both M. leprae 
(Teles et al., 2013) and M. tuberculosis infections (McNab et al., 2014).  In mice, 
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hypervirulent strains of M. tuberculosis induce more type I interferon, and IFNAR 
knockout mice survive infection longer (Manca et al., 2005), pointing to a role for type I 
interferon in driving disease progression.  Similarly, a virulence plasmid that stimulates 
production of type I and type III interferons is associated with increased pathogenesis of 
Borrelia burgdorferi, the causative agent of Lyme disease. (Krupna-Gaylord et al., 2014) 
 
Effect of type I interferon on the IL-12 pathway 
Studies have shown both constructive and detrimental effects of type I interferon 
on the induction of Th1 cytokines including IL-12. High levels of type I interferon were 
shown to inhibit production of IL-12p70 in both human and mouse cells.  Addition of 
IFN-a or IFN-b inhibited IL-12p70 secretion in response to SAC (fixed S. aureus Cowan 
strain, a potent inducer of IL-12) in mouse spleen cells (Cousens et al., 1997) and in 
primary human monocytes (Byrnes et al., 2001).  In a contrasting study, type I interferon 
was found to enhance IL-12p70 secretion in response to SAC (Hermann et al., 1998).  
Furthermore, IL-12p70 secretion in response to combinations of TLR ligands was 
suppressed in bone marrow-derived macrophages (BMDM) derived from IFNAR 
knockout mice. A similar result was achieved in human monocyte-derived dendritic cells 
(mDC) by blocking IFNAR with neutralizing antibodies (Gautier et al., 2005).  The 
discrepancy in results may be explained by a divergent role for type I interferon 
signaling in different cell types, or stages of immune response.  Type I interferon 
appears to exert a direct effect on IL12B transcription by inhibiting binding of 
transcription factors to an enhancer element in the IL12B promoter (Byrnes et al., 2001).  
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However, the main method for type I interferon suppression of IL-12 seems to be 
indirect, via induction of IL-10 which is a potent inhibitor of both IL12A and IL12B 
transcription.  Thus, the positive effect of type I interferon can be detected in 
experiments carried out in the presence of IL-10 neutralizing antibodies.  Type I 
interferon was also shown to suppress IL-10 in monocytes and macrophages, while 
enhancing IL-10 production in T cells, indicating different roles for type I interferon in 
early vs. late immune response (Feng et al., 2002).  
 
Modulation of IFN-g signaling by type I interferon 
Studies also show conflicting results as to whether type I interferon enhances 
(Hunter et al., 1997) or inhibits (McRae et al., 1998) secretion of IFN-g.  These 
paradoxical effects of type I interferon may be explained by the timing of target cell 
exposure to interferon (Taro et al., 2003).  IFN-a enhanced secretion of IL-12p70 in 
immature human dendritic cells, but repressed secretion from mature dendritic cells 
(Heystek et al., 2003).  Furthermore, TLR stimulation of immature human dendritic cells 
induced IFN-g production in gdT cells, an innate-like subset of T cells (Devilder et al., 
2009).  This pathway for IFN-g secretion was shown to be mediated by type I interferon, 
and was not reprised using mature dendritic cells, consistent with the idea that type I 
interferon induces different pathways during the initial and sustained immune response.   
Type I interferon has also been shown to synergize with IL-18 (Matikainen et al., 
2001) or IL-12 (Duluc et al., 2009) to stimulate IFN-g secretion and Th1 immunity in the 
context of viral infection (Matikainen et al., 1998) (Malmgaard and Paludan, 2003).  
	 14	
IFN-a/b also induces production of ISG15, an “interferon stimulated gene” recently 
discovered as a necessary component for IFN-g production during mycobacterial 
infection (Bogunovic et al., 2012).  In addition to acting in synergy with IL-12 to induce 
IFN-g secretion, ISG15 attenuates IFN-a/b production (Zhang et al., 2015).  However, 
IFN-a and IFN-b were both shown to inhibit the ability of monocytes to mount a Th1 
response to bacteria stimuli (de Paus et al., 2013).  Still, it is possible that a small 
amount of type I interferon produced during the beginning of the innate immune 
response may synergize with signals from additional microbial stimuli to initiate Th1 
polarization and cytokine production.  
 
Innate recognition of M. tuberculosis cell wall components 
The ability of the innate immune system to combat infection involves activation of 
pattern recognition receptors (PRRs) that detect evolutionarily conserved pathogen-
associated molecular patterns (PAMPs), including nucleic acids and lipoproteins 
(Figure1-2).  Activation of PRRs, including Toll-like receptors (TLRs), induces secretion 
of inflammatory and immunomodulatory cytokines that instruct adaptive immune 
pathways for T cell differentiation.  The cell wall of M. tuberculosis contains numerous 
PAMPs that can be recognized by cell surface PRR (Figure 1-3).  The mycobacterial 
plasma membrane is interspersed with a variety of lipoproteins which are surrounded by 
layers of peptidoglycan and arabinogalactan, followed by a coating of mycolic acids 
from which the bacterium derives its waxy appearance and acid fastness.  Many of 
these components are recognized by innate immune receptors, and modulate the host 
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immune response.  Trehalose dimycolate (TDM), the most abundant glycolipid on M. 
tuberculosis cell surface has been demonstrated to inhibit fusion of liposomes (Spargo 
et al., 1991) and delay phagosomal acidification (Axelrod et al., 2008).  However, 
studies also show that TDM is a potent immune activator detected by the carbohydrate-
binding C-type lectin receptors in both murine and human cells (Ishikawa et al., 2009; 
Ostrop et al., 2015).  
TLR2 can form a heterodimeric receptor in combination with TLR1 or TLR4, and 
recognizes a wide variety of lipoproteins and glycoproteins; however, whether this leads 
to an immune state beneficial or detrimental to host survival is still contested.  
Lipoproteins extracted from the cell wall of virulent M. tuberculosis H37Rv activated 
both human and mouse macrophages in a TLR2 dependent manner (Brightbill et al., 
1999).  Further studies employed the M. tuberculosis 19kD lipoprotein to activate TLR2 
in macrophages infected with the avirulent strain M. tuberculosis H37Ra, which led to 
decreased bacterial survival (Thoma-Uszynski et al., 2001).  Later, it was found that, in 
human primary monocytes cultured in vitamin D sufficient serum, TLR2 induces 
production of the antimicrobial peptides cathelicidin and beta defensin 2, which directly 
kill mycobacteria (Liu et al., 2007b).  However, despite the ability of TLR2 to activate 
production of inducible nitric oxide synthase (iNOS), which produces nitric oxide (NO), a 
critical antimicrobial response in mouse macrophages, some studies have found TLR2 
to be dispensable for in vivo control of M. tuberculosis infection in mice (Holscher et al., 
2008).  TLR2 activation was shown to suppress IFN-g mediated response to M. 
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tuberculosis in human macrophages, inhibiting antigen presentation (Gehring et al., 
2003).  
The cytoplasmic PRR, NOD2, which detects bacterial peptidoglycan (PGN), has 
also been demonstrated to contribute to anti-mycobacterial immunity.  Activation of 
NOD2 with muramyl dipeptide (MDP), the minimal immunostimulatory motif from PGN,  
induced production of cathelicidin in human alveolar macrophages, and led to increased 
control of M. tuberculosis H37Rv infection (Juarez et al., 2012).  
 
Detection of M. tuberculosis by endosomal PRR 
Following phagocytosis by a host cell, M. tuberculosis is contained within a 
phagocytic vacuole where it may encounter endosomal TLRs.  TLR3, TLR7, TLR8 and 
TLR9 all detect nucleic acids, and are sequestered in a subcellular compartment to 
avoid detection of self-RNA/DNA in the cytosol.  TLR3 detects double stranded RNA 
(dsRNA); TLR7 and TLR8 sense single stranded RNA (ssRNA), although they are 
preferentially activated by different nucleotide sequences, and TLR9 recognizes 
unmethylated CpG-DNA.  These TLRs are differentially expressed by subsets of 
immune cells.  TLR3 is predominately expressed in myeloid dendritic cells (mDC), NK 
cells and T cells; TLR7 and TLR9 are expressed by B cells and plasmacytoid dendritic 
cells (pDC); and TLR8 is primarily expressed by monocytes (Hornung et al., 2002; 
Kadowaki et al., 2001).  
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Innate recognition of bacterial DNA 
The potential for bacterial nucleic acids to trigger the innate immune response is 
beginning to be elucidated (Yamashiro et al., 2014).  Within the past 10 years, M. 
tuberculosis DNA has been established as a ligand for the endosomally located TLR9, 
which detects the unmethylated GC motifs common in bacterial DNA.  In mice, 
detection of mycobacterial DNA by TLR9 was demonstrated to synergize with TLR2 to 
control high-dose infection in vivo (Bafica et al., 2005); although a later study found that 
double (TLR2/9) and triple (TLR2/4/9) knockout mice were able to control infection 
(Holscher et al., 2008).  In human macrophages, BCG-derived DNA induced TNF-a, 
which was dependent on phagosomal acidification.  
Mycobacterial DNA also activates cytosolic DNA receptors.  In mice, DNA from 
virulent M. tuberculosis activated the AIM2 inflammasome, leading to activation of 
caspase-1 and secretion of proinflammatory IL-1b. (Saiga et al., 2012) (Yang et al., 
2013).  The AIM2 inflammasome is critical for control of other intracellular bacteria such 
as Francisella tularensis (Fernandes-Alnemri et al., 2010) and Streptococcus 
pneumoniae (Fang et al., 2011).  Recently, STING (stimulator of interferon genes) has 
been identified as a receptor for extracellular (Watson et al., 2012) and cytosolic (Collins 
et al., 2015) M. tuberculosis DNA. STING is critical for production of type I interferon 
(Wassermann et al., 2015) in response to M. tuberculosis.  
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Innate recognition of bacterial RNA  
 There are several indications that M. tuberculosis RNA also activates an innate 
immune response.  Extracellular RNA fragments isolated from M. tuberculosis broth 
culture were found to induce apoptosis in human monocytes.  Protein kinase-R (PKR), 
an interferon-inducible dsRNA detector, was shown to be critical for secretion of 
proinflammatory cytokines in BCG-infected primary human monocytes.  A detrimental 
effect of bacterial RNA was demonstrated in a murine model, where transfection of 
BCG-RNA induced secretion of IL-10 and suppressed Th1 polarization, an effect that 
was dependent on the endosomal dsRNA receptor TLR3 (Bai et al., 2014).  
Studies of other intracellular pathogens have detailed more extensive modulation 
of the immune response through recognition of bacterial RNA.  E.coli RNA activated the 
NLRP3 inflammasome in human and mouse macrophages, leading to secretion of IL-18 
and IL-1b (Sha et al., 2014).  Borrelia burgdorferi RNA activated TLR8 in human 
monocytes, inducing secretion of IFN-b, and synergizing with pathogen-bound TLR2 to 
control infection (Cervantes et al., 2011; Cervantes et al., 2013).  TLR8 was also found 
to detect RNA from Staphylococcus aureus (Bergstrom et al., 2015) and Streptococcus 
pyogenes (Eigenbrod et al., 2015) and induce secretion of IFN-b and inflammatory 
cytokines.  
 
Role of IL-18  
IL-18 is a proinflammatory cytokine that can modulate induction of both Th1 and 
Th2 immunity, though it is more commonly associated with production of Th1 cytokines 
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(Nakanishi et al., 2001).  Many cells types express IL18 mRNA, but the protein is most 
commonly secreted by monocytes, macrophages, granulocytes and keratinocytes.  
IL-18 is initially produced in a non-functional precursor form, pro-IL-18, that must 
undergo proteolytic processing to yield mature IL-18 protein.  Like the related cytokine 
IL-1b, IL-18 can be processed by the proteases caspase-1 or caspase-4, which 
themselves exist as inactive precursors until recruited during inflammasome assembly 
(Akita et al., 1997; Kajiwara et al., 2014), which is initiated in response to a variety of 
toxins, cell stress signals, and microbial ligands.  Secretion of IL-18 and IL-1b typically 
requires two signals: one to activate NF-kb, as in a microbial ligand binding a TLR, 
leading to precursor protein production, and another to signal cell damage and trigger 
inflammasome assembly.  Fresh monocytes, however, are particularly proficient 
producers of IL-18 since they already contain active caspase-1, due to inflammasome 
activation by endogenously generated ATP (Netea et al., 2009).  
When originally discovered, IL-18 was described as interferon gamma inducing 
factor (IGIF) (Okamura et al., 1995).  True to its name, IL-18 acts in synergy with a 
variety of cytokines for the purpose of inducing IFN-g secretion by NK and T cells.  It is 
considered a characteristic inducer of Th1 cell polarization, but some studies have 
found the opposite effect within a different cytokine milieu.  In mice, in the absence of 
IL-12, IL-18 can synergize with IL-2 to induce secretion of IL-13 and promote Th2 
proliferation (Hoshino et al., 1999).  Consistent with this observation, it was found that 
the presence of IL-12 or IL-4 determined whether addition of IL-18 would lead to 
promotion of Th1 or Th2 proliferation in a murine model (Smeltz et al., 2001).  
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 Evidence points to a positive role for IL-18 in the control of mycobacterial 
infection in both humans and mice.  IL-18 has been demonstrated to promote 
production of Th1 cytokines by M. leprae-infected human cells (Garcia et al., 1999), and 
IL18 knockout mice succumbed rapidly to M. tuberculosis infection (Schneider et al., 
2010).  
 
Role of TLR8 
Genome-wide association studies (GWAS) compare genetic variations between 
large groups of individuals with the intent of discovering variants connected to a trait of 
interest, such as susceptibility to a disease.  These studies have identified 
polymorphisms in TLR8 that are associated with altering progression of multiple 
diseases, including HIV, HCV, and tuberculosis (Davila et al., 2008; Oh et al., 2008; 
Wang et al., 2014).  Of particular interest is the single-nucleotide polymorphism (SNP) 
rs3764880, an AàG substitution that alters the TLR8 start codon, resulting in a 
truncation of the first three amino acids.  This polymorphism was associated with the 
progression of HIV disease.  Patients with the TLR8-G variant exhibited a more gradual 
decline in CD4+ T cell count, thus were slower to progress to AIDS (defined as having 
counts of less than 200 CD4+ T cells/µl), suggesting a protective effect for the TLR8-G 
variant (Oh et al., 2008).   
Surprisingly, a GWAS comparing pulmonary tuberculosis patients to healthy 
controls found an association between the TLR8-G variant and resistance to developing 
active infection in Indonesian and Russian populations (Davila et al., 2008).  Since then, 
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it has been correlated with a protective effect against tuberculosis in Pakistani, Turkish 
and South African populations (Bukhari et al., 2015; Dalgic et al., 2011; Salie et al., 
2015).  While studies found no association in South African or female Indonesian 
populations (Chimusa et al., 2014; Kobayashi et al., 2012), a meta-analysis found a 
correlation between TLR8-A and susceptibility to tuberculosis.  
The possibility that TLR8 may play a role the response to tuberculosis is 
particularly interesting, since the nucleic acid-sensing, endosomal TLR have been 
primarily studied in the context of viral infection.  TLR8 has long been established as a 
receptor for uridine-rich ssRNA, and a contributor to defense against viral infections, but 
how this might contribute during bacterial infection was unknown.  In recent years, TLR8 
has been demonstrated to recognize RNA during infection by the pathogens Borrelia 
burgdorferi, Streptococcus pyogenes, and Staphylococcus aureus (Bergstrom et al., 
2015; Cervantes et al., 2013; Eigenbrod et al., 2015). TLR8 is upregulated in response 
to BCG infection of THP-1 macrophages (Tang et al., 2016).  
It is possible that perturbation of TLR8 activity could influence the outcome of M. 
tuberculosis infection.  Stimulation of HIV-infected human PBMC with the TLR8 agonist, 
ssPolyU RNA, has been shown to inhibit viral replication and induce production of 
antiviral molecules (Buitendijk et al., 2014). The synthetic TLR8 agonist VTX-1463 is 
currently being investigated as a potential treatment for allergic rhinitis (Horak, 2011); 
the mechanism of action appears to be due to shifting the balance of T cell activation to 
favor development of Th1 vs. Th2 response.  Since new tuberculosis therapies involving 
drug delivery directly into the lungs of infected persons are being investigated (Man et 
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al., 2016), it may be possible to develop a treatment that modifies the immune response 
to M. tuberculosis locally in the lungs.  Further research is required to determine if 
activation of TLR8 during M. tuberculosis infection will have a positive effect on disease 
outcome.  Indeed, overproduction of Th1 cytokines such as IFN-g during infection has 
been associated with immunopathology (Couper et al., 2008), so care must be taken.  
However, it is worth investigating if locally enhancing a Th1 response in the lungs will 
have an effect on clearance of M. tuberculosis infection.  
 TLR8 is unique, in that it is particularly disposed to induce secretion of IL-12p70 
in the absence of signals from other receptors, whereas other TLRs require exogenous 
cytokine signals to induce IL-12p70 (Bekeredjian-Ding et al., 2006).  Stable extracellular 
RNA has been detected in the supernatant of cultured M. tuberculosis, with tRNA being 
the most highly represented species of RNA (Obregon-Henao et al., 2012).  Since tRNA 
contains regions of both single and double stranded RNA, we hypothesized that it may 
act as a ligand for TLR8.  Also, TLR8 has been shown to be activated by products of 
RNA degradation (Tanji et al., 2015).  TLR8 is present in the endosomal compartment 
of monocytes, macrophages and myeloid dendritic cells, the cell types most likely to 
encounter and phagocytose M. tuberculosis during initial infection.  Thus it is possible 
that signaling through TLR8 could contribute to direction of the early innate immune 
response to M. tuberculosis.  I wanted to explore the possible contribution of tRNA to 
the immune response to M. tuberculosis in contrast to the pathways induced by other 
TLR ligands. 
  
Figure 1-1: IL-12/IFN-g positive feedback loop between macrophages/dendritic 
cells and natural killer/T cells during M. tuberculosis infection.
Adapted from Chapman and Hill, 2012.
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Figure 1-2: Human TLRs and their ligands. Adapted from Liu et al., 2007. 
24
Figure 1-3: Cell wall structure of mycobacteria.  Adapted from Brown et al., 2015. 
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We investigated the mechanisms by which T-cell cytokines are able
to inﬂuence the Toll-like receptor (TLR)-induced, vitamin D-
dependent antimicrobial pathway in human monocytes. T-cell
cytokines differentially inﬂuenced TLR2/1-induced expression of
the antimicrobial peptides cathelicidin and DEFB4, being up-
regulated by IFN-γ, down-regulated by IL-4, and unaffected by
IL-17. The Th1 cytokine IFN-γ up-regulated TLR2/1 induction of
25-hydroxyvitamin D-1α-hydroxylase (i.e., CYP27B1), leading to en-
hanced bioconversion of 25-hydroxyvitamin D3 (25D3) to its active
metabolite 1,25D3. In contrast, the Th2 cytokine IL-4, by itself and in
combination with the TLR2/1 ligand, induced catabolism of 25D3 to
the inactive metabolite 24,25D3, and was dependent on expression
of vitamin D-24-hydroxylase (i.e., CYP24A1). Therefore, the ability
of T-cell cytokines to differentially control monocyte vitamin D me-
tabolism represents a mechanism by which cell-mediated immune
responses can regulate innate immune mechanisms to defend
against microbial pathogens.
innate immune response | interferon-γ | interleukin-4 |
Mycobacterium tuberculosis
The ability of Toll-like receptors (TLRs) to trigger a direct an-timicrobial activity is a key aspect of their role in innate im-
munity. In mouse monocytes, activation of the TLR2/1 hetero-
dimer by microbial lipoproteins (1–3), induces an antimicrobial
activity against Mycobacterium tuberculosis that is nitric oxide
(NO)-dependent, but in human monocytes is NO-independent
(4). Instead, a key antimicrobial mechanism for TLR-activated
human monocytes involves induction of the 25-hydroxyvitamin
D-1α-hydroxylase (i.e., CYP27B1), which enzymatically converts
the major circulating form of vitamin D, 25-hydroxyvitamin D3
(25D3) into the active form of vitamin D, 1,25D3. Parallel TLR-
mediated up-regulation of the vitamin D receptor (VDR) and
activation of this receptor by 1,25D3 leads to downstream in-
duction of the genes encoding the antimicrobial peptides cath-
elicidin and DEFB4 (5–10). Here, we tested the hypothesis that
adaptive T-cell cytokines, including key cytokines of the Th1,
Th2, and Th17 pattern, regulate the TLR2/1-induced, vitamin D-
dependent antimicrobial pathway.
Results
Effect of T-Cell Cytokines on TLR2/1 Induction of Cathelicidin and
DEFB4.To determine the role of individual cytokines on the TLR-
triggered vitamin D-dependent induction of antimicrobial pep-
tides, monocytes were treated with TLR2/1L with or without
a speciﬁc T-cell cytokine, and cathelicidin and DEFB4 mRNAs
measured at 24 h. IFN-γ by itself up-regulated cathelicidin and
DEFB4 mRNA levels by twofold (Fig. 1A; P < 0.05 and P <
0.001). Consistent with previous ﬁndings, TLR2/1L induced both
cathelicidin and DEFB4 mRNAs (8, 10). However, whereas
IFN-γ augmented TLR2/1L-triggered induction of cathelicidin
by 4.1-fold (P < 0.01), it had no effect on TLR2/1L-mediated
induction of DEFB4 (Fig. 1A). The addition of IL-17 had no
effect on induction of antimicrobial peptide gene expression in
the presence or absence of TLR2/1L (Fig. 1B).
Whereas IFN-γ augmented TLR2/1 induction of cathelicidin,
IL-4 had the opposite effect. IL-4 inhibited TLR2/1 induction of
both cathelicidin and DEFB4 mRNA by greater than 90% (Fig.
1C; P < 0.05). IL-4 also affected baseline expression of both
cathelicidin and DEFB4 in the absence of TLR2/1 induction, re-
ducing mRNA levels by 20% to 40% (Fig. 1C; P < 0.001 and P <
0.05). Together, these data indicate that IFN-γ and IL-4 differ-
entially modulate TLR2/1-induced expression of cathelicidin
and DEFB4.
Effect of T-Cell Cytokines on TLR2/1 Induction of CYP27B1 and the
VDR. To explore the mechanism by which the T-cell cytokines
IFN-γ and IL-4 differentially regulated TLR2/1-induced anti-
microbial peptide gene expression, we investigated the mRNA
levels for CYP27B1 and the VDR. TLR2/1 activation of human
monocytes is known to up-regulate both CYP27B1 and the
VDR, the activity of both being required for induction of cath-
elicidin expression (8). IFN-γ induced by 2.4-fold the expression
of CYP27B1 in human monocytes, but synergized with TLR2/1L
to induce CYP27B1 mRNA levels to 6.9-fold over media control
(P< 0.01) and 2.5-fold over cells treated with TLR2/1L alone (P<
0.05; Fig. 2A). In addition, IFN-γ increased TLR2/1L up-
regulation of VDR expression, although the effect was less pro-
nounced (2.1-fold; P < 0.05).
Surprisingly, the effect of IL-4 on CYP27B1 and VDR ex-
pression was similar to that of IFN-γ. IL-4 augmented TLR2/1-
induced CYP27B1 (sixfold; P < 0.05) and VDR (threefold; P <
0.05) mRNA expression in human monocytes (Fig. 2B). There-
fore, although IFN-γ and IL-4 differentially regulated TLR2/1L
induction of antimicrobial peptide gene expression, they had
identical effects on TLR2/1-induced expression of key vitamin D
pathway genes, CYP27B1, and the VDR.
Effect of IL-4 on Monocyte Vitamin D Response. To explore the
possible mechanisms by which IL-4 inhibited TLR2/1L-induced
antimicrobial peptide expression despite increasing CYP27B1
and VDR, the effect of IL-4 on direct VDR activation was in-
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vestigated. The simultaneous addition of IL-4 with 1,25D3 to
monocytes inhibited cathelicidin expression (Fig. 3A). Similarly,
when monocytes were pretreated for 6 h with IL-4, there was
inhibition of 1,25D3-induced cathelicidin expression (Fig. 3B). In
these experiments, the addition of exogenous 1,25D3 was limited
to 10−8 M, after which the amount of 1,25D3 affected cellular
viability. However, in both cases, increasing 1,25D3 to concen-
trations higher than 10−8 M did not overcome the IL-4 inhibition
of cathelicidin expression. This is most likely a result of the well
recognized ability of 1,25D3 to self-induce expression and activity
of the catabolic enzyme CYP24A1, leading to the rapid in-
activation of bioactive vitamin D (11).
The vitamin D host defense against mycobacteria requires the
up-regulation of cathelicidin as well as the induction of autophagy,
a critical cellular process for inducing phagosome maturation (7,
12). Given that IL-4 has been shown to inhibit starvation and IFN-
γ–induced autophagy (13), we next examined whether IL-4 could
inhibit 1,25D3-induced autophagy. Primary human monocytes
incubated with 1,25D3 showed a 3.8-fold enhancement of auto-
phagy (P < 0.01) as measured by an increase in the percentage of
LC3 punctate cells (Fig. 3 C and D). Preincubation of monocytes
with IL-4 for 6 h before the addition of 1,25D3 resulted in a marked
decrease in LC3 punctate cells, reaching levels lower than media-
treated background levels (P < 0.001). Therefore, IL-4 inhibits vi-
tamin D-induced autophagy in primary human monocytes.
Effect of T-Cell Cytokines on Monocyte Vitamin D Metabolism. The
differential ability of IFN-γ and IL-4 to affect TLR2/1-induced
cathelicidin expression, as well as the effects of IL-4 on 1,25D3-
induced host responses, suggested that these cytokines achieve at
least some of their effects by regulating monocyte vitamin D
metabolism. Therefore, we next examined the bioconversion of
25D3 to its active metabolite 1,25D3 as well as the inactive me-
tabolite 24,25D3. This was accomplished by adding 3H-25D3 to
TLR2/1L and/or T-cell cytokine treated monocytes and mea-
suring conversion to the resulting 3H-vitamin D metabolites by
HPLC. TLR2/1L-treated monocytes converted 25D3 to 1,25D3
at a slightly higher rate (9.5 fmol/h per million cells) compared
with media control cells (8.7 fmol/h per million cells), both
shown as a summary of ﬁve separate experiments (Fig. 4A; P <
0.05). Treatment of monocytes with IFN-γ alone induced a sim-
ilar conversion of 25D3 to 1,25D3 as observed in cells treated
with TLR2/1L (11.4 fmol/h per million cells; P < 0.05; Fig. 4A).
However, IFN-γ in combination with TLR2/1L strongly induced
bioconversion of 25D3 to active 1,25D3 (45.4 fmol/h per million
cells), to levels sevenfold higher than media control cells (Fig.
4A; P < 0.05). The Th2 cytokine IL-4 alone had no effect on
CYP27B1 activity (6.4 fmols/h per million cells; Fig. 4A). How-
ever, in combination with TLR2/1L, IL-4 induced bioconversion
of 25D3 to 1,25D3 (14.6 fmol/h per million cells; P < 0.05; Fig.
4A). Together, these data indicated that IFN-γ potentiation of
TLR2/1-induced antimicrobial peptides is associated with the
synergistic effects of IFN-γ plus TLR2/1 on CYP27B1 activity
leading to enhanced bioconversion of 25D3 to 1,25D3.
Given that IL-4 inhibited TLR2/1-induced antimicrobial pep-
tide expression but also enhanced CYP27B1 activity, we next
examined the effects of IFN-γ and IL-4 on vitamin D catabolism,
Fig. 1. T-cell cytokines differentially inﬂuence TLR2/1-induced expression of
the antimicrobial peptides cathelicidin and DEFB4. Primary human mono-
cytes were stimulated with TLR2/1L (10 μg/mL) with or without the T-cell
cytokines (A) IFN-γ (1 ng/mL), (B) IL-17A (10 μg/mL), or (C) IL-4 (103 U/mL) for
24 h in vitamin D sufﬁcient serum. mRNA levels of cathelicidin and DEFB4
were determined by qPCR and fold change (FC) was calculated. Data rep-
resent mean values ± SEM from three to eight independent experiments
(*P < 0.05, **P < 0.01, ***P < 0.001).
Fig. 2. IFN-γ and IL-4 up-regulate vitamin D pathway genes in TLR2/1-acti-
vatedmonocytes. Primarymonocyteswere stimulatedwithTLR2/1L (10 μg/mL)
with orwithout the T-cell cytokines (A) IFN-γ (1 ng/mL) or (B) IL-4 (103U/mL) for
24 h. mRNA levels of CYP27B1 and the VDR were subsequently determined
by qPCR and fold change (FC) was calculated. Data represent mean values ±
SEM from four to seven independent experiments (*P < 0.05, **P < 0.01,
***P < 0.001).
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measuring conversion of 25D3 to the inactivate metabolite
24,25D3. TLR2/1 activation had no statistically signiﬁcant effect
on vitamin D catabolism in monocytes (Fig. 4B). Similarly, IFN-γ
alone or together with TLR2/1L had no effect on the conversion of
25D3 to 24,25D3, which was similar to media control monocytes.
Strikingly, treatment of monocytes with the Th2 cytokine IL-4
alone strongly induced 24-hydroxlyase activity, increasing the
production of 24,25D3 byﬁvefold overmedia controlmonocytes to
a rate of 51.0 fmol/h per million cells compared with 10.6± fmol/h
permillion cells inmedia control cells (Fig. 4B; P< 0.05). IL-4 had
a comparable effect in TLR2/1L-treated monocytes, inducing
catabolism of 25D3 to 24,25D3 at a rate of 40.7 fmol/h per million
cells comparedwith 10.6 fmol/h permillion cells in control-treated
cells (Fig. 4B; P < 0.05). These data suggest that up-regulation of
vitamin D catabolism (i.e., conversion of 25D3 to 24,25D3) pro-
vides a mechanism to explain the IL-4–mediated inhibition of
TLR2/1-induced antimicrobial protein expression. Although IFN-γ
and IL-4 both up-regulated TLR-induced CYP27B1 mRNA ex-
pression by approximately twofold, the TLR-induced conversion of
25D3 to 1,25D3 was threefold greater in the presence of IFN-γ
versus IL-4. Interestingly, treatment of monocytes with 1,25D3
alone (10−8 M) induced 24-hydroxylase activity to a level (65.8
fmol/h per million cells) similar to that observed for treatment with
IL-4, providing a potential explanation for the inability of exoge-
nously added 1,25D3 to overcome the cathelicidin-suppressive
effects of IL-4 (Fig. S1).
IL-4–Induced Catabolism of Vitamin D Is Dependent on CYP24. To
investigate the mechanism by which IL-4 up-regulates 24-hy-
droxylation of 25D3, further studies were carried out to charac-
terize expression of CYP24A1, the primary enzyme involved in
catalyzing 24-hydroxylation of vitamin D metabolites (11). In-
triguingly, IL-4 inhibited the baseline expression of CYP24A1
mRNA (35%; P < 0.01), and also inhibited the TLR2/1-induced
up-regulation of CYP24A1 expression (84%; P < 0.05; Fig. 5A).
Wewere also unable to detect any signiﬁcant changes in CYP24A1
protein expressionor alterations inmRNAencoding theCYP24A1
splice variant (14) (Fig. 5B). A number of other cytochrome p450
enzymes (CYP3A1, CYP2J2, CYP27A1) have been suggested to
exhibit potential 24-hydroxylase activity; however, none of these
were found to be up-regulated in monocytes following treatment
with IL-4 (Fig. S2).
To directly measure the contribution of CYP24A1 to the 24-
hydroxylase activity in monocytes treated with IL-4, monocytes
were transfected with siRNA oligos speciﬁc for human CYP24A1
or a nonspeciﬁc control (siCTRL) and then treated with IL-4.
Knockdown of CYP24A1 expression inhibited the conversion of
25D3 to 24,25D3 by 58% relative to the control siRNA (P < 0.05;
Fig. 5C), whereas conversion of 25D3 to 1,25D3 increased by 235%
(P = 0.059; Fig. 5D). The effect of CYP24A1 knockdown on IL-4
suppression of TLR2/1 responses was next investigated. In siCTRL
transfected monocytes, IL-4 signiﬁcantly inhibited TLR2/1L-in-
duced cathelicidin (P < 0.05; Fig. 5E) and DEFB4 mRNA ex-
pression (P < 0.05; Fig. 5F). The effect of IL-4 was reversed in
siCYP24A1 transfected monocytes, restoring TLR2/1L-induced
responses. It was also noted that TLR2/1L-induced cathelicidin
trended to be increased in CYP24A1 knockdown monocytes, sug-
gesting a regulatory role for CYP24A1 even in the absence of IL-4.
Given that IL-4 inhibited 1,25D3-induced autophagy, we next
determined whether the effect of IL-4 was dependent on
CYP24A1 expression. In monocytes transfected with siCYP24A1,
Fig. 3. Effects on IL-4 on 1,25D3 responsiveness. (A) Primary monocytes were cotreated with IL-4 (10
3 U/mL) and 1,25D3 (10
−10 to 10−8 M) for 18 h or (B)
pretreated with IL-4 (103 U/mL) for 6 h and then stimulated with 1,25D3 (2.5 × 10−10 to 10−8 M) for 18 h. mRNA levels of cathelicidin were subsequently
determined by qPCR and fold change (FC) was calculated as ratio to media control cells. Data represent mean values ± SEM from four to seven independent
experiments. Primary monocytes were treated as in B and immunolabeled for intracellular LC3 expression (green) and cellular nuclei (blue). Cells were vi-
sualized using confocal microscopy (C) and enumerated (D) for the percentage of cells positive for LC3-punctate formation. Data displayed are the average
percentage of cells positive for LC3-punctate formation per ﬁeld of view from three independent donors ± SEM (n > 7; *P < 0.05, **P < 0.01, ***P < 0.001).
Fig. 4. IFN-γ and IL-4 differentially regulate vitamin D metabolism. Primary
monocytes treated with TLR2/1L with or without IFN-γ (100 ng/mL) or IL-4
(103 U/mL) for 48 h and the ability to convert [3H]-25D3 to [3H]-1,25D3 and
[3H]-24,25D3 was measured by HPLC. The rate of conversion of (A) [
3H]-25D3
to [3H]-1,25D3 and (B) [
3H]-24,25D3 was calculated (n = 5) and presented in
box-and-whisker plots depicting minimum value, lower quartile, median,
upper quartile, and maximum value (*P < 0.05).
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IL-4 treatment had no effect on 1,25D3-induced autophagy
(Fig. 5G). In contrast, in monocytes transfected with siCTRL, IL-
4 inhibited 1,25D3-induced autophagy by 62% (P < 0.001; Fig.
5G). These observations conﬁrmed that although IL-4 had no
effect on monocyte expression or activity of CYP24A1, the en-
zyme mediated, at least in part, IL-4–induced 24-hydroxylase
activity as well as IL-4 inhibition of TLR2/1-induced antimicro-
bial peptide expression and autophagy.
Discussion
Although a key function of the innate immune response is to
instruct the acquired T-cell response, it has become increasingly
clear that T-cell cytokines regulate the innate immune response.
We therefore investigated whether speciﬁc T-cell cytokines
regulate the TLR2/1-induced, vitamin D-dependent antimicro-
bial pathway in human monocytes. The striking result was that
IFN-γ and IL-4 differentially affected TLR2/1 induction of the
antimicrobial peptides cathelicidin and DEFB4 by different
mechanisms. TLR2/1 and IFN-γ together up-regulated expres-
sion of CYP27B1 and monocyte conversion of 25D3 to the active
metabolite 1,25D3, resulting in activation of the VDR and
downstream induction of cathelicidin and DEFB4. In contrast,
IL-4 induced CYP24A1-dependent conversion of 25D3 to the
inactive metabolite 24,25D3, inhibiting TLR2/1 induction of
antimicrobial peptide expression and autophagy. Therefore, Th1
and Th2 cytokine responses differentially affect innate antimi-
crobial pathways through regulation of opposing facets of mono-
cyte vitamin D metabolism.
A key ﬁnding of the present study was that IL-4 was found to
have a previously unrecognized and dramatic effect on monocyte
vitamin D metabolism. IL-4, alone or in the presence of TLR2/
1L, enhanced conversion of 25D3 to the inactive catabolic prod-
uct 24,25D3. However, there was no detectable up-regulation, as
measured by quantitative PCR (qPCR) or Western blot, of cy-
tochrome P450 enzymes with known or potential 24-hydroxylase
activity in IL-4–treated monocytes. Nevertheless, we were able to
demonstrate by siRNA knockdown a role for the established
24-hyroxylase CYP24A1 in mediating the conversion of 25D3 to
24,25D3. Knockdown of CYP24A1 also reversed the ability of
IL-4 to inhibit TLR2/1-induced antimicrobial peptide expression
as well as 1,25D3-mediated autophagy. There is evidence to
suggest that increases in 24-hyrdoxylase activity can occur in the
absence of elevated enzyme levels, but may instead be a result of
preferential delivery of the substrate to a mitochondrial micro-
environment containing the enzyme (15). Although our data in-
dicate that one mechanism by which IL-4 inhibits TLR2/1-
Fig. 5. Regulation of 24-hydroxlase activity by IL-4. (A) Primary human monocytes were stimulated with TLR2/1L (10 μg/mL) with or without IL-4 (103 U/mL)
for 24 h in vitamin D sufﬁcient serum. mRNA levels of CYP24A1 were subsequently determined by qPCR and fold change (FC) was calculated. Data represent
mean values ± SEM from ﬁve independent experiments. (B) Western blot was performed on total cell lysates from primary human monocytes stimulated with
TLR2/1L (10 μg/mL) with or without IFN-γ (100 ng/mL) or IL-4 (103 U/mL) for 48 h. 1,25D3 (10−8 M) was included as a positive control. (C) Primary human
monocytes were transfected with siRNA oligos speciﬁc for CYP24A1 (siCYP24) or nonspeciﬁc (siCTRL), then treated with IL-4 (103 U/mL) for 40 h, followed by
25D3 bioconversion as measured by HPLC. The rate of conversion of [
3H]-25D3 to [
3H]-24,25D3 and [
3H]-1,25D3 was calculated (n = 3). Primary human
monocytes transfected with siCTRL or siCYP24 were stimulated with TLR2/1L and IL-4 as detailed in A. (E) Cathelicidin and (F) DEFB4 mRNA levels were
measured by using qPCR. Data represent mean values ± SEM from ﬁve independent donors. (G) Primary monocytes transfected with siCYP24 or siCTRL, then
treated with IL-4 (103 U/mL) for 6 h followed by the addition of 1,25D3 (10
−8 M) for 18 h. The cells were immunolabeled for intracellular LC3 expression and
cellular nuclei. Cells were visualized by using confocal microscopy and enumerated for the percentage of cells positive for LC3-punctate formation. Data
displayed are the average percentage of cells positive for LC3-punctate formation per ﬁeld of view from two independent donors ± SEM (n > 23; *P < 0.05,
**P < 0.01, ***P < 0.001; ns, not signiﬁcant).
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induced and 1,25D3-triggered responses is via up-regulation of
24-hydroxylase activity, we cannot exclude that IL-4 inhibits
1,25D3 induction of antimicrobial peptide expression and
autophagy via other mechanisms. In addition, it will be of interest
to determine the effect of IL-4 on vitamin D metabolism in other
cell types, including macrophages. Nevertheless, inhibition of
CYP24A1 expression by siRNA also led to increased conversion
of 25D3 to 1,25D3, presumably by (i) maintaining the pool of
substrate 25D3 available to the CYP27B1-hydroxylase and (ii)
inhibiting the conversion of active metabolite 1,25D3 to inactive,
24-hydroxylated metabolites. The present ﬁndings are clinically
relevant, as increased IL-4 responses have been observed in
patients with tuberculosis in developing countries (16–18) and
associated with the development of tuberculosis in health care
workers in a developed country (19).
In contrast to the action of IL-4 on vitamin D metabolism,
IFN-γ enhanced TLR2/1L induction of the 1-α hydroxylase
CYP27B1, potentiating the conversion of 25D3 to 1,25D3. IFN-γ
has been shown to up-regulate conversion of 25D3 to 1,25D3 in
activated macrophages from patients with tuberculosis and sar-
coidosis (20, 21) and was later shown to induce CYP27B1 di-
rectly (22, 23). In addition, local IFN-γ production was seen in
disease lesions of patients with localized mycobacterial infection,
including tuberculosis pleuritis (24).
We previously reported that Th1 and Th2 cytokines differen-
tially affect TLR2/1-induced proinﬂammatory cytokine release,
speciﬁcally IL-12p40 and TNF-α (25). This was related in part to
the ability of IFN-γ to up-regulate TLR1 expression and IL-4 to
inhibit TLR2 expression. However, both of these cytokines up-
regulated expression of the mRNAs encoding for CYP27B1 and
CYP24A1, yet differentially affected monocyte vitamin D me-
tabolism and subsequent expression of antimicrobial peptide
mRNAs, providing a unique mechanism by which these cytokines
affect host immune responses. These cytokines inﬂuence a number
of other key host defense pathways, for example autophagy, which
facilitates endosomal maturation, required for inhibiting the
growth of intracellular M. tuberculosis (12, 26). IFN-γ has been
shown to induce autophagy (27), whereas IL-4 can block starva-
tion-induced or IFN-γ–induced autophagy and autophagic control
of intracellularM. tuberculosis growth (13). In data presented here,
vitamin D-induced autophagy (12) was also blocked by treatment
with IL-4. More recently, the TLR2/1L-induced, vitamin D-de-
pendent antimicrobial pathway has been shown to involve
autophagy (28). It is therefore reasonable to hypothesize that the
ability of IFN-γ and IL-4 to differentially regulate monocyte vi-
tamin D metabolism controls the monocyte autophagy program.
In summary, our data point to a key and differential role for
Th1 versus Th2 cytokines in regulating TLR-induced antimicro-
bial responses through their ability to trigger distinct monocyte
vitamin D metabolic pathways, providing a unique mechanism by
which IL-4 regulates innate immune responses.
Materials and Methods
Reagents. TLR2/1L is a triacylated lipopeptide of the M. tuberculosis 19-kDa
antigen (EMC Microcollections). Recombinant human cytokines used were
IFN-γ (BD Biosciences), IL-4 (PeproTech), and IL-17A (eBioscience). Prede-
signed siRNA oligos were purchased (Thermo Scientiﬁc) and used as rec-
ommended by the manufacturer. Radiolabeled 3H-25D3 (speciﬁc activity, 155
Ci/mmol; Perkin-Elmer) and unlabeled 1,25D3 (Biomol) were purchased.
Antibodies used for Western blot were rabbit anti-human CYP24 (Santa Cruz
Biotechnology), mouse anti-human GAPDH (BioVision), and HRP-conjugated
goat anti-mouse and goat anti-rabbit (Thermo Scientiﬁc). Antibodies used
for confocal were mouse anti-human LC3 antibodies (MBL International) and
Alexa 488-labeled goat anti-mouse IgG1 secondary antibody (Invitrogen).
Cell Culture. All donors were healthy and provided written informed consent,
with approval by the institutional review board of the University of Cal-
ifornia, Los Angeles, for the collection of peripheral blood and subsequent
analysis. Human monocytes were puriﬁed from peripheral blood mono-
nuclear cells through plastic adherence, and cultured in 10% FCS or 10%
vitamin D sufﬁcient human serum as reported (8). For transfections, Percoll-
enriched monocytes were transfected with 100 pmol of siRNA oligos by
using the Amaxa Nucleofection System and the Human Monocyte Kit
(Lonza) as previously described (10). For measurement of autophagy, mon-
ocytes were adhered onto glass chamber slides and then treated as noted.
The cells were then immunolabeled for LC3 as previously described (12) and
visualized by using confocal microscopy.
Real-Time qPCR. Following stimulation, RNA was isolated, cDNA synthesized,
and qPCR performed as previously described (8). Reactions use SYBR Green
PCR Master Mix and were run on a DNA Engine Opticon II (Bio-Rad). The
relative quantities of the gene tested per sample were calculated against
36B4 using the delta delta cycle threshold formula as previously described
(29). The data were normalized by fold change to media control samples.
Measurement of 25D3 Bioconversion. Cells were treated for 48 h, followed by
incubation with radiolabeled 3H-25D3 for 5 h in serum-free media. Mea-
surement of 25D3 bioconversion to 1,25D3 or 24,25D3 was carried out as
previously described (9).
Western Blot Analysis. Monocytes were treated with for 48 h and total cell
extracts prepared using M-PER reagent with protease inhibitors (Thermo
Scientiﬁc) according to the manufacturer’s recommendations. Equal amount
of protein were loaded onto 12% Bis-Tris NuPage minigels (Invitrogen) and
electrophoresed for 1 h at 125 V. Western blotting was performed by
standard methods. Brieﬂy, resolved proteins were transblotted onto nitro-
cellulose membrane for 1 h at 95 V, then blocked for 1 h followed by
overnight incubation at 4 °C with primary antibody. The appropriate sec-
ondary antibody was incubated for 1 h at room temperature and speciﬁc
protein detected by using SuperSignal West Pico Chemiluminescent Sub-
strate (Thermo Scientiﬁc).
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Fig. S1. Primary monocytes treated with IL-4 (103 U/mL) or 1,25D3 (10
−8M) for 48 h were cultured with [3H]-25D3 for 5 h and the amount of conversion to [
3H]-
24,25D3 was measured by HPLC. Data represent mean values ± SEM from ﬁve independent experiments (*P < 0.05, ***P < 0.001).
Fig. S2. mRNA expression levels of cytochrome p450 enzymes in TLR2/1 activated monocytes with or without IL-4. Primary human monocytes were stimulated
as in Fig. 5A and mRNA levels of CYP3A4 (A), CYP2J2 (B), and CYP27A1 (C) were determined by qPCR. Fold change (FC) was calculated as ratio to media control
cells (−). Data represent mean values ± SEM from three to ﬁve independent experiments (*P < 0.05, **P < 0.01).
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Mycobacterium tuberculosis tRNA triggers a  
gene network for instruction of Th1 cells 
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Abstract 
 The ability of the innate immune system to utilize specific pattern recognition 
receptors (PRRs) to recognize distinct microbial components termed pathogen 
associated molecular patterns (PAMPs) triggers common and unique host response 
pathways.  These PRRs are located in specific cellular compartments to facilitate 
recognition of the pathogen.  Yet for Mycobacterium tuberculosis, which resides in 
endosomes, there is little information about how innate recognition of bacterial 
components might contribute to host defense.  We therefore compared the gene 
expression profiles of M. tuberculosis tRNA, a stable component of the culture filtrate, 
with triacylated lipopeptide, which is recognized by Toll-like receptor 2/1 (TLR2/1) 
located on the cell surface.  Integrated bioinformatics analysis of RNA-seq data from 
stimulated peripheral blood mononuclear cells (PBMC) identified a tRNA-induced 
pathway for induction of Th1 cells involving NK cell activation as well as IL-18, IFN-g 
and IL-12.  Functional studies demonstrated that M. tuberculosis tRNA specifically 
induced IL-18, which was required for upregulation of IFN-g in NK cells, with both 
required for optimal induction of IL-12p70.  Finally, the ability of M. tuberculosis tRNA to 
trigger this pathway was TLR8 dependent, and could be reconstituted by the co-addition 
of TLR3 and TLR8 specific ligands.  In summary, M. tuberculosis tRNA triggers the 
endosomal PRR TLR8, leading to the IL-18 and IFN-g dependent upregulation of IL-
12p70, relevant for induction of a Th1 response. 
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Introduction 
 To defend the host against infection, the innate immune system utilizes distinct 
‘pathogen recognition receptors’ (PRRs) to recognize a diverse array of microbial 
determinants called ‘pathogen associated molecular patterns’ (PAMPs).  In some cases, 
these PRRs are redundant, triggering nearly identical immune responses, but different 
PAMPs located in distinct cellular compartments, can also induce distinct immunologic 
pathways.  For example, in mycobacteria, muramyl dipeptide triggers the cytoplasmic 
receptor NOD2 in monocytes/macrophages to induce a specific DC pathway not 
induced by triacylated lipopeptide which triggers the cell surface receptor TLR2/1 
(Schenk et al., 2012).  Furthermore, DNA from mycobacteria, which reside in the host 
phagosome, gains access to the cytoplasm to trigger nucleotide sensors such as 
STING, leading to a type I interferon response (Collins et al., 2015; Manzanillo et al., 
2012; Wassermann et al., 2015; Watson et al., 2012).  As such, the host has deployed 
PRRs in a variety of subcellular locations to recognize distinct microbial ligands and 
mount both common and specific immune effector responses. 
 In addition to proteins and DNA, M. tuberculosis releases RNA into the culture 
filtrate.  Examination of the RNA present in M. tuberculosis culture filtrate revealed that 
tRNA was the most abundant form (Obregon-Henao et al., 2012).  Treatment of human 
monocytes with M. tuberculosis tRNA induced apoptosis, which may contribute to 
disease pathogenesis.  However, the extent of the immune response triggered by M. 
tuberculosis tRNA is unknown, and it is unclear whether tRNA induces common or 
specific immune responses in comparison to other mycobacterial ligands.  Also, the 
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PRR which recognizes M. tuberculosis is not defined, but we expect that one possibility 
is that the ligand is recognized in the endosomal pathway, such that TLR8 is a likely 
candidate.  Therefore, we undertook to investigate the innate immune response to M. 
tuberculosis tRNA with the hypothesis that M. tuberculosis tRNA, via activation of TLR8, 
triggered distinct immune responses as compared to mycobacterial lipopeptide, which 
activates a TLR2/1 heterodimer.   
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Results 
 
M. tuberculosis tRNA and bacterial lipopeptide induce distinct gene expression patterns.   
To test the hypothesis that M. tuberculosis tRNA, via activation of TLR8, 
triggered distinct immune responses as compared to mycobacterial lipopeptide, which 
activates a TLR2/1 heterodimer, we compared the response of human peripheral blood 
mononuclear cells (PBMC).  The gene expression profiles induced by M. tuberculosis 
tRNA were derived by performing RNA-seq on stimulated PBMC.  M. tuberculosis tRNA 
was prepared from strain as described  (Chan et al., 2015).  A ssRNA 30-mer derived 
from an HIV-1 sequence served as a positive control.  In addition, we compared the 
response to a mycobacterial 19-kDa triacylated lipopeptide, which activates cell surface 
TLR2/1 (TLR2/1 ligand, TLR2/1L).  The optimal concentrations of these ligands was 
determined by dose titration or used as previously established in the lab. 
PBMC from three donors were stimulated with the various ligands, and the cells 
collected after 1, 6 and 24 h.  The mRNAs were isolated, libraries prepared and gene 
expression profiles obtained by RNA-seq.  Principal component analysis of the DESeq2 
normalized counts was used to first identify samples displaying similar trends in gene 
expression (Fig. 3-1A) (5).  At 6 and 24 hour timepoints, PCA analysis indicated that 
gene expression for M. tuberculosis tRNA and ssRNA treated PBMC were similar, while 
gene expression for lipopeptide treated and untreated PBMC formed distinct groups.  
PCA analysis of gene expression data at 1h formed a single group, with all three ligands 
inducing similar profiles.   
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 A second unsupervised analysis, hierarchical clustering, was performed to 
identify the specific relationships between samples (Fig. 3-1B).  Consistent with the 
PCA, gene expression profiles for both tRNA and ssRNA at the 6 and 24h timepoints 
clustered together.  The samples for TLR2/1L at 6h formed their own group, as did the 
samples for the untreated controls at 6 and 24h.  All the 1h samples, regardless of the 
stimulus, clustered on a separate branch from the 6 and 24h samples, likely indicating 
that there was little difference in the transcriptional response by the various stimuli at 
this early timepoint. 	
To determine the gene signatures induced in PBMC by each ligand, differential 
gene expression was calculated with DEseq2 (Love et al., 2014), using a threshold of 
FC > 2 as compared to unstimulated cells.  To study the gene signatures, a FDR < 0.05 
was used to filter significantly regulated genes for use in downstream analyses.  We 
calculated the gene signature for each ligand by calculating the maximum induction of a 
given gene over all timepoints for a given ligand.  Comparison of the overall gene 
signatures showed a striking overlap of the tRNA and ssRNA signatures, with 1,465 
common genes out of a total of 1,692 genes for tRNA and 1,791 for ssRNA (Fig. 3-1C).  
Although there was some overlap with the genes induced by TLR2/1L, there were 1,069 
common genes that were exclusively induced by both tRNA and ssRNA, contributing to 
the common canonical pathways and biologic functions observed for the two ligands.  In 
contrast, TLR2/1L induced a distinct signature, with 720 significantly induced genes, of 
which 215 were unique to TLR2/1 activation and 324 were distinct from the 
tRNA/ssRNA common signature. 
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A series of supervised analyses were performed to investigate the immune 
pathways induced by each ligand (Fig 3-1D).  This included parallel bioinformatics 
analyses of gene signatures using the canonical pathways and biofunction tools in 
Ingenuity, as well as analysis of key modules derived by Weighted Gene Correlation 
Network Analysis (WGCNA).  Ingenuity analysis of the biologic functions in Ingenuity 
showed overlap between tRNA and ssRNA gene signatures, identifying roles for NK 
cells, DC, monocytes, T cells including Th1 cells.  In contrast, the biologic functions of 
the TLR2/1L induced gene profile indicated monocytes, macrophages and neutrophil 
associated pathways.  Ingenuity analysis of the ligand-induced signatures identified 
several canonical pathways that were more significantly induced by tRNA as compared 
to TLR2/1L (Fig. 3-1E).  These include DC maturation, NK-DC crosstalk, IFN signaling, 
PRR recognition of bacteria and viruses, communication between innate and adaptive 
immune cells.  In comparison to the large differences in pathway significance for the 
tRNA and TLR2/1L induced gene signatures, the significance for the enrichment of 
pathway-associated genes was relatively similar for the tRNA and ssRNA signatures.   
 
Identification of gene expression networks induced by M. tuberculosis tRNA.  
To identify modules of highly interconnected genes, we used a systems biology 
approach: weighted gene co-expression network analysis (WGCNA), an unbiased 
approach that defines modules of highly interconnected genes based on pairwise 
correlations (Langfelder and Horvath, 2008b).  WGCNA uses correlations to group 
genes into modules, similar to traditional clustering analysis, but unlike other 
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approaches, raises each correlation to a power, thus lending more weight to stronger, 
more reliable correlations.  As we were interested in identifying gene modules 
correlated with the individual stimuli, we utilized the data from 6 and 24 hour timepoints 
was used for network construction.  To determine which modules were associated with 
each ligand, we performed module eigengene correlation to combined 6 and 24h data 
for each ligand and the media control.  WGCNA identified 31 gene modules, of which 
nine were positively correlated with at least one condition (Fig. 3-2A).  Of these, the 
significantly correlated modules associated with tRNA treatment of PBMC were 
designated MEturquoise (P = 0.03), and MEbrown4 (P = 0.04). MEturquoise was also 
associated with ssRNA, as were MEmagenta4 and MEcoral3.  TLR2/1L activation of 
PBMC was associated with MEantiquewhite4 and MElightyellow.  Several modules 
were associated with the media treated cells.  
 Gene ontology analysis (Bindea et al., 2009) of the antiquewhite4 module 
associated with TLR2/1L revealed significant enrichment of terms including ‘regulation 
of macroautophagy’ and ‘IL-1 signaling pathway’ (Fig. 3-2B).  The lightyellow module 
was enriched for genes associated with ‘chemotaxis’ and ‘chemokine signaling 
pathway’.  Analysis of the turquoise module, which correlated with tRNA and ssRNA, 
revealed significant enrichment of terms including ‘immune system’, ‘IFN gamma 
signaling’, ‘TLR signaling pathway’ and ‘defense response’.  We noted the presence of 
IL18, IFNG, and IL12A consistent with the biologic function analysis of the tRNA 
induced genes that identified a Th1 signature.   
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 The turquoise module, which contained 2239 genes, was filtered using the 
‘immune system’ GO term, identifying 339 genes and was inclusive of the key Th1-
associated genes.  A heatmap showing the fold-change induction of these genes in 
each samples relative to all samples showed that all genes were more robustly induced 
by tRNA and ssRNA, although the magnitude of the response was variable.  This clearly 
illustrated that these genes were differentially induction by tRNA and ssRNA as 
compared to the TLR2/1L and media, although the level of induction varied (Fig. 3-2C).  
Therefore, we performed further filtering for significant induction by tRNA at either 
timepoint, which identified 241 genes.  The correlation of these individual genes as 
calculated by WGCNA was visualized by a connectivity map (Hu et al., 2004) 
(Fig. 3-2D).  We filtered by edge weight of 0.2, removing genes not connected to IL18, 
IFNG and IL12A, which yielded 120 genes.  This analysis identified that IL-18, IFNG 
and IL12A were connected to each other and were multiply connected to other genes in 
the module.  These included IL18R1, IL18RAP and IL12RB2, which encode relevant 
cytokine receptors, as well as STAT1, STAT2, STAT3 and STAT5A, which encode 
proteins involved in signaling pathways related to the induction or downstream effects of 
the identified cytokines.  A number of Type I interferon genes were identified as well as 
IFN-induced genes.  We noted the expression of CASP4, TLR3 and ISG15.   
Integration of the bioinformatics analysis of the gene expression profiles for the 
tRNA treatment of PBMC and the WGCNA turquoise module was performed to link 
individual cell types with specific genes and functional pathways (Fig. 3-3E).  This 
analysis identified that M. tuberculosis tRNA directly or indirectly triggered pathways 
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associated with monocytes, NK, DC and T cells, including Th1 cells, to induce a set of 
genes including IL18, IL18R1, IFNG, JAK2, STAT1, IL12A, IL12B, IL12RB2, and 
STAT4.  These genes are contained within functional pathways including ‘Role of PRR 
recognition of Bacteria and Viruses’, ‘TLR signaling’, ‘IFN-g signaling’, ‘DC maturation’, 
‘T helper differentiation’ and ‘defense response’.  Together, these data suggest a model 
in which tRNA activates specific cell types that interact to establish a host-defense gene 
network involved in the innate instruction of an adaptive Th1 response.  
 
Validation of M. tuberculosis tRNA gene expression profiles.   
The key genes identified by the integrative informatics analysis as part of the M. 
tuberculosis-tRNA induced Th1 pathway were visualized using log2 normalized counts 
at the different timepoints (Fig 3-4A).  Both tRNA and ssRNA, but not TLR2/1L, 
significantly induced expression of IL18 mRNA (IL18: tRNA FC = 2.7 vs. media, P = 
0.005) and its receptor heterodimer (IL18R1: tRNA FC = 2.8, P = 0.0001, IL18RAP: 
tRNA FC = 3.2, P = 1.6 x 10-15).  IFNG mRNA was strikingly upregulated by both RNA 
treatments at 6t (IFNG: tRNA FC = 426, P = 7.7 x 10-52), while no significant change 
was observed in response to TLR2/1L.  IL12A, which encodes the IL-12p35 component 
of the biologically active IL-12p70 heterodimer, was induced by 8-12 fold only in 
response to tRNA and ssRNA.  IL12B, which encodes the p40 subunit of the IL-12p70 
heterodimer, was significantly induced by all three ligands, although expression was 5-6 
times greater in response to tRNA and ssRNA than TLR2/1L.  IL23A, which encodes 
IL-23p19 and combines with IL-12p40 to form active IL-23, was not significantly induced 
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by any of the treatments.  IL6 mRNA was strongly induced by all three ligands.  This 
analysis revealed that additional genes connected to the central genes in the Th1 
pathway, including TLR3, CASP4, and ISG15, were also upregulated, but again only in 
response to tRNA and ssRNA, not TLR2/1L.   
To determine whether the induction of the cytokine mRNAs leads to protein 
production, we stimulated PBMC with M. tuberculosis tRNA, ssRNA40, and TLR2/1L, 
collected supernatants at 24h and measured cytokines by ELISA or CBA.  Consistent 
with the gene expression data, PBMC secreted IL-18, IFN-g and IL-12p70 in response 
to tRNA (IL-18: 59±6 pg/ml, IFN-g: 14366±2275 pg/ml, IL-12p70: 433±85 pg/ml, P = 
0.0001 Fig 3-4B) and ssRNA, but not media or TLR2/1L. IL-12p40 was secreted in 
response to all treatments, although tRNA and ssRNA induced approximately seven 
times more IL-12p40 protein than TLR2/1L.  IL-6 secretion was induced for all 
treatments. Low levels of IL-23 were detected in supernatants of all three treatments. 
The differential production of IL-12p70 and IL-23 is consistent with the informatics 
analysis indicating a gene network for instruction of a Th1 immune response. 
To determine the sequence of cytokine induction in response to the M. 
tuberculosis tRNA, the timecourse of IL-18, IFN-g and IL-12p70 protein production was 
measured (Fig. 3-4C).  The earliest detected response was the production of IL-18 at 6h 
in response to tRNA and ssRNA (tRNA: 45±5 pg/ml vs. media11±3 pg/ml, FC = 4.1, P = 
0.0001; ssRNA: 50±7 pg/ml, FC = 4.5, P = 0.0001).  IL-18 protein increased twofold by 
24h (76±2 pg/ml vs. media 15±8 pg/ml, FC = 5.0, P= 0.0001).  In contrast for IFN-g and 
IL-12p70, little protein was measured at 1h or 6h, but there was significant induction by 
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24h (IFN-g: 15715±4287 pg/ml, FC = 1048,  P = 0.0001 vs. media 14±9 pg/ml,; 
IL-12p70: 139±22 pg/ml P = 0.0001 vs. media n.d.). The temporal pattern of IL-6 
secretion was similar to that of IL-18, protein was detected by 6h and concentration 
doubled by 24h.  These data indicate that IL-18 secretion is triggered early, followed by 
secretion of IFN-g and IL-12p70. 
 
Interdependence of tRNA induced cytokines in the induction of IL-12p70 
Given that IL-18 was secreted earliest, we determined its role on downstream 
cytokine secretion by pre-treating PBMC with IL-18 neutralizing antibodies prior to 
addition of the microbial ligands.  Pre-treatment of PBMC with anti-IL-18 dramatically 
reduced tRNA-induced secretion of both IFN-g (93% reduction, P=0.0003) and IL-12p70 
(70% reduction, P<0.0001) (Fig 3-5A).  As a control, we measured induction of IL-6, 
which was not affected by anti-IL-18 treatment.     
Since IL-18 is known to enhance secretion of IFN-g (Garcia et al., 1999; Lee et 
al., 2011; Ushio et al., 1996) and IFN-g primes IL12A transcription (Liu et al., 2004), we 
hypothesized that IFN-g contributed to the production of IL-12p70.  The pre-treatment of 
PBMC with neutralizing anti-IFN-g antibodies reduced the M. tuberculosis tRNA-induced 
secretion of IL-12p70 as compared to media (62% reduction, P < 0.0001) as well as the 
isotype control (Fig 3-5B).  Secretion of IL-18 was unaffected by anti-IFN-g treatment, 
which is expected given the earlier induction of IL-18.  Again, IL-6 production was not 
diminished by the addition of anti-IFN-g antibodies.  
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Previous studies have shown that CD56+ cells secrete IFN-g in response to a 
variety of TLR stimuli including TLR7/8 agonists (Gorski et al., 2006).  In order to 
determine if CD56+ cells were required for M. tuberculosis induction of IFN-g, we 
depleted from PBMC and measured IFN-g release.  In PBMC depleted of CD56+ cells, 
M. tuberculosis tRNA induced IFN-g was almost entirely eliminated (tRNA: 141±118 
pg/ml CD56 depleted vs. 4557±4157 pg/ml PBMC, 97% reduction, P=0.0215; ssRNA: 
313±244 pg/ml CD56 depleted vs. 12730±12005 pg/ml PBMC, also 97% reduction, 
P=0.0097) (Fig 3-5C).  We further demonstrated that CD56+ cells were the major source 
of IFN-g by flow cytometry (Fig 3-8).  PBMC were stimulated as above, then stained with 
antibodies for IFN-g, CD3 and CD56 to measure intracellular IFN-g and differentiate NK, 
NKT and T cell populations.  IFN-g was detectable above background in mTB tRNA and 
ssRNA–treated PBMC, and of IFN-g positive lymphocytes, the majority were 
CD56+CD3- (mTB tRNA: 62±9%; ssRNA 69±9%) followed by CD56-CD3+ (mTB tRNA: 
28±10%; ssRNA: 22±8%), and a small number of CD56+CD3+ (mTB tRNA: 2.8±1.5%; 
ssRNA: 2.4±1%) (Fig 3-5D).  Since the frequency of NK cells in PBMC is much lower 
than that of T cells (~10% vs. ~75%) this indicated that the populations were 
differentially predisposed to produce IFN-g in response to RNA stimuli.  To quantify this, 
the frequency of IFN-g positive cells within each lymphocyte subpopulation was 
calculated. NK cells had the highest frequency of IFN-g-producing cells (mTB tRNA: 
10±5%; ssRNA 40±13%) followed by NKT cells (mTB tRNA: 3.1±2%; ssRNA: 12±6%), 
and only a small fraction of T cells were IFN-g+ (mTB tRNA: 0.3±0.1%; ssRNA: 
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1.2±0.4%).  Although T cells are major producers of IFN-g during the adaptive immune 
response, this early timepoint measures the innate immune response, in which NK cells 
produce the majority of IFN-g production. 
 
tRNA induces cytokine responses via TLR8 
The secondary structure of tRNA includes both single and double stranded RNA 
regions.  Given that we detected induction of both TLR8 (a PRR for single stranded 
RNA) and TLR3 (a PRR for double stranded RNA) mRNAs by M. tuberculosis tRNA, we 
explore the role of these PRRs in triggering the Th1 cytokine network.   
In order to test the requirement of TLR8 signaling for tRNA induction of the Th1 
pathway, we utilized a specific TLR8 antagonist.  A dose titration was performed to 
determine the optimal concentration for the antagonist and preclude off-target effects.  
PBMC were pre-treated with the TLR8-antagonist VTX-3119 or control molecule 
VTX-764, and stimulated with TL8-506, a synthetic TLR8-specific agonist (Lu et al., 
2012).  Pre-treatment with the TLR8 antagonist suppressed cytokine response to the 
TLR8 agonist vs. pre-treatment with control compound (IL-18: 60% reduction P<0.0001; 
IFN-g: 67% reduction P=0.024; IL-12p70: 47% reduction P=0.0004).  (Fig 3-6A). 
 Next, PBMC were pre-incubated with the TLR8 antagonist or control compound, 
then stimulated with M. tuberculosis tRNA, ssRNA or TLR2/1L.  Treatment with the 
TLR8 antagonist reduced secretion of IL-18 by 64% for activation by mTB tRNA (mTB 
tRNA: 12±6 pg/ml vs. 35±16 pg/ml, P<0.0001) and 54% for ssRNA. IFN-g secretion was 
90% lower for (mTB tRNA: 695±224 pg/ml vs. 7536±2788 pg/ml P<0.0001) and 46% for 
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ssRNA.  Secretion of IL-12p70 was diminished by 82% for mTB tRNA (mTB tRNA: 
42±15 pg/ml vs. 232±57 pg/ml, P<0.0001) and 67% for ssRNA (Fig 3-6B).  IL-6 
secretion was not significantly affected for any treatment. 
To further define the role of TLR8 in the induction of IL-12p70, we surveyed the 
ability of various oligomers and base analogues targeting endosomal and cytosolic 
nucleic acid PRR for ability to induce secretion of this cytokine in PBMC (Fig 3-7C).  As 
before, mTB tRNA and ssRNA induced IL-18, and induction also seen for synthetic 
TLR7 and TLR8 agonists. IFN-g was strongly induced by ssRNA as well as, to a lesser 
extent, mTB tRNA and TLR8-specific ligand. High levels of IL-12p70 were secreted in 
response to ssRNA and mTB tRNA.  Despite their induction of IL-18 and IFN-g, only low 
amounts of IL-12p70 were produced in response to synthetic agonists for R848, 3M-002 
(TLR7/8), and TL8-506 (TLR8).  By itself, poly I:C (TLR3) was a weak inducer of IL-18, 
IFN-g and IL-12p70.  Even lower levels of these cytokines were observed in response to 
Imiquimod (TLR7), CpG DNA (TLR9), cyclic-di-GMP (STING), dA:dT (STING/CDS) 
(Ablasser et al., 2009; Ma et al., 2015; Zhang et al., 2011). These data suggest that 
TLR8 activation alone was not sufficient to explain the strong induction of IL-12p70 by 
M. tuberculosis tRNA.  
We next addressed whether a combination of a specific TLR8 ligand plus a 
second ligand activating a different PRR could lead to IL-12p70 secretion.  Given that 
tRNA has both single and double stranded RNA regions, and previously tRNA has been 
shown to induce type I IFN via activation of TLR3 (Wang et al., 2006), it was logical to 
ask whether activation of both TLR8 and TLR3 could induce IL-12p70.  We found that 
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the TLR3 agonist weakly induced IL-18, that induction was greater with the TLR8 
agonist, and when combined, the induction of IL-18 by the TLR3 and TLR8 ligands was 
additive.  In contrast, the TLR3 and TLR8 ligands by themselves weakly induced IFN-g 
and IL-12p70, but the combination of the two ligands resulted in the synergistic 
induction of these cytokines (Fig 3-7D).  
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Discussion 
The ability of the immune system to mount a Th1 response is critical for host 
defense against many intracellular bacteria including M. tuberculosis.  To generate a 
Th1 response, the innate immune system must recognize the microbial invader and 
instruct the adaptive T cell response, yet the classic pathogen associated molecular 
patterns (PAMPs) of mycobacteria that trigger the innate response, lipoproteins which 
activate TLR2/1 and muramyl dipeptide, which activates NOD2, are weak inducers of 
Th1 cells.  Here, we found that M. tuberculosis tRNA, found in the culture filtrate, 
induces IL-12p70, a potent trigger of Th1 cells.  Exploring tRNA induced gene 
expression profiles in PBMC, we identified a pathway for the induction of Th1 
responses, beginning with the production of IL-18, which led to NK cell secretion of IFN-
g, and the subsequent induction of IL-12p70.  The ability of M. tuberculosis tRNA to 
trigger this Th1 gene network was dependent on TLR8 and upregulated by TLR3 ligand, 
suggesting a role for nucleotide receptors in mounting a cell-mediated immune 
response against mycobacteria.   
Our data provide a mechanism by which M. tuberculosis induces NK cell 
production of IFN-g, involving bacterial tRNA triggering of TLR8 to induce the production 
of IL-18.  This provides a pathway for induction of IFN-g by the innate immune system 
independent of the adaptive T cell response.  The role of NK cells in tuberculosis was 
suggested by studies in mouse models of disease, in which NK cells are recruited to the 
lung as early as 7 days after infection (Junqueira-Kipnis et al., 2003), with a role in 
preventing tissue damage (Feng et al., 2006).  In human tuberculosis, NK cells have 
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been identified at the site of infection in patients, both in the pleural fluid (Schierloh et 
al., 2005) and in granulomas in pulmonary lesions (Portevin et al., 2012). 
In addition to, and dependent upon the induction of IFN-g from NK cells, M. 
tuberculosis tRNA was a potent inducer of IL-12p70, a key cytokine of the innate 
immune system which leads to the instruction of Th1 cells.  As such, the tRNAàIL-
18àIFN-gàIL-12p70 pathway, by induction of Th1 cells, would lead to sustained 
induction of IFN-g, a cytokine essential to host defense against mycobacterial infection.  
Mice lacking the gene for IFN-g died from M. tuberculosis challenge 2-3 weeks from iv 
challenge and within a month from aerosol challenge (Flynn et al., 1993).  Activation of 
mouse macrophages by IFN-g and TNF-α induced killing of intracellular bacteria through 
the induction of nitric oxide (Chan et al., 1995; MacMicking et al., 1997).  A key role for 
IFN-g in the human immune response to M. tuberculosis was indicated by studies 
finding that individuals with genetic disorders leading to the decreased production of, or 
response to IFN-g, are highly susceptible to tuberculosis and other mycobacterial 
diseases (Altare et al., 1998; Jouanguy et al., 1999; Newport et al., 1996).  One 
mechanism by which IFN-g contributes to host defense against M. tuberculosis in 
humans is through activation of macrophage antimicrobial activity via the vitamin-D 
dependent induction of the antimicrobial peptides cathelicidin and DEFB4 (Fabri et al., 
2011).   
Both M. tuberculosis tRNA and ssRNA induced a gene network, determined by 
using WGCNA to detect correlated genes, that was associated with innate instruction of 
an adaptive T cell response.  In addition to IL18, IL12A, IL12B, and IFNG, which are 
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known to polarize towards a Th1 adaptive response, we found upregulation of multiple 
T-cell costimulatory molecules, including CD40 and CD80 (Hermann et al., 1998; Klug-
Micu et al., 2013). Also of note were chemoattractants, such as CXCL10, which recruit 
T cells, NK cells, DC, and monocytes to the site of infection (Lande et al., 2003), and 
ISG15 which enhances the IFN-g response to mycobacterial infection (Fan and Zhang, 
2013). 
In addition to the induction of IFN-g, M. tuberculosis tRNA and ssRNA strongly 
induced type I interferon mRNAs and protein. Although in general, type I interferon 
antagonizes cell-mediated immunity in bacterial infection (O'Garra et al., 2013; Teles et 
al., 2013), type I interferon may also enhance a pathway for induction of  IL-12p70 and 
IFN-g in the same context.  Type I interferon was required for induction of IL-18 during 
Streptococcus pneumoniae infection in a mouse model (Fang et al., 2014). The 
augmented induction of IL-18 by type I interferon may involve IRF1 signaling and 
inflammasome activation.  IFN-a has been shown to synergize with IL-18 to induce 
secretion of IFN-g from human NK cells (Matikainen et al., 2001). IFN-a, at low levels 
has been shown to augment the ability of TLR ligands to trigger IL-12p70 production in 
both monocytes and DC (Gautier et al., 2005; Hermann et al., 1998).  However, in 
situations where type I interferon levels are high, there may be inhibition of IL-12p70 
(Guarda et al., 2011; Manca et al., 2005) resulting in pathogenesis (Orme et al., 2015).  
An early burst of type I interferon may enhance production of cytokines that initiate Th1 
polarization, while sustained type 1 interferon signaling enhances release of IL-10 and 
suppresses the Th1 pathway.   
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Transfer RNA was identified as an abundant RNA in M. tuberculosis culture 
filtrate (Obregon-Henao et al., 2012), perhaps accumulating as stable products, likely 
through bacterial lysis.  In considering how the innate immune system recognizes this 
tRNA, we considered that M. tuberculosis resides primarily in the endosomal pathway, 
which is surveyed by nucleotide-sensing TLRs including TLR3 (dsRNA), TLR7 (ssRNA), 
TLR8 (ssRNA) and TLR9 (dsDNA).  Human monocytes express primarily TLR8  
(Kadowaki et al., 2001) and is localized to endosomes/phagosomes, providing the 
innate immune system to distinguish self RNA (cytoplasm) vs non-self RNA 
(endosome/phagosome).  Our data indicate that this tRNA induces the Th1 pathway via 
TLR8, as a specific antagonist blocked cytokine production.  This is consistent with 
TLR8 recognition of ssRNA, including single stranded regions present in stem loops 
sequences which are present in tRNA, for example in the anti-codon sequence  (Chan 
and Lowe, 2009).  Finally, a TLR8 gain of function polymorphism (TLR8 A1G), 
correlates with increased resistance to tuberculosis in humans (Bukhari et al., 2015; 
Davila et al., 2008; Daya et al., 2014; Lai et al., 2016; Salie et al., 2015; Sun et al., 
2015; Wu et al., 2015).  Clearly, it will be important to link TLR8 to recognition of 
M. tuberculosis in infected macrophages, which requires an understanding of the 
kinetics of tRNA release in cells and the dissociation of other pathways that trigger IL-18 
induction.  Another issue is that mouse TLR8 is a weak sensor of RNA, precluding 
studies in knockout animals.  Nevertheless, TLR8 recognizes Borrelia burgdorferi RNA 
in infected human macrophages (Cervantes et al., 2013)  
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Although M. tuberculosis was a potent inducer of IL-12p70, and did so in a TLR8-
dependent fashion, a TLR8 agonist alone was not sufficient to upregulate IL-12p70 
production.  The structure of tRNA, containing both ssRNA and dsRNA regions, led us 
to a set of experiments looking at the response to a combination of ligands including a 
synthetic ligand which activates TLR8 and dsRNA which activates TLR3.  We found that 
although the combination of TLR3 and TLR8 ligands induced IL-18 in an additive 
manner, but were synergistic in the induction of IFN-g and IL-12p70.  The ability of the 
TLR3 ligand to act synergistically with the TLR8 ligand may relate to a direct activation 
of NK cells (Schmidt et al., 2004) or induction of other cytokines such as IL-15 (Zhou et 
al., 2007) that enhance IFN-g and IL-12p70 production.  The concept that tRNA induces 
a unique innate response via induction of both TLR8 and TLR3 is consistent with 
studies demonstrating that this ligand activates both TLR8 (Sha et al., 2014) and TLR3 
(Wang et al., 2006) individually.  Therefore, the ability of a single microbial ligand to 
induce multiple PRRs thereby induces a distinct innate immune response.   
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Materials and Methods 
Cell purification and culture 
Whole blood was obtained from healthy donors who provided written informed consent 
(UCLA Institutional Review Board).  PBMC were isolated by Ficoll-hpyaque (GE 
Healthcare) density gradient centrifugation and cultured in RPMI (Gibco) supplemented 
with 10% FCS (Hyclone) and 1 % Pen/Strep glutamine (Gibco) at a density of 2x106 / ml 
in 96-well flat bottomed plates (Corning) at 37°C with 4% CO¬2.   
 
Reagents for Cell Stimulation 
TLR2/1L, a synthetic lipopeptide derived from the 19kDa mycobacterial lipoprotein was 
obtained from EMC Microcollections and used at 10 µg/ml.  PolyI:C (HMW) and TLR-
506 were from Invivogen and used at 2 µg/ml and 500 nM respectively.  ssRNA40 
(phosphothioate backbone, HPLC purified) was synthesized by IDT and used at 500 
ng/ml.  Purified tRNA from M. tuberculosis H37Rv, prepared as described(Chan et al., 
2015), was gift from Peter Dedon and used at 1 µg/ml.  Nucleic acid ligands were 
complexed with Dotap (Roche) according to manufacturer’s instructions to facilitate 
delivery to the endosome.  Reagents were determined to be endotoxin-free by Limulus 
amoebocyte lysate assay (Lonza).  
 
Cytokine Quantification 
Cell supernatants were harvested at 24h unless otherwise noted.  Cytokines measured 
by sandwich ELISA using antibody pairs were as follows: IL-18 (MBL Intl.), IFN-g (BD), 
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IL-6 and IL-12p40 (Invitrogen).  IFN-a, IL-1b, IL-10, IL-12p70 and TNF-a were 
measured by CBA (BD, Flex Sets).  
 
Blocking Antibodies and TLR inhibitors 
PBMC were treated with the following monoclonal neutralizing antibodies compounds 
for 30 min before stimulation.  IL-18 10 µg/ml (MBL Intl), IFN-g 10 µg/ml (BD), IgG1 
10	µg/ml from corresponding manufacturer was used as a control.  The specific TLR8-
inhibitor VTX-3119 and related control compound VTX-764 were gifts from VentiRx 
Pharmaceuticals and were used at a concentration of 100 nM which was determined by 
dose titration to provide optimal inhibition without off-target effects. 
 
CD56 depletion  
PBMC were depleted of CD56+ cells using CD56 MicroBeads (Miltenyi Biotech) as 
directed by manufacturer’s protocol.  Depletion was confirmed at >99% purity by flow 
cytometry.  CD56 depleted PBMC were cultured at 1.8x106/ml to reflect the loss of 
CD56+ cells, estimated to comprise 10% of PBMC.  
 
Flow cytometry 
PBMC were labeled with antibodies to CD3 (CD3-FITC Invitrogen) and CD56 (CD56-PE 
eBioscience), or isotype control.  For intracellular detection of IFN-g, PBMC were 
treated with GolgiPlug (BD) 4h prior to harvest.  Following surface staining and fixation, 
cells were treated with Perm/Wash Buffer (BD) and stained with IFNg-APC (Invitrogen) 
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or isotype control.  Flow cytometry was performed on a LSRII (BD Biosciences) in the 
UCLA Jonsson Comprehensive Cancer Center (JCCC) and Center for AIDS Research 
Flow Cytometry Core Facility that is supported by National Institutes of Health awards 
P30 CA016042 and 5P30 AI028697.  Analysis was performed in FlowJo (Tree Star 
Inc.).  
 
RNA sequencing 
PBMC were stimulated as described.  RNA was harvested at 1, 6 and 24h and isolated 
with RNeasy micro kit (Qiagen) according to manufacturer’s directions, including on-
column DNase digestion.  RNA was quantified by Nanodrop and quality assessed by 
Agilent 2100 Bioanalyzer.  Libraries were created from high quality RNA using TruSeq 
RNA Library Prep Kit v2 (Illumina).  Library construction was performed by Marco 
Morselli and Arturo Rinaldi.  Libraries were quantified by Qubit, pooled by donor in 
groups of 12, and sequenced in duplicate on a HiSeq 2500 Sequencing System 
(Illumina) at the UCLA Clinical Microarray Core. 
 
Differential Expression Analysis 
Sequenced reads were aligned to the human reference genome (build hg19 UCSC) 
using TopHat and Bowtie2.  Raw counts were calculated with HTseq using the hg19 
Ensembl annotation.  Normalization to a negative binomial distribution and differential 
expression analysis was performed using the DESeq2 package for R.  FDR was 
controlled by applying the Benjamin-Hochberg correction to P-values.  Sequence 
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alignment, mapping and DEG analysis was performed by Jing Lu.  Differentially 
expressed genes were identified using the cutoffs FC > 2 vs Media and adjusted P-
value < 0.05.  Hierarchical clustering was performed with “hclust”, principle component 
analysis via “prcomp” and heatmaps using “pheatmap” in R (version 3.2.4).  Weighted 
Gene Correlation Network Analysis was performed using the WGCNA package as 
described (Langfelder and Horvath, 2008a).  A network of relevant gene relationships 
as calculated by WGCNA was visualized using visANT.   
 
Functional Analysis 
Functional analysis of differentially expressed genes was performed using Ingenuity 
Pathway Analysis (Qiagen).  Gene ontology term analysis was performed using the 
ClueGO plugin (version 2.2.5) for Cytoscape (version 3.3.0) using the GO term 
database files from 08.06.2016.  Significantly enriched terms were identified by right-
sided hypergeometric test with Benjamini-Hochberg P-value correction using a cutoff of 
P < 0.05.  A network connecting canonical pathways and biological functions from IPA, 
GO terms, and differentially expressed genes was visualized using Gephi (beta version 
0.9.1).  
 
Statistics 
Results are shown as mean ± SEM.  Statistical analysis was performed using 
GraphPad Prism 7.  Cytokine data was transformed using log10(x+1), and parametric 
distribution assessed using the Shapiro-Wilk test of normality.  One-way ANOVA was 
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performed for comparisons between three or more groups followed by Tukey post-test.  
Two-way repeated measures ANOVA was used to assess significance in experiments 
with multiple factors, followed by Tukey post test for multiple comparisons.   
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Fig 3-1.  Network analysis.  (A) Principle component analysis of correlation of gene 
expression from RNAseq on rLog() matrix output from DESeq2.  Ellipse denotes 95% 
confidence interval from kmeans clustering of PC1 and PC2 variance.  (B)  Hierarchical 
clustering of rLog() transformed counts.  Euclidean distance, complete clustering.  (C)  
Overlap of significantly induced genes by mTB tRNA, ssRNA and TLR2/1L, defined by 
FC > 2 over Media and FDR < 0.05.  (D)  Top Bio Functions identified by Ingenuity 
Pathway Analysis of significantly induced genes for mTB tRNA, ssRNA or TLR2/1L.  (D)  
Comparison of significantly induced functional pathways induced by mTB tRNA to 
ssRNA or TLR2/1L.  
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Fig 3-2.  Identification of RNA – correlated modules and associated functional 
analysis.  (A) WGCNA eigengene modules correlated to at least one treatment 
condition P<0.05.  Red indicates positive correlation and green inverse correlation.  (B)  
Heatmap of median-centered rLog() normalized counts for genes in MEturquoise 
module.  (C)  Top hits for functional term annotation of WGCNA modules positively 
correlated with mTB tRNA and ssRNA or TLR2/1L signatures.  (D)  Visualization of top 
correlated genes to select genes associated with Th1 response to mTB infection.   
Fig 3-3. (E)  Integrated network of gene expression and functional analysis terms.  
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Fig 3-4.  Analysis of Th1 associated genes and validation in PBMC.  (A) rLog 
normalized counts for select genes at 6h and 24h.  (B)  PBMC were stimulated with 
mTB tRNA, ssRNA or TLR2/1L and cytokine secretion measured at 24h. (n>=20) (C) 
Cytokine secretion at 1h, 6h and 24h from PBMC stimulated as above. (n>=7).  Data 
are represented as mean ± SEM.  
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Fig 3-5.  Role of IL-18 and NK cells.  (A)  PBMC were pre-treated with monoclonal 
anti-IL-18 neutralizing antibody or IgG1 isotype control for 30m before stimulation with 
TLR2/1L, ssRNA or mTB tRNA.  Supernatants were collected at 24h and cytokine 
secretion measured (n=5).  Statistical significance calculated by two-way repeated 
measures ANOVA and multiple comparisons by Tukey post-hoc test. * P < 0.05, 
** P < 0.01.  (B)  PBMC were pre-treated with monoclonal anti-IFN-g neutralizing 
antibody for 30m before stimulation as previous. Cytokine secretion was measured at 
24h (n=3).  Statistics were calculated as above.  (C)  PMBC were depleted of CD56+ 
cells, stimulated as shown and cytokine secretion measured at 24h. (n=3) Statistical 
significance calculated by one-way repeated measures ANOVA and Šidák correction 
applied to comparison between PBMC and CD56 depleted populations. (D)  PBMC 
were stimulated, and BrefeldinA added at 20h to arrest cytokine secretion. Cells were 
collected at 24h, stained with CD3-FITC, CD56-PE and IFN-g-APC and measured by 
Flow cytometry.  IFN-g+ lymphocytes were divided into subpopulations determined by 
CD3/CD56 staining and shown as percentage of parent (IFN-g+) population or (E) 
divided first by CD3/CD56 markers then percent IFN-g+ cells calculated. Data are 
represented as mean ± SEM. 
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Fig 3-6.  Role of TLR8 and synergy with TLR3.  (A)  Inhibition of cytokine response to 
ultra-selective TLR8 agonist TL8-506 by selective TLR8 antagonist VTX-3119.  (B)  
PBMC were pre-treated with TLR8 antagonist or control for 30m before treatment with 
TLR2/1L, ssRNA and mTB tRNA. Cytokine secretion was measured at 24h. (IL-18: n=3; 
IL-12p70 and IFN-g (n=5).  Statistical significance calculated by two-way repeated 
measures ANOVA and multiple comparisons by Tukey post-hoc test. * P < 0.05, 
** P < 0.01.   
Fig 3-7. (C)  PBMC were stimulated with nucleotide oligomers complexed with Dotap 
(endosomal PRR) or Lipofectamine2000 (cytosolic PRR) or synthetic agonists for 24h 
(n>=4).  (D)  PBMC were stimulated with poly I:C, TL8-506 or combination and cytokine 
secretion measured at 24h (n=3).  Statistical significance calculated by one-way 
repeated measures ANOVA and multiple comparisons by Tukey post-test.  Data are 
represented as mean ± SEM. 
Fig 3-8. Gating strategy and representative Flow staining of PBMC stimulated with TLR 
ligands.  
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Figure 3-2: Network analysis of pathways and functions activated by 
tRNA/ssRNA or TLR2/1L
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Figure 3-4: Gene expression and cytokine secretion by PBMC
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Figure 3-5: Role for IL-18 and NK cells
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Figure 3-6: Role of TLR8
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Figure 3-7: Cytokine secretion by nucleic acid PAMP; synergy with TLR3 
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Figure 3-8: IFN-g expression in PBMC
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gene log2FC padj timepoint log2FC padj timepoint log2FC padj timepoint gene description
A2M -2.88 5.61E-04 24h -3.06 4.80E-05 6h -3.36 5.58E-06 24h alpha-2-macroglobulin 
ABCA1 2.30 5.58E-04 24h 1.40 3.63E-02 24h 1.94 1.51E-03 24h ATP-binding cassette, sub-family A (ABC1), member 1 
ABCB5 2.52 1.50E-04 6h 1.98 2.30E-03 24h 0.71 3.58E-01 24h ATP-binding cassette, sub-family B (MDR/TAP), member 5 
ABCC3 0.03 1.00E+00 1h -2.40 1.15E-03 24h -3.37 1.11E-06 24h ATP-binding cassette, sub-family C (CFTR/MRP), member 3 
ABTB2 2.81 5.64E-07 6h 4.24 6.07E-17 24h 4.89 1.14E-22 24h ankyrin repeat and BTB (POZ) domain containing 2 
AC021860.1 0.21 1.00E+00 1h -2.12 1.30E-03 24h -1.33 4.51E-02 6h Uncharacterized protein  
ACER1 -2.00 1.78E-03 24h -1.69 1.53E-03 6h -1.72 2.29E-03 24h alkaline ceramidase 1 
ADAM15 -1.59 3.94E-08 24h -1.81 2.25E-11 6h -1.97 2.31E-13 24h ADAM metallopeptidase domain 15 
ADAM19 0.73 4.05E-01 24h 3.29 9.93E-12 24h 3.30 5.65E-12 24h ADAM metallopeptidase domain 19 
ADAM23 -1.41 1.29E-02 24h -1.35 4.26E-03 6h -1.61 9.49E-04 24h ADAM metallopeptidase domain 23 
ADAM28 -1.61 1.07E-03 24h -1.70 1.41E-04 24h -1.76 5.44E-05 24h ADAM metallopeptidase domain 28 
ADAMTS10 -0.90 3.03E-01 24h -1.67 3.59E-03 6h -2.31 1.97E-05 6h ADAM metallopeptidase with thrombospondin type 1 motif, 10 
ADAMTS14 3.09 7.79E-04 24h 2.20 1.38E-02 24h 1.66 6.73E-02 24h ADAM metallopeptidase with thrombospondin type 1 motif, 14 
ADORA2A 3.20 2.93E-10 6h 3.12 9.73E-11 6h 2.90 1.93E-09 6h adenosine A2a receptor 
ADORA3 -1.88 7.74E-03 24h -4.27 5.66E-13 6h -4.19 5.05E-13 24h adenosine A3 receptor 
ADRA2A 0.31 1.00E+00 1h -1.63 3.63E-02 24h -2.44 8.93E-04 24h adrenoceptor alpha 2A 
ADRA2B 2.67 1.96E-04 1h 0.82 1.00E+00 1h 0.31 7.48E-01 6h adrenoceptor alpha 2B 
ADRB1 1.98 2.39E-02 1h -2.11 3.82E-03 6h -1.69 3.73E-02 24h adrenoceptor beta 1 
ADTRP 2.87 2.01E-09 24h 1.97 4.39E-05 24h 1.77 2.08E-04 24h androgen-dependent TFPI-regulating protein 
AIFM3 -1.45 6.68E-03 24h -1.63 5.16E-04 6h -1.80 1.01E-04 24h apoptosis-inducing factor, mitochondrion-associated, 3 
AIM2 -0.25 8.11E-01 24h 3.05 7.29E-16 24h 3.52 2.04E-21 24h absent in melanoma 2 
AK4 3.86 2.02E-08 6h 3.31 5.47E-07 6h 2.78 3.12E-05 6h adenylate kinase 4 
AK5 -2.00 2.69E-07 6h -1.55 1.63E-05 6h -1.85 3.46E-08 24h adenylate kinase 5 
ALDH1A1 -1.52 1.20E-02 24h -1.52 5.11E-03 24h -1.78 4.65E-04 6h aldehyde dehydrogenase 1 family, member A1 
ALDH2 -1.44 5.97E-03 6h -1.68 1.53E-04 6h -1.57 3.90E-04 6h aldehyde dehydrogenase 2 family (mitochondrial) 
ALDH7A1 -1.52 4.10E-02 6h -1.47 1.54E-02 6h -1.78 2.84E-03 6h aldehyde dehydrogenase 7 family, member A1 
ALOX15B 2.74 3.86E-04 24h 2.68 1.94E-04 24h 2.24 1.79E-03 24h arachidonate 15-lipoxygenase, type B 
ALOXE3 0.12 1.00E+00 1h -2.62 9.03E-04 24h -2.29 5.14E-03 6h arachidonate lipoxygenase 3 
ALS2CL -1.78 4.98E-07 24h -2.30 1.06E-11 24h -2.49 2.46E-14 24h ALS2 C-terminal like 
AMICA1 -1.55 4.83E-04 6h -3.03 4.32E-16 6h -3.60 1.13E-22 6h adhesion molecule, interacts with CXADR antigen 1 
AMOTL2 2.43 1.83E-03 24h 6.29 1.59E-24 6h 6.43 1.03E-25 6h angiomotin like 2 
ANG -1.92 1.00E-02 6h -2.19 5.12E-04 6h -1.89 3.86E-03 24h angiogenin, ribonuclease, RNase A family, 5 
ANGPT1 -1.64 3.45E-02 6h -1.74 5.57E-03 6h 0.42 1.00E+00 1h angiopoietin 1 
ANKRD1 2.94 2.76E-03 24h 4.76 1.09E-08 24h 3.17 2.26E-04 24h ankyrin repeat domain 1 (cardiac muscle) 
ANKRD22 0.18 1.00E+00 1h 3.66 1.54E-07 24h 4.06 2.38E-09 6h ankyrin repeat domain 22 
ANKRD55 -1.51 2.39E-02 24h -1.72 3.15E-03 24h -2.05 1.86E-04 24h ankyrin repeat domain 55 
ANTXR1 0.53 1.00E+00 1h -2.42 9.75E-03 24h -2.43 7.16E-03 24h anthrax toxin receptor 1 
ANXA9 -1.14 1.13E-02 24h -2.37 8.40E-09 24h -2.64 4.41E-11 6h annexin A9 
AP003774.4 -2.62 3.83E-05 24h -1.82 3.61E-03 24h -1.40 1.83E-02 24h HCG1652096, isoform CRA_a; Uncharacterized protein
APCDD1L 2.95 1.22E-03 6h 2.53 5.47E-03 24h 0.97 3.64E-01 24h adenomatosis polyposis coli down-regulated 1-like 
APOBEC3A -1.65 2.73E-02 6h 5.69 8.09E-26 24h 6.10 1.06E-29 24h apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A 
APOBEC3B 0.09 1.00E+00 1h 5.60 3.75E-23 24h 5.71 3.72E-24 24h apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B 
APOC1 -2.11 1.51E-02 6h -2.91 4.18E-05 6h -3.17 6.30E-06 6h apolipoprotein C-I 
APOE -1.99 2.23E-02 6h -2.96 1.97E-05 6h -3.03 9.80E-06 24h apolipoprotein E 
APOL1 0.33 7.44E-01 6h 3.32 1.34E-21 6h 3.49 5.50E-24 6h apolipoprotein L, 1 
APOL6 0.07 1.00E+00 1h 3.39 3.53E-17 6h 3.70 1.39E-20 6h apolipoprotein L, 6 
AQP9 3.05 2.52E-05 24h 3.12 3.41E-06 6h 3.31 6.08E-07 24h aquaporin 9 
ARHGAP23 0.64 4.90E-01 6h 2.81 8.88E-11 6h 3.34 1.51E-14 24h Rho GTPase activating protein 23 
ARHGAP6 0.20 1.00E+00 1h -2.15 3.05E-04 24h -2.84 5.79E-07 24h Rho GTPase activating protein 6 
ARNT2 3.37 3.17E-05 24h 4.76 6.19E-11 24h 5.38 4.93E-14 24h aryl-hydrocarbon receptor nuclear translocator 2 
ASB9 -2.34 3.81E-03 6h -1.65 1.51E-02 6h -1.74 1.29E-02 24h ankyrin repeat and SOCS box containing 9 
ASGR1 -2.23 7.42E-03 6h -3.79 2.39E-08 6h -3.87 1.15E-08 24h asialoglycoprotein receptor 1 
ASGR2 -2.38 1.59E-02 6h -3.42 2.21E-05 24h -3.14 8.55E-05 24h asialoglycoprotein receptor 2 
ASIC1 -0.41 7.92E-01 24h -2.64 2.29E-04 24h -2.58 1.43E-04 24h acid-sensing (proton-gated) ion channel 1 
ATF3 1.44 2.73E-01 1h 3.50 4.75E-11 6h 3.54 2.01E-11 6h activating transcription factor 3 
ATP13A3 3.18 1.25E-08 24h 2.16 9.39E-05 6h 2.03 2.32E-04 6h ATPase type 13A3 
ATP6V0D2 0.32 1.00E+00 1h -2.55 2.37E-03 24h -2.39 2.80E-03 24h ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 
AVPI1 0.35 7.11E-01 24h -1.83 1.10E-05 6h -3.10 3.75E-14 6h arginine vasopressin-induced 1 
AVPR2 -1.11 2.82E-01 6h -2.04 2.64E-03 6h -2.37 4.96E-04 6h arginine vasopressin receptor 2 
AXL -2.65 7.18E-07 24h 2.25 2.77E-06 6h 2.34 7.34E-07 6h AXL receptor tyrosine kinase 
B4GALNT1 2.32 3.36E-02 6h 3.00 6.27E-04 24h 3.15 1.71E-04 24h beta-1,4-N-acetyl-galactosaminyl transferase 1 
BAALC 2.50 1.01E-05 6h 3.15 1.19E-09 24h 2.27 1.88E-05 24h brain and acute leukemia, cytoplasmic 
BASP1 2.38 8.69E-10 24h 2.04 6.87E-08 24h 2.74 4.20E-14 24h brain abundant, membrane attached signal protein 1 
BATF 2.48 5.21E-06 6h 2.99 1.53E-09 6h 3.93 2.86E-16 6h basic leucine zipper transcription factor, ATF-like 
BATF2 0.27 1.00E+00 1h 3.87 2.56E-07 6h 3.88 1.83E-07 6h basic leucine zipper transcription factor, ATF-like 2 
BATF3 1.55 1.51E-02 6h 3.83 4.88E-15 24h 3.75 7.62E-15 6h basic leucine zipper transcription factor, ATF-like 3 
BCAT1 2.70 7.24E-11 24h 1.78 1.60E-05 6h 1.58 1.54E-04 24h branched chain amino-acid transaminase 1, cytosolic 
BCL2A1 2.29 2.02E-04 6h 3.50 5.13E-11 6h 3.94 6.38E-14 6h BCL2-related protein A1 
BCL2L14 1.35 2.20E-02 6h 6.54 7.57E-55 24h 6.98 9.39E-63 24h BCL2-like 14 (apoptosis facilitator) 
BHLHE22 2.56 1.11E-02 1h 4.77 4.38E-14 6h 6.08 2.42E-22 24h basic helix-loop-helix family, member e22 
BMF -1.11 1.10E-03 6h -2.17 1.15E-14 6h -1.62 1.74E-08 24h Bcl2 modifying factor 
BNC2 -0.92 3.26E-01 24h -2.21 7.11E-04 24h -2.05 7.94E-04 24h basonuclin 2 
C10orf10 1.99 2.64E-04 6h 2.91 3.73E-10 6h 4.93 5.23E-29 6h chromosome 10 open reading frame 10 
C10orf105 -3.06 7.94E-05 6h -3.60 4.59E-07 6h -3.46 1.35E-06 6h chromosome 10 open reading frame 105 
C10orf54 0.11 1.00E+00 1h -2.38 2.37E-06 6h -1.85 3.20E-04 6h chromosome 10 open reading frame 54 
C11orf21 -1.42 2.81E-07 24h -1.95 1.62E-14 6h -1.98 5.56E-15 6h chromosome 11 open reading frame 21 
C11orf45 0.46 1.00E+00 1h -2.42 2.25E-03 24h -3.29 1.15E-05 24h chromosome 11 open reading frame 45 
C11orf96 3.60 4.01E-05 6h 3.26 6.30E-05 6h 2.17 1.13E-02 24h chromosome 11 open reading frame 96 
C14orf132 0.09 1.00E+00 1h -2.63 2.97E-06 24h -2.98 2.84E-08 24h chromosome 14 open reading frame 132 
C15orf38 0.52 1.00E+00 1h -2.33 7.22E-04 6h -2.50 2.11E-04 6h chromosome 15 open reading frame 38 
C16orf74 -1.43 4.58E-02 24h -2.50 7.31E-06 6h -3.30 1.36E-09 24h chromosome 16 open reading frame 74 
C19orf35 -0.92 3.21E-01 6h -2.30 2.45E-05 6h -2.52 2.47E-06 6h chromosome 19 open reading frame 35 
C1orf127 -2.84 6.32E-04 24h -3.56 5.90E-06 24h -3.49 3.94E-06 24h chromosome 1 open reading frame 127 
C1orf162 -1.20 2.88E-02 6h -2.15 3.31E-07 6h -2.33 2.23E-08 24h chromosome 1 open reading frame 162 
C1orf173 0.90 1.00E+00 1h 5.48 1.14E-20 6h 6.03 4.38E-25 6h chromosome 1 open reading frame 173 
C1orf204 -0.80 5.48E-01 6h 0.14 1.00E+00 1h -2.28 7.48E-04 24h chromosome 1 open reading frame 204 
C1orf233 -0.25 8.35E-01 24h -2.24 7.42E-07 6h -1.82 7.04E-05 6h chromosome 1 open reading frame 233 
C1QTNF1 6.80 5.01E-33 6h 6.05 4.19E-27 6h 3.79 3.36E-11 24h C1q and tumor necrosis factor related protein 1 
C20orf197 -1.37 1.99E-01 24h -2.00 6.84E-03 6h -2.62 4.23E-04 6h chromosome 20 open reading frame 197 
C22orf42 2.67 1.29E-03 6h 3.29 8.47E-06 24h 2.43 1.05E-03 6h chromosome 22 open reading frame 42 
C2CD4A 3.20 1.80E-06 6h 2.70 2.55E-05 6h 2.75 1.43E-05 6h C2 calcium-dependent domain containing 4A 
C2CD4B 3.51 1.78E-04 6h 2.49 5.36E-03 6h 3.35 7.44E-05 6h C2 calcium-dependent domain containing 4B 
C2orf40 -1.60 1.49E-02 24h -2.82 5.54E-06 24h -3.75 1.88E-09 24h chromosome 2 open reading frame 40 
C2orf66 0.04 9.91E-01 6h 3.49 3.87E-06 6h 3.48 3.56E-06 6h chromosome 2 open reading frame 66 
C5AR2 -1.29 5.56E-02 6h -2.43 1.01E-06 6h -3.10 1.38E-10 6h complement component 5a receptor 2 
C8orf56 2.82 5.45E-03 6h 3.70 1.48E-05 24h 2.73 1.79E-03 24h chromosome 8 open reading frame 56 
M. tuberculosis 19kD lipopeptide ssRNA40M. tuberculosis tRNA
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C9orf139 -1.58 3.69E-02 6h -3.04 2.16E-07 6h -2.69 4.42E-06 6h chromosome 9 open reading frame 139 
C9orf173 0.69 1.00E+00 1h -2.74 2.59E-04 24h -1.73 1.40E-02 24h chromosome 9 open reading frame 173 
CA12 5.64 1.92E-11 24h 3.05 4.74E-04 24h 3.04 3.61E-04 24h carbonic anhydrase XII 
CA4 -1.96 6.31E-02 24h 0.62 1.00E+00 1h -2.02 1.82E-02 24h carbonic anhydrase IV 
CACNA1A 0.20 9.09E-01 6h 4.51 5.97E-25 6h 4.73 1.25E-27 6h calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
CACNA1I -1.79 2.07E-03 24h -2.10 4.93E-05 24h -2.50 5.15E-07 24h calcium channel, voltage-dependent, T type, alpha 1I subunit 
CALHM2 -1.32 6.26E-04 6h -2.32 9.20E-13 6h -2.32 1.14E-12 24h calcium homeostasis modulator 2 
CALY -1.84 3.04E-02 24h -1.75 2.25E-02 24h -2.87 6.18E-05 24h calcyon neuron-specific vesicular protein 
CAMK1 0.46 1.00E+00 1h -3.31 4.22E-06 24h -3.14 7.70E-06 24h calcium/calmodulin-dependent protein kinase I 
CAMK1G 3.74 2.02E-08 6h 5.17 1.14E-17 6h 5.41 1.86E-19 6h calcium/calmodulin-dependent protein kinase IG 
CARD9 -0.49 7.90E-01 6h -3.19 5.01E-07 6h -3.39 6.80E-08 24h caspase recruitment domain family, member 9 
CASP5 2.35 6.14E-04 24h 1.96 2.28E-03 6h 3.03 3.85E-07 6h caspase 5, apoptosis-related cysteine peptidase 
CATSPER1 -1.25 5.32E-02 24h -2.19 2.41E-05 24h -3.07 4.82E-10 24h cation channel, sperm associated 1 
CAV1 2.32 8.89E-04 24h 1.03 1.53E-01 6h 0.44 6.15E-01 6h caveolin 1, caveolae protein, 22kDa 
CCDC65 -1.51 3.90E-06 24h -2.30 2.03E-14 6h -2.58 6.76E-16 24h coiled-coil domain containing 65 
CCDC68 -2.01 3.83E-02 6h -1.80 2.39E-02 6h 0.56 1.00E+00 1h coiled-coil domain containing 68 
CCDC80 2.20 8.30E-03 24h 2.13 5.11E-03 24h 3.38 6.38E-07 24h coiled-coil domain containing 80 
CCL1 5.40 7.20E-10 6h 3.69 2.44E-05 24h 2.85 1.37E-03 24h chemokine (C-C motif) ligand 1 
CCL13 2.91 5.12E-03 6h 2.43 9.09E-03 6h 2.37 9.88E-03 6h chemokine (C-C motif) ligand 13 
CCL15 0.50 8.48E-01 6h 3.33 8.28E-05 24h 2.32 7.92E-03 24h chemokine (C-C motif) ligand 15 
CCL17 3.06 1.44E-03 6h 2.91 1.08E-03 24h 2.02 2.79E-02 24h chemokine (C-C motif) ligand 17 
CCL18 3.59 5.32E-05 6h 3.78 2.88E-06 6h 3.33 4.16E-05 24h chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) 
CCL19 1.41 3.75E-01 6h 4.68 6.88E-08 24h 5.15 1.37E-09 24h chemokine (C-C motif) ligand 19 
CCL2 5.27 1.95E-21 24h 6.10 2.92E-30 6h 6.13 1.42E-30 6h chemokine (C-C motif) ligand 2 
CCL20 3.22 7.95E-03 1h 2.96 1.14E-03 6h 1.59 1.13E-01 6h chemokine (C-C motif) ligand 20 
CCL23 2.88 3.44E-05 6h 2.56 7.70E-05 6h 1.84 5.90E-03 24h chemokine (C-C motif) ligand 23 
CCL25 1.09 1.00E+00 1h 3.35 1.14E-04 24h 2.66 2.40E-03 24h chemokine (C-C motif) ligand 25 
CCL3 3.80 7.64E-07 1h 4.90 7.78E-14 6h 4.68 9.24E-13 6h chemokine (C-C motif) ligand 3 
CCL3L1 3.00 7.87E-03 1h 3.94 9.29E-07 6h 3.44 2.13E-05 6h chemokine (C-C motif) ligand 3-like 1 
CCL3L3 2.93 1.29E-02 1h 3.02 4.07E-04 24h 3.31 6.23E-05 24h chemokine (C-C motif) ligand 3-like 3 
CCL4 3.22 1.32E-04 1h 4.35 1.59E-10 6h 4.33 1.56E-10 6h chemokine (C-C motif) ligand 4 
CCL4L1 3.33 2.03E-05 1h 4.37 1.39E-11 6h 4.21 6.30E-11 6h chemokine (C-C motif) ligand 4-like 1 
CCL4L2 3.51 1.43E-05 1h 2.99 1.86E-05 6h 3.31 7.90E-04 1h chemokine (C-C motif) ligand 4-like 2 
CCL7 4.90 4.06E-12 24h 6.27 2.33E-21 6h 6.13 1.67E-20 6h chemokine (C-C motif) ligand 7 
CCL8 1.56 8.04E-02 6h 7.55 3.02E-37 6h 7.61 6.05E-38 6h chemokine (C-C motif) ligand 8 
CCM2L 3.75 2.96E-05 24h 2.06 2.55E-02 6h 3.68 9.47E-06 6h cerebral cavernous malformation 2-like 
CCNA1 1.69 1.76E-02 6h 4.31 1.01E-15 24h 3.50 1.09E-10 24h cyclin A1 
CCR2 -2.26 8.82E-04 6h -4.49 2.16E-15 6h -4.39 8.56E-15 24h chemokine (C-C motif) receptor 2 
CCSER1 -1.71 3.74E-02 6h 0.89 2.20E-01 6h 1.13 9.78E-02 24h coiled-coil serine-rich protein 1 
CD101 -2.15 3.88E-03 6h -3.24 2.07E-07 24h -3.55 5.47E-09 24h CD101 molecule 
CD163L1 -1.98 2.14E-02 24h -3.51 7.16E-07 24h -1.89 1.05E-02 24h CD163 molecule-like 1 
CD180 -1.99 2.25E-05 24h -2.48 1.20E-08 24h -2.39 2.14E-08 24h CD180 molecule 
CD1B 0.50 8.58E-01 6h -2.11 2.91E-02 6h -2.44 8.54E-03 24h CD1b molecule 
CD1C -2.25 7.33E-03 24h -2.19 3.28E-03 6h -1.94 9.83E-03 6h CD1c molecule 
CD1D -2.36 7.95E-04 24h -1.73 9.61E-03 6h 0.09 1.00E+00 1h CD1d molecule 
CD1E -2.79 6.62E-03 24h -3.41 1.15E-04 6h -3.45 7.73E-05 6h CD1e molecule 
CD248 -0.75 4.10E-01 24h -2.50 2.04E-06 6h -2.73 1.62E-07 6h CD248 molecule, endosialin 
CD27 -1.13 7.80E-04 24h -1.94 2.39E-11 6h -2.40 4.23E-17 24h CD27 molecule 
CD274 2.79 2.94E-07 6h 4.88 1.06E-23 6h 5.18 8.42E-27 6h CD274 molecule 
CD300LB 0.02 1.00E+00 1h -2.11 1.44E-02 6h -2.28 6.46E-03 6h CD300 molecule-like family member b 
CD300LD 0.48 1.00E+00 1h -2.11 1.41E-02 24h 0.73 1.00E+00 1h CD300 molecule-like family member d 
CD302 -1.75 4.71E-04 6h -2.36 1.46E-06 24h -2.47 2.76E-08 6h CD302 molecule 
CD36 -2.97 8.51E-07 6h -3.56 2.23E-10 24h -1.87 1.58E-03 24h CD36 molecule (thrombospondin receptor) 
CD38 0.39 7.57E-01 6h 4.24 2.31E-23 24h 4.46 6.24E-26 24h CD38 molecule 
CD4 -1.91 4.85E-08 24h -2.28 3.62E-12 24h -2.33 6.79E-13 24h CD4 molecule 
CD40 1.01 2.26E-01 6h 3.88 7.16E-15 24h 4.15 4.23E-17 24h CD40 molecule, TNF receptor superfamily member 5 
CD69 0.86 1.00E+00 1h 3.78 4.72E-10 6h 3.66 1.47E-09 6h CD69 molecule 
CD80 2.44 1.31E-03 24h 5.05 1.78E-15 24h 5.29 3.72E-17 24h CD80 molecule 
CD9 -2.24 2.27E-03 24h -2.75 2.18E-05 24h -2.99 2.19E-06 24h CD9 molecule 
CDC42EP5 4.79 1.94E-10 24h 2.30 2.05E-03 6h 3.95 6.58E-08 24h CDC42 effector protein (Rho GTPase binding) 5 
CDH23 -1.51 8.58E-05 24h -1.27 6.92E-04 24h -1.26 4.76E-04 24h cadherin-related 23 
CDH26 -1.40 1.08E-02 6h -1.62 1.88E-03 24h -2.20 3.85E-06 6h cadherin 26 
CDKN1C -1.95 3.56E-02 6h 1.63 4.06E-02 24h 1.32 9.95E-02 24h cyclin-dependent kinase inhibitor 1C (p57, Kip2) 
CEBPA -2.43 3.94E-04 24h -3.37 1.47E-07 24h -3.50 1.31E-08 24h CCAAT/enhancer binding protein (C/EBP), alpha 
CECR1 -1.59 1.62E-10 24h 0.36 1.00E+00 1h 0.98 7.64E-05 6h cat eye syndrome chromosome region, candidate 1 
CFB 1.55 2.28E-01 6h 3.81 2.12E-06 6h 4.34 3.34E-08 24h complement factor B 
CH25H 1.56 9.26E-01 1h 3.73 2.52E-07 24h 3.71 2.07E-07 24h cholesterol 25-hydroxylase 
CHRD -1.95 2.34E-02 6h 0.10 1.00E+00 1h -1.39 4.98E-02 24h chordin 
CHRNA6 3.10 2.42E-07 24h 3.29 4.69E-10 6h 3.61 4.06E-12 6h cholinergic receptor, nicotinic, alpha 6 (neuronal) 
CHST13 -2.81 3.57E-05 24h -3.73 1.21E-08 24h -3.75 2.61E-09 24h carbohydrate (chondroitin 4) sulfotransferase 13 
CHST3 1.21 3.44E-01 24h 3.45 5.50E-06 24h 2.43 1.92E-03 24h carbohydrate (chondroitin 6) sulfotransferase 3 
CKB 2.42 2.00E-04 24h 3.25 2.22E-08 24h 2.96 3.27E-07 24h creatine kinase, brain 
CLCN4 -1.26 3.20E-03 24h -2.32 9.51E-09 24h -2.30 1.22E-09 24h chloride channel, voltage-sensitive 4 
CLEC10A -3.73 3.42E-05 24h -4.06 1.21E-06 24h -4.26 2.05E-07 24h C-type lectin domain family 10, member A 
CLEC12B -1.59 2.84E-02 6h -1.03 1.05E-01 6h -1.54 9.79E-03 6h C-type lectin domain family 12, member B 
CLEC4A 0.50 7.05E-01 24h -1.77 3.59E-03 6h -2.74 1.63E-06 24h C-type lectin domain family 4, member A 
CLEC4F -2.36 1.62E-03 24h 1.37 5.20E-02 24h 0.09 1.00E+00 1h C-type lectin domain family 4, member F 
CLEC9A -2.18 1.23E-02 24h -1.83 1.53E-02 6h -2.14 4.44E-03 6h C-type lectin domain family 9, member A 
CLGN 2.97 3.43E-04 6h 1.28 1.51E-01 6h 0.84 3.91E-01 6h calmegin 
CLTCL1 -1.19 2.39E-02 24h -2.38 1.03E-07 24h -2.61 9.39E-10 24h clathrin, heavy chain-like 1 
CMPK2 0.18 1.00E+00 1h 5.39 7.38E-43 6h 5.66 2.73E-47 24h cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 
CNTNAP2 -1.28 3.48E-02 24h -2.62 6.44E-07 24h -2.48 1.85E-07 6h contactin associated protein-like 2 
COL13A1 0.41 8.41E-01 6h -2.05 7.16E-03 24h -2.31 1.25E-03 24h collagen, type XIII, alpha 1 
COL23A1 0.14 9.56E-01 24h -3.16 1.64E-04 24h -2.91 4.38E-04 24h collagen, type XXIII, alpha 1 
COL26A1 -1.47 4.41E-02 24h -1.99 2.23E-03 24h -2.96 3.16E-06 24h collagen, type XXVI, alpha 1 
COL5A1 0.55 1.00E+00 1h -2.22 8.99E-05 24h -1.21 2.11E-02 24h collagen, type V, alpha 1 
COL6A3 0.12 1.00E+00 1h -2.16 4.25E-04 24h -2.07 4.63E-04 24h collagen, type VI, alpha 3 
COL8A2 -2.12 1.45E-03 24h -1.53 1.48E-02 6h 0.40 1.00E+00 1h collagen, type VIII, alpha 2 
COLEC12 -1.81 4.67E-02 24h -1.95 1.19E-02 24h -2.24 2.17E-03 24h collectin sub-family member 12 
CPED1 -2.43 3.94E-03 6h -2.57 6.25E-04 24h 0.63 1.00E+00 1h cadherin-like and PC-esterase domain containing 1 
CPM 1.78 8.80E-04 6h 2.40 1.90E-07 6h 3.44 7.94E-15 6h carboxypeptidase M 
CPNE7 -0.66 1.00E+00 1h -1.89 7.61E-05 6h -2.33 5.72E-07 6h copine VII 
CREB5 -1.81 1.71E-05 24h -0.88 3.77E-02 6h -1.06 9.63E-03 6h cAMP responsive element binding protein 5 
CRIP3 -1.19 7.69E-02 24h -2.29 6.49E-06 6h -2.51 1.30E-06 6h cysteine-rich protein 3 
CRYBB1 -1.80 4.47E-02 24h -2.51 1.14E-03 24h -3.01 4.71E-05 24h crystallin, beta B1 
CSF1 3.16 2.98E-06 6h 2.56 9.20E-05 24h 2.36 2.61E-04 24h colony stimulating factor 1 (macrophage) 
CSF1R 0.16 9.33E-01 24h -2.29 1.57E-04 24h -2.69 3.93E-06 24h colony stimulating factor 1 receptor 
CSF2 3.97 1.64E-09 6h 4.19 1.39E-11 6h 3.43 4.86E-08 6h colony stimulating factor 2 (granulocyte-macrophage) 
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CSF3 5.60 7.19E-12 6h 5.12 5.74E-11 6h 2.42 4.48E-03 24h colony stimulating factor 3 (granulocyte) 
CSF3R -1.43 4.69E-02 6h -1.20 4.76E-02 6h -1.18 4.77E-02 24h colony stimulating factor 3 receptor (granulocyte) 
CSPG4 -2.05 4.51E-02 24h -2.59 2.82E-03 24h 0.74 1.00E+00 1h chondroitin sulfate proteoglycan 4 
CSRP2 1.37 1.48E-01 6h 3.50 3.66E-09 6h 4.30 9.32E-14 6h cysteine and glycine-rich protein 2 
CST3 -2.27 3.07E-06 24h 0.28 1.00E+00 1h -1.04 3.90E-02 24h cystatin C 
CST6 -3.83 1.21E-05 24h -1.88 4.06E-02 24h -2.53 2.82E-03 24h cystatin E/M 
CTHRC1 2.78 2.94E-03 24h 1.94 3.62E-02 6h 1.77 5.23E-02 24h collagen triple helix repeat containing 1 
CTNND2 2.71 1.53E-03 6h 1.97 1.69E-02 24h 0.57 5.67E-01 24h catenin (cadherin-associated protein), delta 2 
CTSF -0.91 8.53E-02 24h -1.96 6.16E-07 24h -2.79 1.13E-13 24h cathepsin F 
CTSL 3.21 6.03E-08 6h 3.66 3.60E-11 24h 3.19 9.34E-09 24h cathepsin L 
CTTNBP2 -2.57 8.45E-03 6h -3.74 4.94E-06 24h -2.39 4.00E-03 24h cortactin binding protein 2 
CUX2 -1.46 1.19E-02 24h -0.86 9.79E-02 6h -1.04 3.85E-02 6h cut-like homeobox 2 
CX3CR1 -1.81 1.21E-03 6h -2.57 1.40E-07 24h -2.28 2.59E-06 24h chemokine (C-X3-C motif) receptor 1 
CXCL1 5.90 6.38E-21 24h 5.19 3.85E-17 6h 3.46 5.84E-08 24h chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 
CXCL10 -2.58 3.20E-03 24h 5.36 7.59E-14 6h 5.40 3.18E-14 6h chemokine (C-X-C motif) ligand 10 
CXCL11 -2.05 3.74E-02 24h 6.34 1.46E-18 6h 6.43 3.36E-19 6h chemokine (C-X-C motif) ligand 11 
CXCL13 2.77 3.91E-03 24h 3.67 1.02E-05 24h 5.19 5.08E-11 24h chemokine (C-X-C motif) ligand 13 
CXCL2 3.95 1.38E-08 24h 2.89 2.32E-05 6h 2.35 1.34E-01 1h chemokine (C-X-C motif) ligand 2 
CXCL3 4.28 3.05E-08 24h 2.89 1.58E-04 6h 1.77 1.00E+00 1h chemokine (C-X-C motif) ligand 3 
CXCL5 6.67 2.17E-17 24h 4.07 3.30E-07 6h 1.80 4.26E-02 6h chemokine (C-X-C motif) ligand 5 
CXCL6 4.59 4.07E-08 6h 3.43 2.68E-05 6h 1.84 3.85E-02 6h chemokine (C-X-C motif) ligand 6 
CXCL9 -2.38 1.31E-02 24h 4.25 3.78E-08 6h 4.20 4.62E-08 6h chemokine (C-X-C motif) ligand 9 
CXCR1 -1.59 4.97E-02 6h -1.76 6.43E-03 6h -1.77 5.44E-03 6h chemokine (C-X-C motif) receptor 1 
CXCR2 -2.32 2.22E-08 6h -3.13 1.14E-15 6h -3.00 2.03E-14 6h chemokine (C-X-C motif) receptor 2 
CXXC4 0.25 1.00E+00 1h -2.12 2.54E-03 6h -1.97 5.35E-03 6h CXXC finger protein 4 
CYB5R2 2.94 6.24E-05 24h 2.90 2.48E-05 24h 3.26 1.03E-06 24h cytochrome b5 reductase 2 
CYBRD1 -1.94 4.54E-05 6h -2.45 7.73E-09 6h -2.28 8.39E-08 6h cytochrome b reductase 1 
CYP19A1 1.29 3.02E-01 6h 6.17 5.24E-20 6h 7.35 2.15E-28 6h cytochrome P450, family 19, subfamily A, polypeptide 1 
CYP1A1 -1.44 3.23E-01 6h -1.92 4.19E-02 6h -2.31 1.01E-02 6h cytochrome P450, family 1, subfamily A, polypeptide 1 
CYP24A1 0.61 7.76E-01 24h -2.10 2.31E-02 6h -2.47 5.71E-03 6h cytochrome P450, family 24, subfamily A, polypeptide 1 
CYP27B1 3.62 1.69E-06 24h 5.11 9.96E-14 24h 4.98 3.13E-13 24h cytochrome P450, family 27, subfamily B, polypeptide 1 
CYP2J2 0.85 4.16E-01 6h 4.89 2.58E-23 6h 4.98 2.97E-24 6h cytochrome P450, family 2, subfamily J, polypeptide 2 
CYP2S1 0.04 1.00E+00 1h -2.07 5.48E-03 6h -3.12 7.64E-06 6h cytochrome P450, family 2, subfamily S, polypeptide 1 
CYP3A5 2.42 1.69E-04 6h 1.71 4.34E-01 1h 0.17 8.50E-01 24h cytochrome P450, family 3, subfamily A, polypeptide 5 
CYP3A7 1.51 1.80E-01 24h 3.47 4.01E-06 24h 3.02 5.39E-05 24h cytochrome P450, family 3, subfamily A, polypeptide 7 
CYP4F12 0.15 1.00E+00 1h -2.37 2.32E-03 24h -1.90 9.82E-03 24h cytochrome P450, family 4, subfamily F, polypeptide 12 
CYP7B1 1.44 1.70E-01 24h 4.21 3.92E-10 24h 5.44 1.77E-17 24h cytochrome P450, family 7, subfamily B, polypeptide 1 
CYTL1 -1.69 3.81E-02 6h -2.53 1.87E-04 6h -3.29 6.38E-07 24h cytokine-like 1 
DAB2 0.27 8.79E-01 6h -2.62 2.10E-06 24h -3.06 1.05E-08 24h Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) 
DBNDD1 -1.62 5.82E-03 24h -2.62 1.32E-07 6h -2.69 7.90E-07 24h dysbindin (dystrobrevin binding protein 1) domain containing 1 
DBP -1.24 2.30E-02 24h -2.51 4.47E-09 6h -2.49 5.12E-09 6h D site of albumin promoter (albumin D-box) binding protein 
DDX58 0.23 1.00E+00 1h 4.06 9.95E-33 6h 4.27 3.33E-36 6h DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 
DDX60 0.32 1.00E+00 1h 3.73 3.51E-22 6h 3.92 1.34E-24 6h DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 
DDX60L 0.58 3.95E-01 24h 3.30 4.15E-19 6h 3.48 3.47E-21 24h DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like 
DEFB1 -1.33 3.21E-01 6h 6.24 6.74E-18 24h 5.68 5.56E-15 24h defensin, beta 1 
DEPDC7 0.01 1.00E+00 1h -1.53 9.19E-04 6h -2.52 1.57E-07 6h DEP domain containing 7 
DEPTOR -2.17 4.52E-04 24h -3.47 6.60E-09 24h -3.03 6.66E-08 24h DEP domain containing MTOR-interacting protein 
DFNA5 2.86 3.10E-08 24h 1.86 3.90E-04 24h 0.75 2.10E-01 24h deafness, autosomal dominant 5 
DGKI 2.93 3.06E-03 24h 1.40 1.00E+00 1h 0.24 8.63E-01 6h diacylglycerol kinase, iota 
DHRS9 -3.53 1.52E-08 6h -1.51 2.08E-02 6h -2.10 5.85E-04 6h dehydrogenase/reductase (SDR family) member 9 
DHX58 -0.31 5.41E-01 24h 3.51 4.76E-49 24h 3.43 5.82E-47 24h DEXH (Asp-Glu-X-His) box polypeptide 58 
DLL1 3.43 6.69E-11 24h 2.97 3.90E-09 6h 2.99 2.46E-09 6h delta-like 1 (Drosophila) 
DLL4 2.78 6.61E-03 6h 4.00 2.55E-06 24h 4.90 2.14E-09 24h delta-like 4 (Drosophila) 
DNAAF1 2.90 1.96E-04 1h 4.24 9.04E-12 6h 4.59 7.57E-14 6h dynein, axonemal, assembly factor 1 
DNAJB13 -1.38 5.74E-02 24h -2.37 2.13E-04 24h -3.24 2.76E-07 24h DnaJ (Hsp40) homolog, subfamily B, member 13 
DNER 2.76 6.62E-03 24h 0.79 5.04E-01 6h 0.41 7.51E-01 6h delta/notch-like EGF repeat containing 
DOK2 -1.03 1.62E-01 6h -2.13 1.32E-05 6h -2.23 4.15E-06 24h docking protein 2, 56kDa 
DPEP2 -1.50 3.69E-07 24h -2.66 1.06E-23 6h -3.00 5.14E-30 24h dipeptidase 2 
DPEP3 -1.15 9.44E-03 6h -2.14 1.44E-08 6h -2.52 5.83E-11 24h dipeptidase 3 
DRAM1 1.93 1.32E-04 6h 3.20 1.68E-13 6h 3.48 5.77E-16 6h DNA-damage regulated autophagy modulator 1 
DSC1 -1.89 2.16E-03 24h -2.25 1.26E-04 24h -2.60 2.72E-06 24h desmocollin 1 
DUOXA2 0.69 1.00E+00 1h 3.73 2.21E-06 24h 3.22 4.46E-05 24h dual oxidase maturation factor 2 
DUSP5 1.99 2.43E-05 6h 3.73 5.39E-20 6h 4.08 7.51E-24 24h dual specificity phosphatase 5 
DYRK3 2.40 1.71E-05 24h 1.73 2.37E-03 24h 1.61 1.64E-03 6h dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 
EBI3 3.60 1.04E-08 6h 3.86 6.88E-11 24h 4.31 1.22E-13 24h Epstein-Barr virus induced 3 
EDN1 1.72 1.12E-01 1h 3.76 2.55E-11 24h 4.19 3.23E-14 24h endothelin 1 
EDN3 0.22 1.00E+00 1h -2.43 2.55E-05 6h -1.96 5.74E-04 6h endothelin 3 
EDNRB 0.27 9.01E-01 24h -2.07 1.47E-02 24h -2.69 7.01E-04 24h endothelin receptor type B 
EEPD1 -0.41 7.24E-01 6h -2.49 2.02E-08 24h -3.01 2.60E-12 24h endonuclease/exonuclease/phosphatase family domain containing 1 
EFNA1 -0.78 3.41E-02 24h -2.32 5.19E-13 6h -2.91 6.02E-16 6h ephrin-A1 
EGR1 2.79 1.32E-04 1h 1.93 4.10E-01 1h 2.55 1.23E-02 1h early growth response 1 
EGR2 2.34 6.11E-04 1h 0.91 1.69E-01 6h 1.12 1.00E+00 1h early growth response 2 
EGR4 2.34 3.98E-02 1h 0.13 1.00E+00 1h 0.24 1.00E+00 1h early growth response 4 
EHF 2.65 1.05E-03 6h 1.17 1.67E-01 6h 1.49 5.24E-02 24h ets homologous factor 
EIF2AK2 0.27 1.00E+00 1h 3.64 8.18E-36 6h 3.82 3.43E-39 24h eukaryotic translation initiation factor 2-alpha kinase 2 
ELFN2 -1.13 1.25E-01 6h -1.55 1.16E-02 24h -2.36 2.50E-05 6h extracellular leucine-rich repeat and fibronectin type III domain containing 2 
ELOVL7 3.92 1.14E-08 6h 4.06 3.29E-10 6h 3.66 2.41E-08 24h ELOVL fatty acid elongase 7 
EMP1 2.31 1.79E-04 24h 2.59 4.47E-06 24h 2.23 7.85E-05 6h epithelial membrane protein 1 
EMR1 2.43 4.99E-05 6h 2.58 2.07E-06 6h 3.39 1.06E-10 6h egf-like module containing, mucin-like, hormone receptor-like 1 
ENHO -2.36 4.50E-03 24h -2.36 1.39E-03 6h -3.19 1.87E-05 6h energy homeostasis associated 
ENPP2 1.13 2.59E-01 24h 3.21 4.71E-07 24h 5.26 2.06E-18 24h ectonucleotide pyrophosphatase/phosphodiesterase 2 
ENTHD1 2.29 2.40E-02 24h 3.18 1.58E-04 24h 3.76 2.55E-06 24h ENTH domain containing 1 
EPHA1 -1.08 3.90E-02 24h -2.11 1.90E-07 6h -2.15 9.63E-08 6h EPH receptor A1 
EPHB2 -3.12 4.00E-06 24h 0.30 1.00E+00 1h 0.10 1.00E+00 1h EPH receptor B2 
EPHB3 -2.55 2.50E-03 6h -2.89 8.31E-05 6h -2.36 1.47E-03 6h EPH receptor B3 
EPPK1 -1.14 5.43E-02 24h -2.78 7.70E-09 24h -3.23 1.64E-11 6h epiplakin 1 
EPS8 -2.17 6.05E-06 24h -1.59 8.35E-04 24h -1.51 9.44E-04 24h epidermal growth factor receptor pathway substrate 8 
EPSTI1 0.15 1.00E+00 1h 3.77 5.81E-28 6h 3.93 1.57E-30 6h epithelial stromal interaction 1 (breast) 
ERBB3 0.13 1.00E+00 1h -2.43 6.13E-09 6h -3.03 5.11E-13 24h v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 
EREG 3.62 7.12E-07 1h 2.23 9.97E-04 6h 1.11 1.00E+00 1h epiregulin 
ETV3L 2.52 9.27E-03 6h 1.39 1.37E-01 6h 2.90 3.33E-04 6h ets variant 3-like 
ETV5 2.60 2.66E-05 24h 0.66 3.82E-01 6h 2.69 2.31E-06 6h ets variant 5 
ETV7 -1.02 3.55E-01 24h 4.75 2.69E-14 6h 4.92 1.96E-15 6h ets variant 7 
EVPL -0.94 2.07E-01 24h -2.46 1.72E-05 24h -2.62 1.14E-05 6h envoplakin 
EXOC3L4 1.02 1.00E+00 1h 3.46 2.78E-05 24h 3.27 5.71E-05 24h exocyst complex component 3-like 4 
EXT1 0.45 1.00E+00 1h 2.36 2.82E-05 6h 3.45 1.04E-10 6h exostosin glycosyltransferase 1 
F13A1 -2.26 2.58E-02 24h -2.23 1.17E-02 24h -2.09 1.58E-02 24h coagulation factor XIII, A1 polypeptide 
F3 3.58 4.88E-04 1h 3.39 6.37E-05 6h 1.40 1.53E-01 6h coagulation factor III (thromboplastin, tissue factor) 
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FABP3 -1.47 1.04E-01 24h -1.95 7.91E-03 24h -2.31 8.25E-04 6h fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) 
FABP4 -4.04 2.20E-05 6h -3.18 4.70E-04 6h -4.01 3.58E-06 6h fatty acid binding protein 4, adipocyte 
FADS1 0.30 1.00E+00 1h -2.11 6.43E-06 24h -2.01 1.12E-05 6h fatty acid desaturase 1 
FAM124A 3.26 3.48E-06 6h 2.21 2.31E-03 24h 0.85 3.10E-01 24h family with sequence similarity 124A 
FAM13A -1.42 3.81E-02 24h -1.22 4.60E-02 24h 0.09 1.00E+00 1h family with sequence similarity 13, member A 
FAM153C -1.53 4.84E-02 24h -1.79 8.90E-03 24h -1.96 2.11E-03 24h family with sequence similarity 153, member C 
FAM167B -0.95 2.93E-01 24h -1.89 1.88E-03 6h -2.84 1.13E-05 24h family with sequence similarity 167, member B 
FAM198B 0.49 1.00E+00 1h -2.84 9.73E-05 24h -3.20 5.54E-06 24h family with sequence similarity 198, member B 
FAM26F -1.70 1.38E-01 24h 3.56 1.13E-05 24h 2.96 2.88E-04 24h family with sequence similarity 26, member F 
FAM3D -2.85 4.76E-03 24h -3.02 7.23E-04 24h -3.15 3.20E-04 24h family with sequence similarity 3, member D 
FBN2 -1.89 9.06E-03 6h -2.66 1.53E-05 24h -1.85 2.78E-03 6h fibrillin 2 
FBXL16 -1.30 3.80E-03 24h -2.38 2.50E-10 6h -2.65 1.95E-12 24h F-box and leucine-rich repeat protein 16 
FBXO6 0.36 6.22E-01 6h 3.27 3.09E-29 6h 3.43 2.60E-32 6h F-box protein 6 
FCER1A -2.36 9.79E-05 6h -2.24 5.69E-05 6h -2.30 2.75E-05 6h Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide 
FCGR2B -1.63 1.62E-02 24h -1.62 7.19E-03 24h -1.69 3.62E-03 24h Fc fragment of IgG, low affinity IIb, receptor (CD32) 
FCGR2C -1.87 2.41E-02 24h -3.46 3.41E-07 24h -2.00 4.19E-03 24h Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene) 
FCGR3B -1.59 6.04E-03 6h 0.51 1.00E+00 1h 0.56 1.00E+00 1h Fc fragment of IgG, low affinity IIIb, receptor (CD16b) 
FCRL4 3.08 1.01E-04 24h 2.92 1.16E-04 24h 3.85 4.69E-08 24h Fc receptor-like 4 
FERMT2 3.03 2.47E-08 6h 3.03 3.25E-09 6h 2.17 4.57E-05 6h fermitin family member 2 
FFAR2 2.57 3.39E-04 1h 3.29 1.15E-08 6h 4.21 5.03E-14 6h free fatty acid receptor 2 
FFAR3 1.54 1.35E-01 24h 2.47 8.46E-04 6h 4.05 3.93E-09 6h free fatty acid receptor 3 
FFAR4 -2.06 1.86E-02 24h -1.82 2.39E-02 24h -2.03 7.88E-03 6h free fatty acid receptor 4 
FGD4 0.42 1.00E+00 1h -1.73 1.65E-04 24h -2.28 1.39E-07 6h FYVE, RhoGEF and PH domain containing 4 
FGF2 2.85 2.61E-03 6h 1.43 1.00E+00 1h 1.07 3.02E-01 6h fibroblast growth factor 2 (basic) 
FGFBP2 -1.48 5.34E-02 24h -2.49 3.04E-05 24h -3.13 5.03E-08 24h fibroblast growth factor binding protein 2 
FGL2 -2.40 3.54E-04 6h 0.20 1.00E+00 1h 0.47 1.00E+00 1h fibrinogen-like 2 
FILIP1L 0.62 1.00E+00 1h -2.19 4.05E-06 6h -2.58 5.24E-08 6h filamin A interacting protein 1-like 
FJX1 3.26 1.73E-06 6h 4.48 2.73E-13 6h 6.32 2.82E-26 6h four jointed box 1 (Drosophila) 
FLRT2 2.50 2.30E-02 24h 0.83 1.00E+00 1h 0.28 1.00E+00 1h fibronectin leucine rich transmembrane protein 2 
FLT1 2.61 3.64E-03 6h 2.42 2.41E-03 6h 2.42 2.13E-03 6h fms-related tyrosine kinase 1 
FN1 -4.87 3.51E-08 24h -4.20 8.93E-07 24h -3.27 1.64E-04 24h fibronectin 1 
FNDC4 3.12 1.01E-03 6h 1.16 2.68E-01 6h 1.04 3.21E-01 6h fibronectin type III domain containing 4 
FOLR2 -1.99 2.15E-02 24h 0.25 1.00E+00 1h -1.71 2.26E-02 24h folate receptor 2 (fetal) 
FOS 0.42 1.00E+00 1h -3.19 6.22E-06 6h -3.27 2.69E-06 6h FBJ murine osteosarcoma viral oncogene homolog 
FOXRED2 -1.46 3.86E-02 24h -2.08 3.64E-04 24h -1.62 5.06E-03 24h FAD-dependent oxidoreductase domain containing 2 
FPR2 3.03 3.71E-05 24h 2.36 8.54E-04 6h 3.67 2.95E-08 6h formyl peptide receptor 2 
FRMD3 0.46 1.00E+00 1h 3.12 4.45E-18 6h 3.96 3.98E-29 6h FERM domain containing 3 
FRMD7 4.44 1.50E-07 1h 2.39 6.63E-03 24h 3.02 1.63E-04 24h FERM domain containing 7 
FSD1L 2.46 9.56E-06 24h 4.05 6.69E-17 6h 5.49 7.20E-31 6h fibronectin type III and SPRY domain containing 1-like 
FUCA1 -1.82 1.98E-02 6h -3.68 8.57E-10 6h -4.25 6.12E-13 24h fucosidase, alpha-L- 1, tissue 
FXYD6 0.09 1.00E+00 1h 2.52 1.40E-03 6h 3.41 5.23E-06 6h FXYD domain containing ion transport regulator 6 
G0S2 3.16 3.66E-04 6h 3.39 2.12E-05 6h 3.69 2.14E-06 6h G0/G1switch 2 
GAL3ST2 3.39 6.83E-05 24h 2.87 3.04E-04 6h 4.00 1.77E-07 24h galactose-3-O-sulfotransferase 2 
GAL3ST4 -1.23 1.94E-01 6h -1.91 2.96E-03 6h -2.37 1.21E-04 6h galactose-3-O-sulfotransferase 4 
GALNT14 0.26 9.02E-01 6h -2.26 9.40E-04 24h -1.09 1.03E-01 24h UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 14
GALNT9 -0.94 4.24E-01 24h -2.45 1.49E-03 24h -1.72 1.95E-02 24h UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 9
GAPT 0.63 1.00E+00 1h -2.25 7.67E-05 24h -2.84 1.99E-07 24h GRB2-binding adaptor protein, transmembrane 
GATM -1.71 2.57E-02 24h -1.81 7.27E-03 24h -1.36 4.27E-02 24h glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
GBA3 3.77 2.17E-05 6h 1.93 3.65E-02 6h 2.58 2.78E-03 6h glucosidase, beta, acid 3 (gene/pseudogene) 
GBP1 1.28 6.20E-01 1h 4.59 7.56E-18 6h 4.87 3.43E-20 6h guanylate binding protein 1, interferon-inducible 
GBP4 0.33 7.90E-01 6h 3.82 1.00E-20 6h 4.07 1.62E-23 6h guanylate binding protein 4 
GBP5 0.34 8.11E-01 6h 4.30 7.34E-22 6h 4.63 2.05E-25 6h guanylate binding protein 5 
GBP6 0.82 4.45E-01 24h 3.36 3.44E-09 24h 3.00 1.09E-07 24h guanylate binding protein family, member 6 
GBP7 1.01 3.61E-01 6h 3.89 1.85E-11 6h 4.20 2.36E-13 6h guanylate binding protein 7 
GCGR 3.22 7.65E-04 24h 2.15 2.47E-02 24h 4.00 1.71E-06 24h glucagon receptor 
GCH1 1.53 1.09E-02 6h 3.77 3.44E-16 6h 3.85 6.62E-17 6h GTP cyclohydrolase 1 
GCKR 4.03 1.14E-06 6h 2.22 8.90E-03 6h 2.11 1.40E-02 24h glucokinase (hexokinase 4) regulator 
GCNT1 -1.82 8.49E-05 24h 0.25 6.93E-01 6h 0.42 4.53E-01 6h glucosaminyl (N-acetyl) transferase 1, core 2 
GEM 2.42 5.84E-04 6h 2.74 1.04E-05 6h 2.13 1.37E-03 24h GTP binding protein overexpressed in skeletal muscle 
GFRA2 -2.09 2.05E-02 24h -3.01 8.86E-05 24h -3.40 3.75E-06 24h GDNF family receptor alpha 2 
GGT5 2.94 1.48E-03 24h 4.33 6.23E-08 24h 2.78 8.19E-04 24h gamma-glutamyltransferase 5 
GJA3 3.54 3.14E-06 6h 3.69 1.66E-07 6h 2.46 8.40E-04 6h gap junction protein, alpha 3, 46kDa 
GJA4 0.69 7.75E-01 6h 5.11 7.45E-10 24h 4.76 8.03E-09 24h gap junction protein, alpha 4, 37kDa 
GJB2 5.08 6.52E-11 24h 4.36 5.73E-09 6h 3.11 6.13E-05 24h gap junction protein, beta 2, 26kDa 
GJB6 -0.84 3.12E-01 6h -2.10 4.67E-05 6h -3.38 1.77E-09 24h gap junction protein, beta 6, 30kDa 
GLIS3 2.65 8.19E-04 24h 0.91 2.96E-01 6h 0.19 1.00E+00 1h GLIS family zinc finger 3 
GMPR -0.84 2.04E-01 6h 4.95 3.53E-37 24h 4.52 3.42E-31 24h guanosine monophosphate reductase 
GOLGA7B 0.17 1.00E+00 1h -2.23 9.12E-04 24h -0.97 1.43E-01 24h Golgin subfamily A member 7B; cDNA FLJ43465 fis, clone OCBBF2036476  
GPBAR1 -1.76 6.04E-03 6h -1.41 1.68E-02 24h -1.61 3.46E-03 24h G protein-coupled bile acid receptor 1 
GPC4 -2.65 5.79E-04 24h -2.03 2.91E-03 6h -2.19 1.12E-03 6h glypican 4 
GPNMB -0.26 9.26E-01 6h -3.10 4.46E-05 24h -3.85 1.31E-07 24h glycoprotein (transmembrane) nmb 
GPR133 0.33 1.00E+00 1h -2.56 6.52E-04 24h -2.46 4.58E-04 6h G protein-coupled receptor 133 
GPR146 -1.54 7.17E-03 24h -1.70 1.64E-03 24h -1.91 1.34E-04 24h G protein-coupled receptor 146 
GPR162 0.24 1.00E+00 1h -3.05 1.47E-05 6h -2.79 7.51E-05 6h G protein-coupled receptor 162 
GPR31 1.91 3.81E-02 6h 3.63 1.26E-07 6h 1.98 7.59E-03 6h G protein-coupled receptor 31 
GPR34 -2.54 1.86E-04 6h -2.79 1.78E-05 24h -2.62 2.61E-05 24h G protein-coupled receptor 34 
GPR42 1.51 2.15E-01 24h 2.57 2.59E-03 24h 3.48 8.60E-06 24h G protein-coupled receptor 42 (gene/pseudogene) 
GUCY2D 0.12 1.00E+00 1h -2.26 9.79E-03 24h -2.13 1.10E-02 24h guanylate cyclase 2D, membrane (retina-specific) 
HAL -1.46 2.37E-03 6h -1.77 1.83E-05 6h -2.13 2.64E-07 6h histidine ammonia-lyase 
HAMP 2.99 1.91E-05 6h 1.96 4.14E-03 6h 3.69 3.07E-09 6h hepcidin antimicrobial peptide 
HAS1 4.27 1.45E-06 6h 3.05 4.19E-04 6h 2.99 4.73E-04 6h hyaluronan synthase 1 
HAS2 1.33 3.26E-01 24h 3.12 1.30E-04 6h 3.53 7.99E-06 6h hyaluronan synthase 2 
HBEGF 2.38 4.01E-05 6h 1.22 8.22E-01 1h -1.78 1.23E-03 6h heparin-binding EGF-like growth factor 
HELZ2 0.30 8.03E-01 6h 4.08 6.48E-27 6h 4.62 2.00E-34 24h helicase with zinc finger 2, transcriptional coactivator 
HERC5 0.21 8.18E-01 24h 5.02 1.96E-54 24h 5.32 2.02E-61 24h HECT and RLD domain containing E3 ubiquitin protein ligase 5 
HERC6 0.26 5.92E-01 24h 4.48 2.25E-96 24h 4.85 7.82E-113 24h HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 
HES1 3.41 1.15E-07 6h 2.53 5.91E-05 6h 2.44 1.34E-04 24h hes family bHLH transcription factor 1 
HES4 0.85 5.18E-01 24h 5.13 3.54E-15 24h 4.40 2.04E-11 24h hes family bHLH transcription factor 4 
HESX1 -0.99 2.68E-01 24h 5.81 9.05E-40 6h 6.08 1.25E-43 6h HESX homeobox 1 
HEY1 4.13 1.64E-09 6h 1.16 1.84E-01 24h 0.78 3.78E-01 24h hes-related family bHLH transcription factor with YRPW motif 1 
HGF -3.07 1.63E-12 6h -1.55 4.19E-04 24h -1.70 3.70E-05 24h hepatocyte growth factor (hepapoietin A; scatter factor) 
HKDC1 -1.68 3.18E-04 24h -2.06 8.18E-06 24h -2.39 4.34E-08 24h hexokinase domain containing 1 
HLA-DMA -1.98 8.15E-05 24h -1.22 1.46E-02 6h -1.61 6.78E-04 24h major histocompatibility complex, class II, DM alpha 
HLA-DMB -1.98 2.72E-03 24h -1.63 7.50E-03 6h -1.94 9.12E-04 6h major histocompatibility complex, class II, DM beta 
HLA-DPA1 -1.53 2.78E-03 24h 0.26 6.87E-01 24h 0.22 1.00E+00 1h major histocompatibility complex, class II, DP alpha 1 
HLA-DPB1 -1.60 4.20E-04 24h 0.22 1.00E+00 1h -0.99 2.47E-02 24h major histocompatibility complex, class II, DP beta 1 
HLA-DQB1 -1.44 3.23E-03 24h -0.36 5.46E-01 6h -0.92 4.84E-02 24h major histocompatibility complex, class II, DQ beta 1 
HLA-DQB2 -1.60 4.51E-03 24h -0.50 4.34E-01 6h 0.10 1.00E+00 1h major histocompatibility complex, class II, DQ beta 2 
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HLA-DRB1 -1.51 4.57E-03 24h 0.45 1.00E+00 1h 0.13 1.00E+00 1h major histocompatibility complex, class II, DR beta 1 
HLA-DRB5 -1.59 4.28E-03 24h -0.33 6.35E-01 6h 0.19 1.00E+00 1h major histocompatibility complex, class II, DR beta 5 
HNF1B 0.43 1.00E+00 1h 2.17 2.18E-02 6h 3.77 1.07E-05 6h HNF1 homeobox B 
HR -2.02 9.38E-03 6h -2.42 2.22E-04 6h -3.47 1.44E-07 6h hair growth associated 
HRH1 2.54 2.99E-05 6h 1.51 1.27E-02 6h 0.61 3.99E-01 6h histamine receptor H1 
HS3ST2 0.77 1.00E+00 1h -3.74 1.34E-05 24h -4.46 8.33E-08 24h heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
HS3ST3B1 2.47 2.96E-07 6h 2.40 1.20E-07 6h 1.47 2.18E-03 6h heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 
HSD11B1 1.26 3.98E-01 6h 3.09 2.39E-04 24h 4.87 4.83E-10 24h hydroxysteroid (11-beta) dehydrogenase 1 
HSD17B3 -1.60 3.63E-02 6h -2.06 2.44E-03 24h -2.21 5.48E-04 24h hydroxysteroid (17-beta) dehydrogenase 3 
HSPG2 -1.25 1.06E-01 6h -2.28 6.30E-05 24h -1.90 7.47E-04 6h heparan sulfate proteoglycan 2 
HTRA1 -1.03 5.75E-01 6h -2.61 3.27E-03 6h -2.50 4.49E-03 24h HtrA serine peptidase 1 
IDO1 2.07 5.02E-04 24h 5.71 7.43E-31 6h 5.60 6.88E-30 6h indoleamine 2,3-dioxygenase 1 
IER3 2.52 2.07E-04 6h 1.96 2.19E-03 6h 1.13 1.04E-01 6h immediate early response 3 
IER5L -1.44 1.30E-01 1h -3.18 1.05E-09 24h -2.99 2.57E-09 24h immediate early response 5-like 
IFI27 0.35 1.00E+00 1h 6.71 2.84E-24 24h 6.19 8.74E-21 24h interferon, alpha-inducible protein 27 
IFI30 -1.80 1.23E-03 1h -0.63 2.45E-01 6h -0.40 4.73E-01 24h interferon, gamma-inducible protein 30 
IFI35 0.08 1.00E+00 1h 3.64 1.71E-24 24h 3.74 4.55E-26 6h interferon-induced protein 35 
IFI44 0.02 1.00E+00 1h 4.60 1.79E-28 24h 4.67 2.06E-29 24h interferon-induced protein 44 
IFI44L 0.34 8.13E-01 24h 5.55 2.22E-27 24h 5.85 1.75E-30 24h interferon-induced protein 44-like 
IFI6 0.09 1.00E+00 1h 5.53 1.93E-40 24h 5.25 1.81E-36 24h interferon, alpha-inducible protein 6 
IFIH1 0.42 1.00E+00 1h 3.94 4.13E-37 6h 4.12 2.12E-40 24h interferon induced with helicase C domain 1 
IFIT1 0.41 1.00E+00 1h 6.06 2.66E-33 24h 6.13 4.56E-34 24h interferon-induced protein with tetratricopeptide repeats 1 
IFIT1B 0.23 9.35E-01 24h 4.19 2.98E-08 24h 4.24 7.73E-09 24h interferon-induced protein with tetratricopeptide repeats 1B 
IFIT2 0.19 1.00E+00 1h 5.21 1.29E-30 6h 5.69 1.90E-36 24h interferon-induced protein with tetratricopeptide repeats 2 
IFIT3 0.36 1.00E+00 1h 5.44 3.31E-32 24h 5.64 1.28E-34 24h interferon-induced protein with tetratricopeptide repeats 3 
IFIT5 -0.18 8.79E-01 6h 3.39 1.63E-24 6h 3.62 6.60E-28 24h interferon-induced protein with tetratricopeptide repeats 5 
IFITM1 0.48 4.44E-01 6h 4.04 3.12E-41 24h 3.55 4.89E-32 24h interferon induced transmembrane protein 1 
IFITM3 0.08 1.00E+00 1h 4.58 4.17E-32 24h 4.42 5.34E-30 6h interferon induced transmembrane protein 3 
IFNA1 0.10 1.00E+00 1h 6.15 1.61E-16 6h 5.08 2.24E-11 6h interferon, alpha 1 
IFNA10 0.53 1.00E+00 1h 5.26 5.66E-11 6h 4.84 1.97E-09 6h interferon, alpha 10 
IFNA13 -0.32 1.00E+00 1h 5.05 1.56E-10 6h 4.28 9.30E-08 6h interferon, alpha 13 
IFNA14 0.15 9.66E-01 6h 5.70 5.16E-12 6h 5.74 2.71E-12 6h interferon, alpha 14 
IFNA16 0.95 1.00E+00 1h 6.62 7.97E-21 6h 5.72 1.43E-15 6h interferon, alpha 16 
IFNA17 -0.17 1.00E+00 1h 6.14 5.85E-16 6h 5.28 6.12E-12 6h interferon, alpha 17 
IFNA2 0.28 9.11E-01 24h 5.76 1.15E-14 6h 5.32 1.08E-12 6h interferon, alpha 2 
IFNA21 0.00 1.00E+00 6h 6.35 4.73E-17 6h 5.58 2.52E-13 6h interferon, alpha 21 
IFNA4 0.10 1.00E+00 1h 5.93 7.83E-16 6h 5.51 9.21E-14 6h interferon, alpha 4 
IFNA5 0.31 1.00E+00 1h 5.45 7.28E-16 6h 4.95 3.49E-13 6h interferon, alpha 5 
IFNA6 0.05 1.00E+00 1h 5.88 1.63E-13 6h 5.15 1.36E-10 6h interferon, alpha 6 
IFNA7 0.55 8.33E-01 6h 6.26 6.45E-17 6h 5.77 1.71E-14 6h interferon, alpha 7 
IFNA8 -0.39 8.73E-01 24h 6.93 1.13E-21 6h 6.19 2.17E-17 6h interferon, alpha 8 
IFNB1 0.45 1.00E+00 1h 6.58 3.38E-21 6h 6.69 5.49E-22 6h interferon, beta 1, fibroblast 
IFNG 1.01 3.71E-01 6h 8.74 7.69E-52 6h 8.16 2.29E-45 6h interferon, gamma 
IFNL1 0.23 9.27E-01 24h 3.52 3.86E-06 6h 2.64 8.14E-04 6h interferon, lambda 1 
IFNW1 0.15 9.55E-01 24h 6.26 4.14E-19 6h 6.09 3.79E-18 6h interferon, omega 1 
IGF2 1.94 9.08E-02 6h 2.11 1.66E-02 6h 5.23 1.02E-12 6h insulin-like growth factor 2 (somatomedin A) 
IGFBP4 0.11 9.54E-01 6h 3.62 2.47E-16 24h 3.44 5.68E-15 24h insulin-like growth factor binding protein 4 
IGFBP6 -1.39 1.85E-01 24h 0.40 1.00E+00 1h -1.98 1.17E-02 6h insulin-like growth factor binding protein 6 
IGFN1 4.75 2.67E-09 24h 2.53 2.10E-03 6h 0.19 8.82E-01 24h immunoglobulin-like and fibronectin type III domain containing 1 
IGHV1OR15-1 -1.57 1.64E-03 24h -1.36 2.55E-03 6h -1.84 2.61E-05 24h immunoglobulin heavy variable 1/OR15-1 (non-functional) 
IGLON5 3.18 4.46E-07 6h 2.43 7.51E-05 6h 1.94 2.41E-03 6h IgLON family member 5 
IGSF22 -1.45 3.98E-02 6h -0.99 9.17E-02 6h -2.02 6.03E-04 6h immunoglobulin superfamily, member 22 
IL10 2.89 3.74E-09 6h 2.82 1.34E-09 6h 5.03 5.92E-30 6h interleukin 10 
IL12A 0.22 9.27E-01 6h 3.00 2.63E-06 6h 3.58 8.47E-09 6h interleukin 12A (natural killer cell stimulatory factor 1) 
IL12B 2.82 5.99E-03 6h 5.14 4.50E-10 6h 5.44 2.64E-11 6h interleukin 12B (natural killer cell stimulatory factor 2) 
IL12RB2 0.56 4.83E-01 6h 3.54 2.01E-21 6h 3.63 1.70E-22 24h interleukin 12 receptor, beta 2 
IL13 3.04 2.03E-04 24h 3.00 4.66E-05 6h 2.82 1.88E-04 24h interleukin 13 
IL15RA 1.70 6.05E-04 6h 4.68 7.87E-31 6h 4.43 7.85E-28 6h interleukin 15 receptor, alpha 
IL17A 3.58 1.60E-04 6h 1.85 6.13E-02 6h 1.64 1.01E-01 6h interleukin 17A 
IL17F 4.14 3.23E-06 24h 3.29 1.31E-04 6h 2.57 3.67E-03 6h interleukin 17F 
IL19 3.83 3.20E-05 6h 2.64 3.07E-03 6h 2.74 1.75E-03 6h interleukin 19 
IL1A 3.21 1.33E-03 6h 3.39 1.30E-04 6h 1.99 3.69E-02 6h interleukin 1, alpha 
IL1B 2.55 2.27E-02 6h 2.61 5.20E-03 6h 2.17 2.25E-02 6h interleukin 1, beta 
IL1RN 3.00 3.11E-06 6h 5.40 1.59E-21 24h 5.85 2.52E-25 24h interleukin 1 receptor antagonist 
IL22 3.52 7.17E-05 6h 3.73 6.61E-06 24h 2.99 3.52E-04 24h interleukin 22 
IL26 0.51 8.20E-01 6h 4.62 3.35E-11 24h 2.94 5.71E-05 24h interleukin 26 
IL27 0.59 7.11E-01 6h 5.83 4.15E-24 6h 6.39 4.90E-29 6h interleukin 27 
IL2RA 2.77 2.11E-06 24h 4.54 3.21E-18 24h 4.61 7.33E-19 24h interleukin 2 receptor, alpha 
IL31RA 0.74 1.00E+00 1h 3.21 2.01E-05 6h 2.92 1.11E-04 6h interleukin 31 receptor A 
IL36B 2.82 3.84E-03 6h 2.88 1.10E-03 24h 0.46 7.14E-01 6h interleukin 36, beta 
IL36G 4.37 1.27E-06 6h 4.36 2.16E-07 6h 3.63 2.03E-05 6h interleukin 36, gamma 
IL36RN 5.13 2.68E-11 24h 5.53 4.11E-14 24h 3.03 1.05E-04 24h interleukin 36 receptor antagonist 
IL5RA 0.23 1.00E+00 1h -2.78 1.00E-04 24h -2.14 1.02E-03 24h interleukin 5 receptor, alpha 
IL6 6.56 1.20E-23 6h 7.78 9.53E-35 6h 7.34 5.08E-31 6h interleukin 6 (interferon, beta 2) 
IL7 2.74 1.22E-06 24h 3.41 8.26E-12 6h 4.54 1.08E-19 24h interleukin 7 
IL8 4.08 2.96E-07 24h 3.52 3.92E-06 6h 1.50 1.00E+00 1h interleukin 8 
INHBA 4.19 4.06E-10 6h 5.23 3.98E-17 6h 3.55 3.64E-08 24h inhibin, beta A 
INSM1 2.91 1.51E-03 6h 2.23 8.97E-03 6h 3.38 1.92E-05 6h insulinoma-associated 1 
INSR 0.37 1.00E+00 1h -2.15 2.35E-05 24h -1.22 2.07E-02 6h insulin receptor 
IQCD 0.36 1.00E+00 1h -2.84 3.00E-04 24h -3.09 3.87E-05 24h IQ motif containing D 
IRAK2 2.31 1.30E-04 6h 2.58 1.88E-06 6h 2.09 1.46E-04 6h interleukin-1 receptor-associated kinase 2 
IRF7 0.04 9.82E-01 6h 3.75 1.43E-20 24h 3.44 1.55E-17 6h interferon regulatory factor 7 
IRG1 3.70 2.23E-07 6h 7.71 4.01E-34 6h 7.82 3.01E-35 6h immunoresponsive 1 homolog (mouse) 
ISG15 0.04 1.00E+00 1h 6.11 1.74E-32 24h 5.55 5.47E-27 24h ISG15 ubiquitin-like modifier 
ISG20 -0.36 6.36E-01 24h 4.37 1.18E-39 24h 3.93 3.54E-32 24h interferon stimulated exonuclease gene 20kDa 
ISLR 1.15 5.27E-01 6h 3.61 4.86E-05 24h 4.17 9.87E-07 24h immunoglobulin superfamily containing leucine-rich repeat 
ISM1 -1.99 6.19E-03 24h -1.79 9.30E-03 24h -1.68 7.90E-03 24h isthmin 1, angiogenesis inhibitor 
ITGA11 -3.26 6.02E-04 24h -2.86 1.41E-03 24h -2.87 8.94E-04 24h integrin, alpha 11 
ITGB5 -1.18 2.42E-01 24h -2.80 3.49E-05 24h -3.41 1.39E-07 24h integrin, beta 5 
ITGB8 5.50 5.78E-36 24h 5.11 1.13E-32 6h 5.13 2.80E-32 24h integrin, beta 8 
KANK1 2.93 1.21E-03 6h 2.06 1.61E-02 6h 1.18 2.12E-01 6h KN motif and ankyrin repeat domains 1 
KCNC3 0.16 1.00E+00 1h -2.33 1.97E-06 24h -1.77 2.95E-04 6h potassium voltage-gated channel, Shaw-related subfamily, member 3 
KCNE1L 3.47 3.50E-07 24h 6.39 6.33E-26 24h 4.92 1.34E-15 24h KCNE1-like 
KCNE3 -1.05 1.20E-01 6h -3.06 1.55E-11 6h -3.76 8.01E-17 6h potassium voltage-gated channel, Isk-related family, member 3 
KCNG1 0.06 1.00E+00 1h -1.98 3.70E-10 6h -2.29 2.03E-12 6h potassium voltage-gated channel, subfamily G, member 1 
KCNH3 -1.26 3.86E-04 6h -1.96 2.99E-10 6h -2.46 1.58E-14 6h potassium voltage-gated channel, subfamily H (eag-related), member 3 
KCNJ2 3.55 6.68E-09 1h 3.95 7.59E-14 6h 4.51 4.88E-18 6h potassium inwardly-rectifying channel, subfamily J, member 2 
KCNJ5 -1.96 3.02E-02 24h -2.06 9.33E-03 24h -2.84 1.22E-04 24h potassium inwardly-rectifying channel, subfamily J, member 5 
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KCNK17 0.28 1.00E+00 1h -2.57 7.00E-05 6h -3.13 4.29E-06 6h potassium channel, subfamily K, member 17 
KCNQ1 -1.68 3.29E-03 6h -1.82 3.09E-04 24h -2.25 2.42E-06 24h potassium voltage-gated channel, KQT-like subfamily, member 1 
KCTD14 0.42 1.00E+00 1h 4.24 3.92E-09 24h 4.47 3.10E-10 6h potassium channel tetramerization domain containing 14 
KIAA0319 2.87 7.06E-04 24h 0.93 3.60E-01 24h 0.50 6.34E-01 24h KIAA0319 
KIAA1199 2.80 2.92E-03 24h 4.11 3.38E-07 24h 5.36 5.12E-12 24h KIAA1199 
KIAA1211 3.39 5.40E-12 6h 2.17 1.18E-05 6h 3.27 1.68E-12 24h KIAA1211 
KIAA1217 1.03 1.00E+00 1h 3.36 1.75E-07 6h 3.62 1.22E-08 6h KIAA1217 
KIAA1549L 1.47 1.00E+00 1h 1.42 1.83E-01 6h 3.88 9.11E-06 6h KIAA1549-like 
KIAA1644 1.80 4.77E-02 24h 2.55 5.00E-04 24h 4.49 6.15E-12 24h KIAA1644 
KLHL3 -1.43 2.26E-03 24h -2.18 1.45E-07 24h -1.87 3.59E-06 24h kelch-like family member 3 
KREMEN1 2.41 4.01E-05 6h 2.22 4.60E-05 6h 2.64 5.44E-07 6h kringle containing transmembrane protein 1 
KRT2 -1.50 1.51E-02 6h -2.84 1.68E-07 6h -3.56 1.70E-09 6h keratin 2 
KRT72 -1.67 4.18E-02 24h -2.24 8.35E-04 24h -3.02 1.79E-06 24h keratin 72 
KRT73 -1.53 3.64E-02 24h -2.28 1.38E-04 6h -2.88 1.16E-06 6h keratin 73 
LAG3 0.67 2.16E-01 6h 4.82 4.13E-53 24h 4.54 3.44E-47 24h lymphocyte-activation gene 3 
LAMA3 0.47 1.00E+00 1h 4.36 6.61E-07 24h 3.37 1.59E-04 24h laminin, alpha 3 
LAMB2 0.22 1.00E+00 1h -2.44 1.35E-03 6h -2.49 9.04E-04 6h laminin, beta 2 (laminin S) 
LAMB3 2.80 7.61E-11 6h 2.66 7.79E-11 6h 3.04 3.68E-14 6h laminin, beta 3 
LAMC2 2.94 3.91E-06 24h 0.98 2.22E-01 24h 0.72 3.62E-01 24h laminin, gamma 2 
LAMP3 1.98 3.47E-08 24h 4.39 7.38E-43 6h 4.69 4.16E-49 24h lysosomal-associated membrane protein 3 
LCN8 -1.70 1.36E-01 24h -3.10 1.91E-04 6h -3.25 8.12E-05 6h lipocalin 8 
LCNL1 -1.65 5.58E-02 6h -1.24 5.33E-02 24h -1.81 3.02E-03 24h lipocalin-like 1 
LDHAL6B 2.52 8.22E-03 24h 2.27 7.59E-03 6h 1.68 6.40E-02 24h lactate dehydrogenase A-like 6B 
LDLRAD3 1.20 8.69E-02 24h 1.12 4.94E-02 6h 3.43 1.68E-12 24h low density lipoprotein receptor class A domain containing 3 
LDLRAP1 -1.10 8.63E-05 24h -2.01 2.27E-16 6h -2.45 2.94E-24 24h low density lipoprotein receptor adaptor protein 1 
LEPREL2 -0.76 3.12E-01 24h -1.69 5.37E-04 6h -2.47 7.02E-07 24h leprecan-like 2 
LGALS3BP 0.13 1.00E+00 1h 3.26 1.06E-32 24h 2.98 1.29E-27 6h lectin, galactoside-binding, soluble, 3 binding protein 
LGR6 -0.69 1.25E-01 24h -1.76 1.08E-07 24h -2.69 3.89E-17 24h leucine-rich repeat containing G protein-coupled receptor 6 
LIF 2.69 1.75E-05 1h 2.87 1.00E-07 6h 2.93 4.20E-08 6h leukemia inhibitory factor 
LIFR 0.58 1.00E+00 1h 3.06 2.46E-04 24h 3.38 2.33E-05 24h leukemia inhibitory factor receptor alpha 
LILRA3 2.46 5.60E-04 24h 2.45 1.67E-04 6h 3.66 2.55E-09 6h leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3 
LILRA5 2.19 9.11E-05 24h 2.96 4.11E-09 24h 4.00 1.80E-16 24h leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5 
LINC00346 4.17 5.00E-07 1h 3.00 2.47E-04 24h 2.00 1.00E+00 1h long intergenic non-protein coding RNA 346 
LINGO3 -0.74 2.96E-01 24h -2.48 2.45E-08 24h -2.50 8.83E-09 6h leucine rich repeat and Ig domain containing 3 
LIPA -1.44 3.32E-02 24h -0.91 1.56E-01 24h 0.29 1.00E+00 1h lipase A, lysosomal acid, cholesterol esterase 
LIPG 0.51 8.24E-01 24h 0.94 4.17E-01 24h 3.47 7.46E-05 24h lipase, endothelial 
LIPM 0.07 1.00E+00 1h 2.73 1.14E-03 24h 3.35 2.82E-05 6h lipase, family member M 
LPAR6 -1.64 6.88E-05 6h -1.19 2.30E-03 6h -1.54 4.00E-05 24h lysophosphatidic acid receptor 6 
LPPR3 0.22 1.00E+00 1h -2.27 6.65E-03 24h -1.75 3.24E-02 24h hsa-mir-3187 
LRP1 0.11 1.00E+00 1h -2.98 8.35E-06 24h -2.34 5.69E-04 6h low density lipoprotein receptor-related protein 1 
LRP5 -1.82 5.66E-05 24h -2.54 3.80E-09 24h -2.00 1.47E-06 24h low density lipoprotein receptor-related protein 5 
LRRC26 0.25 1.00E+00 1h 0.71 1.00E+00 1h -2.50 1.96E-03 6h leucine rich repeat containing 26 
LRRC31 2.43 2.35E-02 24h 0.83 1.00E+00 1h 0.21 1.00E+00 1h leucine rich repeat containing 31 
LRRC38 4.45 4.63E-09 24h 2.10 1.42E-02 24h 0.37 1.00E+00 1h leucine rich repeat containing 38 
LRRC4 -1.02 3.06E-01 6h -2.27 1.68E-04 6h -2.11 4.53E-04 24h leucine rich repeat containing 4 
LRRC6 -1.45 2.00E-02 6h -1.13 3.17E-02 6h -1.62 1.92E-03 6h leucine rich repeat containing 6 
LTBP2 0.58 7.13E-01 24h -2.92 3.41E-05 24h -2.80 5.06E-05 24h latent transforming growth factor beta binding protein 2 
LY6E 0.03 1.00E+00 1h 4.28 1.43E-23 24h 3.85 3.38E-19 24h lymphocyte antigen 6 complex, locus E 
LY86 -1.93 4.31E-03 24h 0.35 1.00E+00 1h -1.61 8.15E-03 24h lymphocyte antigen 86 
LYNX1 -1.91 3.23E-06 24h 0.21 1.00E+00 1h 0.14 1.00E+00 1h Ly6/neurotoxin 1 
LYZ 0.49 1.00E+00 1h -2.44 1.95E-03 24h -2.60 6.49E-04 24h lysozyme 
M1AP -1.90 6.21E-03 24h -2.56 8.00E-05 24h -3.56 3.38E-08 24h meiosis 1 associated protein 
MACC1 2.00 1.66E-04 24h 2.92 9.85E-11 6h 3.89 4.97E-18 24h metastasis associated in colon cancer 1 
MAMLD1 3.05 2.66E-08 24h 2.99 3.68E-09 6h 2.26 2.34E-05 24h mastermind-like domain containing 1 
MAP1LC3A 2.79 3.82E-05 24h 1.85 6.16E-03 24h 1.56 2.09E-02 24h microtubule-associated protein 1 light chain 3 alpha 
MARC1 -1.82 1.76E-02 6h -2.05 1.32E-03 24h -2.25 1.81E-04 24h mitochondrial amidoxime reducing component 1 
MARCH1 -1.40 9.41E-03 6h -1.41 2.39E-03 6h 0.42 4.66E-01 6h membrane-associated ring finger (C3HC4) 1, E3 ubiquitin protein ligase 
MARVELD1 -2.15 2.83E-05 24h -3.39 2.26E-12 24h -3.49 6.86E-14 24h MARVEL domain containing 1 
MAS1 4.72 2.09E-08 24h 3.71 9.60E-06 24h 3.70 6.29E-06 24h MAS1 oncogene 
MDK -1.02 3.07E-01 24h 3.22 5.82E-08 24h 2.83 1.86E-06 24h midkine (neurite growth-promoting factor 2) 
MDS2 -1.85 6.78E-05 24h -1.32 3.38E-03 6h -1.56 2.94E-04 24h myelodysplastic syndrome 2 translocation associated 
MEF2C -1.57 4.07E-08 6h -1.38 9.92E-07 24h -1.50 2.28E-08 6h myocyte enhancer factor 2C 
MET 5.25 5.89E-16 24h 3.08 3.15E-06 6h 1.01 2.01E-01 6h met proto-oncogene 
METTL7A -1.62 6.77E-07 6h -2.90 1.57E-21 24h -2.29 2.04E-14 24h methyltransferase like 7A 
METTL7B 2.46 1.11E-02 24h 1.36 1.70E-01 24h 0.49 6.59E-01 24h methyltransferase like 7B 
MGST2 -1.64 1.53E-03 24h -2.07 7.40E-06 6h -2.50 2.81E-08 24h microsomal glutathione S-transferase 2 
MITF 0.31 1.00E+00 1h 0.10 1.00E+00 1h -2.39 3.32E-06 6h microphthalmia-associated transcription factor 
MMP1 4.36 1.93E-06 24h 1.87 5.92E-02 6h 0.66 5.88E-01 6h matrix metallopeptidase 1 (interstitial collagenase) 
MMP10 5.12 9.89E-10 6h 2.81 1.12E-03 6h 0.51 6.85E-01 6h matrix metallopeptidase 10 (stromelysin 2) 
MMP14 4.65 2.60E-48 6h 3.51 2.98E-28 6h 2.69 8.85E-17 6h matrix metallopeptidase 14 (membrane-inserted) 
MMP19 3.76 3.27E-15 24h 2.74 8.89E-09 24h 1.55 2.10E-03 24h matrix metallopeptidase 19 
MMP2 -1.68 9.54E-02 6h -2.19 3.85E-03 6h -2.32 1.78E-03 6h matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) 
MMP28 0.16 1.00E+00 1h -3.35 2.32E-06 24h -3.98 5.89E-09 24h matrix metallopeptidase 28 
MMP7 4.72 7.11E-15 6h 3.48 1.06E-08 24h 1.80 5.30E-03 6h matrix metallopeptidase 7 (matrilysin, uterine) 
MMP9 2.41 2.16E-02 24h 0.37 1.00E+00 1h -2.30 1.03E-02 24h matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) 
MNDA -3.07 1.52E-10 6h 0.04 9.60E-01 24h 0.50 4.00E-01 24h myeloid cell nuclear differentiation antigen 
MPZL2 -1.73 7.99E-03 24h -2.15 3.33E-04 24h -1.54 7.63E-03 24h myelin protein zero-like 2 
MRC1L1 1.01 6.22E-01 6h -2.87 2.14E-03 24h -3.20 3.84E-04 24h cDNA FLJ56855, highly similar to Macrophage mannose receptor 1  
MRC2 -1.64 3.84E-03 24h -2.24 6.50E-06 24h -2.64 3.50E-08 24h mannose receptor, C type 2 
MS4A12 0.42 1.00E+00 1h 4.16 3.49E-07 6h 4.10 4.53E-07 6h membrane-spanning 4-domains, subfamily A, member 12 
MS4A2 -2.05 1.23E-02 6h -1.45 3.65E-02 6h -2.23 1.56E-03 6h membrane-spanning 4-domains, subfamily A, member 2 
MS4A6A -3.18 5.58E-10 24h -2.80 1.25E-08 6h -3.01 6.81E-10 24h membrane-spanning 4-domains, subfamily A, member 6A 
MSANTD3 2.52 8.79E-13 24h 1.67 3.18E-06 24h 0.39 3.77E-01 24h Myb/SANT-like DNA-binding domain containing 3 
MSC 2.44 2.13E-03 6h 2.30 1.38E-03 24h 1.47 5.06E-02 24h musculin 
MSR1 -3.06 3.47E-08 24h 1.94 4.41E-04 24h 2.09 9.30E-05 6h macrophage scavenger receptor 1 
MSX2 0.10 1.00E+00 1h -1.78 1.21E-02 24h -2.66 1.00E-04 24h msh homeobox 2 
MT1M 1.79 1.63E-01 24h 3.56 8.78E-05 24h 2.86 1.79E-03 24h metallothionein 1M 
MUC1 0.26 8.99E-01 6h 3.38 1.99E-09 24h 3.16 1.77E-08 24h mucin 1, cell surface associated 
MUC8 -1.95 2.94E-02 24h -2.63 9.71E-04 24h -2.65 5.03E-04 24h mucin 8 
MUCL1 1.72 1.52E-01 24h 3.28 1.02E-04 24h 1.81 4.81E-02 24h mucin-like 1 
MX1 0.05 1.00E+00 1h 5.51 1.46E-50 24h 5.54 6.09E-51 24h myxovirus (influenza virus) resistance 1, interferon-inducible protein p78
MX2 0.01 1.00E+00 1h 4.33 2.38E-75 24h 4.53 1.30E-82 24h myxovirus (influenza virus) resistance 2 
MYBPH 3.23 1.01E-04 24h 0.45 7.09E-01 24h 1.77 3.30E-02 6h myosin binding protein H 
MYCL -2.05 1.01E-03 6h -3.75 2.98E-12 24h -4.06 7.16E-15 6h v-myc avian myelocytomatosis viral oncogene lung carcinoma derived homolog 
MYO1B 3.86 1.12E-07 24h 3.38 1.66E-06 24h 3.00 1.95E-05 24h myosin IB 
MYO7A -0.63 6.31E-01 24h -2.31 4.97E-04 24h 0.08 9.43E-01 6h myosin VIIA 
NAMPT 2.89 2.67E-06 24h 2.32 8.60E-05 6h 2.85 6.14E-07 6h nicotinamide phosphoribosyltransferase 
NAMPTL 2.65 7.21E-04 24h 2.10 4.48E-03 6h 2.65 1.71E-04 6h nicotinamide phosphoribosyltransferase-like 
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NDP 5.78 1.28E-12 6h 3.79 2.96E-06 6h 2.56 2.94E-03 6h Norrie disease (pseudoglioma) 
NEFH 2.77 2.05E-03 24h 2.66 1.23E-03 24h 2.09 1.17E-02 24h neurofilament, heavy polypeptide 
NEXN 0.22 1.00E+00 1h 5.17 1.70E-33 24h 5.47 9.36E-38 24h nexilin (F actin binding protein) 
NFAM1 -1.50 3.56E-02 6h -1.93 6.24E-04 6h -2.24 4.18E-05 6h NFAT activating protein with ITAM motif 1 
NFKBIA 2.52 2.20E-05 1h 1.98 1.70E-04 6h 1.97 1.51E-04 6h nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
NFKBIZ 2.66 1.49E-04 1h 2.27 1.54E-04 6h 2.91 4.40E-07 6h nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 
NFXL1 -2.07 1.28E-04 6h -3.16 3.64E-11 24h -2.69 1.50E-08 24h nuclear transcription factor, X-box binding-like 1 
NGF 2.35 4.41E-02 6h 1.90 5.74E-02 24h 1.25 2.30E-01 24h nerve growth factor (beta polypeptide) 
NHS -1.82 3.02E-02 6h -2.28 1.35E-03 24h -2.01 3.48E-03 6h Nance-Horan syndrome (congenital cataracts and dental anomalies) 
NHSL2 -1.29 1.62E-01 6h -2.35 2.71E-04 24h -2.00 1.64E-03 24h NHS-like 2 
NIPAL1 -1.81 1.42E-02 24h -1.77 8.90E-03 24h -1.69 8.16E-03 24h NIPA-like domain containing 1 
NKAIN1 0.51 1.00E+00 1h 2.94 6.47E-04 6h 3.87 1.92E-06 6h Na+/K+ transporting ATPase interacting 1 
NLRP12 -0.73 4.44E-01 6h -2.94 2.16E-09 6h -3.19 5.86E-11 6h NLR family, pyrin domain containing 12 
NLRP3 2.90 3.39E-04 1h 1.83 1.10E-02 6h 1.88 7.47E-03 24h NLR family, pyrin domain containing 3 
NME8 -1.40 3.63E-03 24h 0.14 8.17E-01 6h 0.12 8.52E-01 6h NME/NM23 family member 8 
NMUR1 -2.00 9.15E-06 24h -4.18 4.50E-18 24h -4.06 2.77E-19 24h neuromedin U receptor 1 
NOG -0.67 3.48E-01 24h -2.65 2.00E-10 6h -3.13 2.62E-14 6h noggin 
NOTCH3 3.62 1.42E-05 24h 0.04 1.00E+00 1h -1.93 2.24E-02 6h notch 3 
NPTX1 -0.38 1.00E+00 1h -2.53 2.66E-06 24h -3.07 2.49E-09 6h neuronal pentraxin I 
NRCAM -2.26 1.26E-02 6h -3.31 9.68E-06 24h -2.81 1.50E-04 6h neuronal cell adhesion molecule 
NRG1 0.27 1.00E+00 1h -4.06 8.33E-08 6h -4.00 1.40E-07 24h neuregulin 1 
NRIP3 2.54 1.29E-07 6h 1.73 3.32E-04 24h 1.24 1.21E-02 24h nuclear receptor interacting protein 3 
NRXN2 1.95 1.36E-03 6h 2.32 1.09E-05 6h 4.44 9.46E-20 6h neurexin 2 
NT5C3A 0.14 8.91E-01 24h 4.13 1.02E-40 6h 4.26 1.66E-43 6h 5'-nucleotidase, cytosolic IIIA 
NT5DC2 1.01 2.67E-01 24h -2.33 9.73E-05 24h -3.22 1.28E-08 24h 5'-nucleotidase domain containing 2 
OAS1 -1.13 1.49E-02 24h 4.77 4.31E-43 24h 4.58 8.67E-40 24h 2'-5'-oligoadenylate synthetase 1, 40/46kDa 
OAS2 0.13 1.00E+00 1h 3.84 5.51E-31 24h 4.14 5.68E-36 24h 2'-5'-oligoadenylate synthetase 2, 69/71kDa 
OAS3 0.22 1.00E+00 1h 4.83 5.68E-32 6h 5.32 1.00E-38 24h 2'-5'-oligoadenylate synthetase 3, 100kDa 
OASL -0.24 8.32E-01 24h 4.68 4.90E-31 24h 4.47 2.07E-28 24h 2'-5'-oligoadenylate synthetase-like 
OCM -1.51 3.81E-03 6h -2.21 1.04E-06 6h -2.46 3.16E-07 24h oncomodulin 
OCSTAMP 3.01 3.73E-03 6h 1.16 2.82E-01 24h 0.22 1.00E+00 1h osteoclast stimulatory transmembrane protein 
OLFM1 -2.96 1.05E-04 24h -4.94 1.38E-12 24h -6.48 5.86E-21 24h olfactomedin 1 
OLFM2 -0.81 9.90E-04 24h -2.29 5.61E-25 6h -2.68 1.42E-30 6h olfactomedin 2 
OLFML3 -3.32 4.51E-05 24h -2.22 4.86E-03 24h -2.30 1.92E-03 24h olfactomedin-like 3 
OLIG2 3.06 1.15E-03 24h 2.25 1.17E-02 6h 0.76 4.90E-01 6h oligodendrocyte lineage transcription factor 2 
OR2B11 3.27 2.36E-03 1h 1.64 8.88E-02 6h 1.60 9.00E-02 6h olfactory receptor, family 2, subfamily B, member 11 
OR2W3 -1.56 4.67E-02 24h -0.50 1.00E+00 1h 0.14 8.71E-01 6h olfactory receptor, family 2, subfamily W, member 3 
OSM 2.55 7.03E-05 6h 1.68 8.09E-03 24h 0.88 1.00E+00 1h oncostatin M 
OTOF 0.09 1.00E+00 1h 5.53 1.47E-20 24h 5.75 2.29E-22 24h otoferlin 
P2RX7 1.34 1.16E-01 6h 3.00 2.16E-07 6h 3.52 4.53E-10 6h purinergic receptor P2X, ligand-gated ion channel, 7 
PACSIN1 -1.31 2.44E-04 24h -2.35 2.06E-13 6h -2.46 3.48E-14 6h protein kinase C and casein kinase substrate in neurons 1 
PALD1 -2.79 2.10E-06 24h -3.28 4.09E-09 24h -3.52 7.88E-11 24h phosphatase domain containing, paladin 1 
PAPLN 2.88 1.42E-05 24h 1.85 5.76E-03 24h 0.26 7.66E-01 24h papilin, proteoglycan-like sulfated glycoprotein 
PARP9 0.23 1.00E+00 1h 3.24 4.61E-28 6h 3.40 6.94E-31 24h poly (ADP-ribose) polymerase family, member 9 
PCOLCE -0.90 1.49E-01 6h -2.05 1.75E-06 6h -2.38 3.25E-08 6h procollagen C-endopeptidase enhancer 
PDCD1LG2 0.87 5.54E-01 6h 2.73 8.90E-05 6h 3.80 1.04E-08 6h programmed cell death 1 ligand 2 
PDGFA 1.89 4.71E-03 6h 1.58 8.46E-03 6h 3.48 1.46E-10 24h platelet-derived growth factor alpha polypeptide 
PDGFC 0.34 1.00E+00 1h -2.40 2.32E-05 24h -2.37 1.48E-05 24h platelet derived growth factor C 
PDGFRL 1.77 4.53E-02 24h 7.06 3.15E-31 24h 7.27 2.54E-33 24h platelet-derived growth factor receptor-like 
PDK4 -4.25 7.11E-10 6h -3.75 8.94E-09 6h -4.34 2.47E-11 6h pyruvate dehydrogenase kinase, isozyme 4 
PDPN 3.47 6.20E-09 6h 1.56 1.34E-02 6h 0.95 1.69E-01 6h podoplanin 
PFKFB3 2.32 1.38E-07 6h 2.41 5.33E-09 6h 2.87 1.30E-12 6h 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
PGAP1 0.26 8.43E-01 24h 3.72 1.18E-17 6h 4.18 1.49E-21 24h post-GPI attachment to proteins 1 
PGBD5 -1.46 4.89E-02 6h 0.35 1.00E+00 1h 0.37 6.29E-01 24h piggyBac transposable element derived 5 
PGLYRP2 -0.12 9.47E-01 24h -1.56 2.42E-02 6h -2.33 7.26E-04 6h peptidoglycan recognition protein 2 
PGM5 -2.15 6.35E-04 6h -1.37 9.06E-03 6h -1.46 6.62E-03 6h phosphoglucomutase 5 
PHLDA2 2.29 3.43E-03 6h 2.01 4.58E-03 24h 1.35 6.77E-02 24h pleckstrin homology-like domain, family A, member 2 
PHOSPHO1 -1.34 3.83E-02 24h -3.12 8.23E-09 24h -3.22 4.13E-10 24h phosphatase, orphan 1 
PI16 -1.34 1.77E-02 24h -3.24 6.62E-12 6h -3.21 2.47E-11 6h peptidase inhibitor 16 
PI3 3.49 1.48E-04 24h 2.19 1.78E-02 24h 1.21 2.26E-01 24h peptidase inhibitor 3, skin-derived 
PITPNM2 -1.46 1.12E-05 24h -2.26 1.55E-13 24h -2.28 2.85E-14 24h phosphatidylinositol transfer protein, membrane-associated 2 
PLA1A 0.76 1.00E+00 1h 4.45 6.52E-08 24h 4.25 1.94E-07 24h phospholipase A1 member A 
PLAC9 -0.81 3.58E-01 6h -2.60 4.81E-05 24h -2.04 4.20E-04 24h placenta-specific 9 
PLAT 2.48 1.74E-05 24h 2.59 1.58E-06 24h 2.39 8.24E-06 24h plasminogen activator, tissue 
PLAUR 2.62 7.35E-05 24h 2.19 4.97E-04 6h 1.68 9.19E-03 24h plasminogen activator, urokinase receptor 
PLB1 -1.70 2.13E-02 24h -2.14 7.53E-04 24h -2.09 6.29E-04 24h phospholipase B1 
PLD1 3.31 8.96E-18 24h 1.95 1.09E-06 24h 1.62 5.47E-05 24h phospholipase D1, phosphatidylcholine-specific 
PLEK2 0.34 8.64E-01 6h -1.57 2.16E-02 6h -2.56 5.98E-05 24h pleckstrin 2 
PLEKHA6 -1.46 4.42E-02 24h 0.31 6.80E-01 6h 0.76 2.16E-01 6h pleckstrin homology domain containing, family A member 6 
PLEKHG7 0.76 1.00E+00 1h 3.38 1.12E-10 6h 3.73 5.13E-13 6h pleckstrin homology domain containing, family G (with RhoGef domain) member 7 
PLLP -0.98 3.04E-02 24h -3.23 3.48E-17 6h -3.74 5.95E-18 24h plasmolipin 
PLSCR1 1.53 3.47E-08 24h 3.43 4.83E-44 6h 3.72 1.15E-51 24h phospholipid scramblase 1 
PLSCR4 0.63 7.52E-01 6h 4.32 4.43E-12 6h 4.78 7.36E-15 6h phospholipid scramblase 4 
PML -0.49 2.27E-01 24h 3.19 3.05E-39 6h 3.38 2.69E-44 6h promyelocytic leukemia 
PMP22 2.19 2.55E-02 24h 0.21 1.00E+00 1h -2.26 6.38E-03 6h peripheral myelin protein 22 
PNPLA1 3.09 4.06E-12 6h 2.09 2.10E-06 6h 1.17 1.47E-02 6h patatin-like phospholipase domain containing 1 
PNPT1 0.41 6.07E-01 24h 3.52 5.14E-23 6h 3.56 1.09E-23 6h polyribonucleotide nucleotidyltransferase 1 
PODN -1.42 4.49E-02 24h -1.72 7.16E-03 24h -2.07 1.61E-04 6h podocan 
PP13439 2.46 3.72E-03 24h 1.24 1.90E-01 24h 1.35 1.20E-01 24h
PPAP2B 3.01 4.98E-07 24h 1.01 1.44E-01 24h 0.64 3.87E-01 6h phosphatidic acid phosphatase type 2B 
PPBP 3.13 9.13E-04 6h 0.46 7.06E-01 6h 0.10 1.00E+00 1h pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) 
PPFIA4 -1.63 1.68E-02 24h -3.21 1.68E-07 24h -2.83 9.58E-07 24h protein tyrosine phosphatase, receptor type, f polypeptide, interacting protein, alpha 4 
PRAM1 -1.21 2.01E-01 6h -2.58 2.51E-05 6h -2.86 1.85E-06 6h PML-RARA regulated adaptor molecule 1 
PRLR 1.48 8.61E-02 24h 4.02 3.30E-11 24h 4.46 6.00E-14 24h prolactin receptor 
PROC -3.03 1.12E-07 24h -2.77 1.04E-06 24h -3.43 6.24E-10 24h protein C (inactivator of coagulation factors Va and VIIIa) 
PRR16 2.57 1.57E-04 6h 2.06 1.24E-03 6h 1.83 4.30E-03 6h proline rich 16 
PRRT1 -0.92 9.44E-02 6h -1.83 4.89E-06 6h -2.48 8.43E-10 24h proline-rich transmembrane protein 1 
PRSS23 -1.66 1.57E-08 24h -2.42 2.98E-16 24h -2.50 4.64E-19 24h protease, serine, 23 
PRSS36 -1.22 1.42E-01 24h -2.55 3.28E-05 24h -3.14 7.70E-08 24h protease, serine, 36 
PRUNE2 -1.64 3.22E-03 24h 0.45 1.00E+00 1h 0.17 7.85E-01 24h prune homolog 2 (Drosophila) 
PSRC1 -1.41 3.95E-03 6h -2.75 1.72E-09 24h -3.31 2.91E-13 24h proline/serine-rich coiled-coil 1 
PTGDR 0.04 1.00E+00 1h -2.17 1.28E-05 24h -2.35 5.77E-07 24h prostaglandin D2 receptor (DP) 
PTGES 2.92 5.57E-05 24h 1.50 5.27E-02 24h 0.41 1.00E+00 1h prostaglandin E synthase 
PTGFRN -2.61 1.54E-03 6h -5.04 1.72E-13 6h -5.21 1.78E-14 6h prostaglandin F2 receptor inhibitor 
PTGS2 3.84 1.88E-05 1h 3.66 2.26E-06 6h 3.40 1.13E-05 24h prostaglandin-endoperoxide synthase 2
PTPRU 0.41 7.87E-01 24h 3.47 9.75E-10 24h 3.41 8.38E-10 24h protein tyrosine phosphatase, receptor type, U 
PTRF -1.81 1.51E-02 6h 0.26 1.00E+00 1h -0.88 2.12E-01 24h polymerase I and transcript release factor 
PTX3 2.71 5.97E-03 6h 2.95 4.96E-04 6h 5.22 2.91E-11 6h pentraxin 3, long 
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PVRL4 2.93 5.58E-04 24h 1.04 2.82E-01 24h 0.14 9.04E-01 24h poliovirus receptor-related 4 
RAB37 -1.43 1.58E-03 24h -2.04 2.61E-07 24h -2.24 6.68E-09 24h RAB37, member RAS oncogene family 
RAB3A 0.35 1.00E+00 1h -2.16 1.42E-07 6h -1.87 8.41E-06 24h RAB3A, member RAS oncogene family 
RAB3C 0.05 1.00E+00 1h -2.26 1.50E-02 24h -2.30 1.02E-02 24h RAB3C, member RAS oncogene family 
RAB3D 0.18 8.78E-01 24h -2.26 2.99E-08 6h -2.14 1.52E-07 6h RAB3D, member RAS oncogene family 
RAB3IL1 0.32 9.00E-01 6h -2.38 2.09E-03 24h -1.64 3.57E-02 24h RAB3A interacting protein (rabin3)-like 1 
RAB42 -0.29 9.09E-01 6h -1.68 3.59E-02 24h -2.41 9.76E-04 24h RAB42, member RAS oncogene family 
RAPGEF2 0.83 2.35E-01 24h 2.48 2.45E-08 6h 3.58 6.00E-17 24h Rap guanine nucleotide exchange factor (GEF) 2 
RASAL1 -1.15 3.81E-01 24h -2.67 7.77E-04 6h -3.16 3.97E-05 6h RAS protein activator like 1 (GAP1 like) 
RBMS2 -1.54 9.65E-03 6h 0.31 6.56E-01 24h 0.23 7.26E-01 24h RNA binding motif, single stranded interacting protein 2 
RBP7 -2.45 6.20E-04 6h -2.85 6.91E-06 6h -3.28 2.02E-07 6h retinol binding protein 7, cellular 
RCBTB2 -1.66 1.91E-04 6h -2.07 1.61E-07 6h -2.36 1.22E-09 6h regulator of chromosome condensation and BTB domain containing protein 2 
RCN3 -1.17 1.90E-01 6h -2.87 6.30E-07 6h -2.94 2.52E-07 6h reticulocalbin 3, EF-hand calcium binding domain 
REPS2 -1.18 5.23E-04 24h -2.20 8.63E-12 24h -1.91 1.18E-10 6h RALBP1 associated Eps domain containing 2 
RET 0.60 6.92E-01 6h 2.40 1.19E-04 24h 3.44 1.77E-09 24h ret proto-oncogene 
RGS1 1.25 4.02E-02 24h 4.29 3.89E-22 6h 4.18 5.05E-21 24h regulator of G-protein signaling 1 
RGS14 0.00 1.00E+00 1h -2.44 2.43E-08 6h -2.72 2.38E-10 6h regulator of G-protein signaling 14 
RGS16 2.84 4.07E-12 6h 3.04 3.12E-15 6h 3.38 7.78E-19 6h regulator of G-protein signaling 16 
RGS18 -1.47 2.61E-03 6h -2.25 2.21E-07 24h -1.75 4.20E-05 24h regulator of G-protein signaling 18 
RHBDL1 -1.40 1.22E-02 24h -1.25 7.04E-03 6h -1.20 1.37E-02 24h rhomboid, veinlet-like 1 (Drosophila) 
RHOBTB1 -1.91 3.81E-03 24h -1.72 5.68E-03 24h -2.01 5.61E-04 24h Rho-related BTB domain containing 1 
RIMBP2 -2.26 4.29E-02 24h 0.11 1.00E+00 1h -2.23 1.58E-02 24h RIMS binding protein 2 
RIMBP3 -1.42 1.62E-02 24h -2.15 1.51E-04 24h -2.05 7.66E-05 24h RIMS binding protein 3 
RIN2 2.39 7.67E-05 6h 3.45 6.17E-11 6h 3.98 1.88E-14 6h Ras and Rab interactor 2 
RIPK2 1.22 4.97E-02 6h 3.29 1.16E-13 6h 2.96 2.99E-11 6h receptor-interacting serine-threonine kinase 2 
RNASE1 -3.98 1.81E-05 24h -4.60 7.90E-08 24h -5.06 1.59E-09 24h ribonuclease, RNase A family, 1 (pancreatic) 
RNASE6 -2.04 1.10E-03 6h -3.58 1.08E-11 6h -3.86 1.77E-13 24h ribonuclease, RNase A family, k6 
RNF152 0.23 1.00E+00 1h 3.91 4.64E-12 6h 4.18 7.06E-14 6h ring finger protein 152 
RPGRIP1 -1.48 3.49E-02 6h -1.86 2.96E-03 24h -2.08 2.64E-04 6h retinitis pigmentosa GTPase regulator interacting protein 1 
RPH3A -2.90 3.53E-04 6h -2.31 2.01E-03 6h -2.26 2.38E-03 6h rabphilin 3A homolog (mouse) 
RSAD2 0.40 1.00E+00 1h 6.71 6.22E-54 24h 6.90 4.43E-57 24h radical S-adenosyl methionine domain containing 2 
RSPO3 0.50 8.29E-01 24h 3.46 9.90E-05 6h 1.73 8.29E-02 6h R-spondin 3 
RTN4R -1.02 1.02E-01 24h -2.62 1.97E-08 6h -2.48 1.09E-07 24h reticulon 4 receptor 
RTP4 0.04 9.77E-01 6h 3.63 9.30E-29 6h 3.72 3.43E-30 6h receptor (chemosensory) transporter protein 4 
RUFY4 -1.87 4.62E-02 24h 2.69 2.73E-04 24h 2.43 9.45E-04 24h RUN and FYVE domain containing 4 
RXFP1 0.67 1.00E+00 1h 3.29 2.77E-04 24h 2.91 1.20E-03 24h relaxin/insulin-like family peptide receptor 1 
S100B 2.38 2.78E-03 24h -0.22 1.00E+00 1h -0.63 4.75E-01 24h S100 calcium binding protein B 
S100Z -1.82 8.44E-03 6h -2.39 2.79E-04 24h -2.64 2.23E-05 6h S100 calcium binding protein Z 
SAMD4A 0.17 1.00E+00 1h 3.72 1.14E-16 6h 4.42 1.34E-23 6h sterile alpha motif domain containing 4A 
SAMD9 0.12 1.00E+00 1h 3.28 4.70E-20 6h 3.63 2.21E-24 24h sterile alpha motif domain containing 9 
SAMD9L 0.29 1.00E+00 1h 4.01 1.36E-30 6h 4.31 2.14E-35 6h sterile alpha motif domain containing 9-like 
SBSN 2.80 5.99E-03 6h 2.22 1.60E-02 6h 2.14 1.95E-02 6h suprabasin 
SCARF2 -1.43 2.93E-03 24h -1.41 1.39E-03 6h -1.97 2.88E-06 24h scavenger receptor class F, member 2 
SCG3 0.78 6.41E-01 24h 3.25 3.50E-05 24h 1.96 1.80E-02 24h secretogranin III 
SCG5 3.00 1.03E-04 6h 1.21 1.90E-01 24h 0.44 6.67E-01 24h secretogranin V (7B2 protein) 
SCN4A -1.33 1.05E-01 24h -2.29 9.61E-04 24h -2.02 8.55E-04 6h sodium channel, voltage-gated, type IV, alpha subunit 
SCN4B 0.36 1.00E+00 1h -2.21 5.50E-03 24h -2.59 5.77E-04 24h sodium channel, voltage-gated, type IV, beta subunit 
SCNN1A -1.87 1.37E-05 24h -1.99 3.69E-06 24h -2.20 5.48E-08 24h sodium channel, non-voltage-gated 1 alpha subunit 
SDC2 2.68 6.61E-08 24h 0.86 1.27E-01 6h 1.34 8.05E-03 6h syndecan 2 
SDK2 -0.93 4.64E-01 24h -2.25 2.61E-03 24h -1.86 1.25E-02 24h sidekick cell adhesion molecule 2 
SEMA3C 2.85 1.50E-08 24h 1.59 2.44E-03 24h 2.97 3.26E-10 24h sema domain, Ig domain, short basic domain, secreted, (semaphorin) 3C 
SEMA3F 2.46 1.70E-03 6h 1.96 6.62E-03 6h 1.02 2.47E-01 24h sema domain, Ig domain, short basic domain, secreted, (semaphorin) 3F 
SEMA4C -0.37 6.91E-01 6h -2.79 6.27E-15 24h -2.97 3.83E-17 24h sema domain, Ig domain, TM domain, and short cytoplasmic domain, (semaphorin) 4C 
SEMA6C -1.09 7.81E-03 24h -2.68 1.28E-12 24h -2.47 1.81E-12 24h sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6C 
SEPP1 -3.75 9.99E-07 24h -3.80 2.77E-07 24h -3.17 1.12E-05 24h selenoprotein P, plasma, 1 
SEPT4 -1.45 8.25E-02 24h 2.41 5.07E-05 24h 1.68 5.32E-03 6h septin 4 
SERPINA9 2.95 2.36E-03 6h 1.49 1.00E+00 1h -0.50 6.63E-01 24h serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 
SERPINB2 3.53 1.96E-04 6h 3.35 1.08E-04 6h 2.11 2.13E-02 6h serpin peptidase inhibitor, clade B (ovalbumin), member 2 
SERPINB7 5.07 6.60E-10 24h 5.56 9.77E-13 24h 3.47 2.18E-05 24h serpin peptidase inhibitor, clade B (ovalbumin), member 7 
SERPINB9 2.41 1.06E-05 6h 3.08 3.48E-10 6h 3.18 6.35E-11 6h serpin peptidase inhibitor, clade B (ovalbumin), member 9 
SERPINE1 1.68 1.83E-01 6h -1.43 1.48E-01 24h -2.40 5.44E-03 24h serpin peptidase inhibitor, clade E, member 1 
SERPINF1 -2.52 6.38E-21 24h -2.76 7.61E-25 24h -3.14 4.47E-33 24h serpin peptidase inhibitor, clade F, member 1 
SERPINF2 -2.19 3.01E-05 24h -2.86 8.54E-09 6h -2.56 2.46E-07 6h serpin peptidase inhibitor, clade F, member 2 
SERPING1 -2.17 4.12E-03 24h 4.50 2.62E-13 24h 4.05 5.40E-11 24h serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 
SEZ6L -1.72 3.76E-03 24h 0.33 1.00E+00 1h -1.96 4.41E-04 6h seizure related 6 homolog (mouse)-like 
SFRP5 -1.55 1.39E-03 24h -3.16 4.34E-12 24h -4.22 3.96E-20 24h secreted frizzled-related protein 5 
SGPP2 2.86 1.32E-03 6h 2.60 1.24E-03 6h 1.30 1.50E-01 6h sphingosine-1-phosphate phosphatase 2 
SH3BP4 -1.91 1.97E-05 24h -1.96 5.52E-06 24h -1.74 2.88E-05 24h SH3-domain binding protein 4 
SH3PXD2B 5.42 3.02E-17 24h 2.90 1.53E-05 24h 3.24 6.07E-07 24h SH3 and PX domains 2B 
SIAH3 0.32 1.00E+00 1h -2.95 1.12E-05 24h -2.73 4.72E-05 6h siah E3 ubiquitin protein ligase family member 3 
SIGIRR -1.13 1.36E-02 24h -2.09 1.23E-08 6h -2.43 1.58E-11 24h single immunoglobulin and toll-interleukin 1 receptor (TIR) domain 
SIGLEC1 -3.84 1.82E-10 24h 3.14 5.36E-08 6h 3.59 2.13E-10 6h sialic acid binding Ig-like lectin 1, sialoadhesin 
SIGLEC11 0.05 1.00E+00 1h -2.55 3.60E-03 24h -2.52 2.82E-03 24h sialic acid binding Ig-like lectin 11 
SIGLEC7 0.66 6.29E-01 24h -2.34 5.05E-04 6h 0.37 1.00E+00 1h sialic acid binding Ig-like lectin 7 
SIRPB2 0.29 8.98E-01 24h -2.41 3.74E-03 6h -2.48 2.38E-03 24h signal-regulatory protein beta 2 
SLAMF7 1.74 8.95E-04 6h 3.96 2.72E-20 6h 4.30 6.58E-24 6h SLAM family member 7 
SLAMF9 2.89 9.68E-04 24h 1.42 1.28E-01 24h 0.19 8.77E-01 24h SLAM family member 9 
SLC11A1 2.81 8.05E-04 24h 0.22 8.62E-01 24h -0.68 4.94E-01 6h solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1 
SLC16A10 3.26 6.75E-08 24h 2.01 8.82E-04 6h 1.73 4.68E-03 6h solute carrier family 16 (aromatic amino acid transporter), member 10 
SLC16A6 1.22 3.95E-02 24h -1.08 3.64E-02 6h -2.55 2.07E-08 6h solute carrier family 16, member 6 
SLC1A2 1.90 1.39E-02 24h 3.46 2.50E-08 24h 2.64 2.88E-05 24h solute carrier family 1 (glial high affinity glutamate transporter), member 2 
SLC1A7 -1.78 7.69E-02 24h -1.93 1.40E-02 6h -2.13 7.21E-03 24h solute carrier family 1 (glutamate transporter), member 7 
SLC2A12 0.35 1.00E+00 1h 3.86 5.55E-08 6h 3.97 1.73E-08 6h solute carrier family 2 (facilitated glucose transporter), member 12 
SLC2A4 -1.93 1.12E-02 6h -1.60 2.88E-02 24h 0.80 1.00E+00 1h solute carrier family 2 (facilitated glucose transporter), member 4 
SLC2A9 -1.78 1.48E-03 24h -1.31 1.63E-02 24h -1.76 4.32E-04 24h solute carrier family 2 (facilitated glucose transporter), member 9 
SLC37A2 -1.65 4.08E-02 24h -2.54 8.11E-05 24h -2.26 4.32E-04 6h solute carrier family 37 (glucose-6-phosphate transporter), member 2 
SLC38A5 0.12 8.92E-01 6h 3.61 5.92E-54 24h 3.42 7.03E-49 6h solute carrier family 38, member 5 
SLC46A1 -1.88 6.82E-03 24h -3.48 1.90E-08 24h -3.25 3.71E-08 24h solute carrier family 46 (folate transporter), member 1 
SLC46A2 -2.26 3.77E-02 6h -3.48 3.47E-05 6h -2.37 6.64E-03 24h solute carrier family 46, member 2 
SLC4A3 -1.75 1.82E-02 24h -2.11 1.90E-03 24h -2.38 1.92E-04 24h solute carrier family 4 (anion exchanger), member 3 
SLC7A11 3.01 6.97E-07 24h 1.40 2.82E-02 6h 0.29 7.18E-01 24h solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11 
SLC7A8 0.31 1.00E+00 1h -3.01 4.00E-04 24h -3.82 2.20E-06 24h solute carrier family 7 (amino acid transporter light chain, L system), member 8 
SLCO2B1 0.88 6.88E-01 6h -2.89 1.84E-03 24h -3.57 5.01E-05 24h solute carrier organic anion transporter family, member 2B1 
SLCO4A1 2.90 3.83E-07 6h 2.43 8.65E-06 6h 4.07 2.59E-15 6h solute carrier organic anion transporter family, member 4A1 
SLITRK4 0.36 1.00E+00 1h -2.13 3.38E-03 24h 0.36 1.00E+00 1h SLIT and NTRK-like family, member 4 
SLITRK5 0.04 1.00E+00 1h -1.71 1.90E-02 6h -2.65 4.04E-04 6h SLIT and NTRK-like family, member 5 
SMAD6 -1.65 4.45E-02 6h -3.13 7.21E-07 6h -3.21 2.81E-07 24h SMAD family member 6 
SMCO2 0.94 6.37E-01 6h 4.19 4.09E-07 24h 3.44 3.52E-05 24h single-pass membrane protein with coiled-coil domains 2 
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SMPDL3A 3.31 1.39E-07 24h 1.77 6.31E-03 6h 3.00 4.24E-07 6h sphingomyelin phosphodiesterase, acid-like 3A 
SMTNL2 3.77 3.70E-06 24h 2.97 3.04E-04 24h 3.12 6.97E-05 24h smoothelin-like 2 
SNAI1 3.44 7.22E-08 6h 2.17 6.77E-04 6h 2.23 3.98E-04 6h snail family zinc finger 1 
SOAT2 0.08 1.00E+00 1h -1.26 2.76E-02 6h -2.57 1.78E-05 6h sterol O-acyltransferase 2 
SOBP 0.73 4.45E-01 24h 4.56 2.27E-24 24h 4.14 1.74E-20 24h sine oculis binding protein homolog (Drosophila) 
SOCS1 1.82 7.56E-05 6h 4.80 1.20E-35 24h 4.70 2.56E-34 6h suppressor of cytokine signaling 1 
SOCS3 3.42 3.59E-11 6h 4.07 3.06E-17 6h 4.50 4.14E-21 6h suppressor of cytokine signaling 3 
SOD2 2.77 4.85E-08 6h 2.96 4.26E-10 6h 3.04 1.04E-10 6h superoxide dismutase 2, mitochondrial 
SORL1 -1.23 3.97E-02 6h -2.18 1.46E-06 24h -1.80 7.70E-05 6h sortilin-related receptor, L(DLR class) A repeats containing 
SOWAHD -1.23 6.44E-01 1h -2.59 1.82E-06 6h -2.09 1.11E-04 24h sosondowah ankyrin repeat domain family member D 
SOX5 2.68 9.20E-03 24h 2.09 2.96E-02 24h 3.12 3.49E-04 24h SRY (sex determining region Y)-box 5 
SPAG6 0.92 1.00E+00 1h 3.72 2.25E-11 6h 3.76 1.32E-11 6h sperm associated antigen 6 
SPAG8 0.09 1.00E+00 1h -1.94 2.24E-05 6h -2.32 3.61E-07 24h sperm associated antigen 8 
SPATS2L 0.74 5.85E-02 6h 3.99 8.52E-52 6h 4.30 2.78E-60 6h spermatogenesis associated, serine-rich 2-like 
SPINK1 3.82 1.78E-09 24h 2.34 4.25E-04 24h 0.48 5.37E-01 6h serine peptidase inhibitor, Kazal type 1 
SPP1 2.38 1.19E-02 6h 2.19 7.62E-03 6h 2.28 4.48E-03 6h secreted phosphoprotein 1 
SRPX 1.56 2.14E-01 24h 1.10 2.95E-01 6h 3.53 1.78E-05 6h sushi-repeat containing protein, X-linked 
SSTR2 1.95 7.59E-02 24h 6.07 3.34E-15 24h 5.34 5.30E-12 24h somatostatin receptor 2 
STAB1 -1.05 5.23E-01 6h -3.65 6.03E-06 24h -3.28 4.38E-05 24h stabilin 1 
STAC3 -1.61 3.76E-03 24h 0.43 1.00E+00 1h 0.18 1.00E+00 1h SH3 and cysteine rich domain 3 
STARD13 0.24 1.00E+00 1h -2.20 6.86E-04 24h -2.17 4.69E-04 24h StAR-related lipid transfer (START) domain containing 13 
STEAP1B 3.04 8.97E-04 24h 3.44 3.44E-05 24h 4.35 3.30E-08 24h STEAP family member 1B 
STEAP3 2.64 1.17E-06 6h 0.66 3.23E-01 24h 1.45 7.74E-03 6h STEAP family member 3, metalloreductase 
STON2 2.25 1.12E-02 24h 1.70 4.19E-02 24h 3.52 1.07E-06 24h stonin 2 
STXBP1 0.12 1.00E+00 1h -1.91 3.50E-04 24h -2.35 1.84E-06 6h syntaxin binding protein 1 
SUCNR1 2.27 6.80E-03 6h 3.18 4.85E-06 6h 5.39 1.80E-16 6h succinate receptor 1 
SVEP1 1.29 3.51E-01 24h 4.67 5.37E-09 24h 3.86 1.61E-06 24h sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 
SYNPO2 1.96 4.05E-01 1h 3.09 1.85E-04 24h 4.07 2.09E-07 24h synaptopodin 2 
TBC1D30 2.44 3.70E-12 24h 1.35 1.54E-04 6h 1.52 1.50E-05 24h TBC1 domain family, member 30 
TBXAS1 0.29 1.00E+00 1h -2.63 2.27E-05 24h -3.01 5.07E-07 24h thromboxane A synthase 1 (platelet) 
TCEA3 -1.08 2.40E-02 24h -2.29 2.88E-09 6h -2.69 5.18E-12 6h transcription elongation factor A (SII), 3 
TCN2 -2.03 2.02E-03 24h 1.43 2.28E-02 24h 1.22 5.01E-02 24h transcobalamin II 
TDRD6 2.31 1.65E-07 24h 0.79 1.08E-01 6h -0.25 6.92E-01 6h tudor domain containing 6 
TENM1 -1.42 8.81E-02 6h -1.57 1.70E-02 24h 0.01 1.00E+00 1h teneurin transmembrane protein 1 
TET1 0.39 1.00E+00 1h 0.60 1.00E+00 1h -2.73 8.88E-05 6h tet methylcytosine dioxygenase 1 
TFCP2L1 -1.18 4.63E-02 24h -2.64 1.16E-06 24h -2.87 7.45E-10 6h transcription factor CP2-like 1 
TFPI2 5.15 1.26E-14 6h 3.47 1.81E-07 6h 1.91 7.89E-03 6h tissue factor pathway inhibitor 2 
TFRC 1.77 1.91E-04 24h 1.70 1.13E-04 6h 3.46 1.57E-17 6h transferrin receptor 
TGFBI 0.11 1.00E+00 1h -1.93 1.12E-02 24h -2.44 6.61E-04 24h transforming growth factor, beta-induced, 68kDa 
TGM3 3.47 2.78E-05 6h 1.67 5.25E-02 6h 1.69 4.80E-02 24h transglutaminase 3 
TGM5 -2.86 1.26E-03 24h -3.95 1.26E-06 24h -4.46 2.13E-08 24h transglutaminase 5 
THAP2 2.40 6.86E-06 1h 0.96 7.32E-02 6h 0.87 1.06E-01 6h THAP domain containing, apoptosis associated protein 2 
TIMD4 -1.56 2.32E-03 24h 0.91 2.58E-02 6h 1.45 9.82E-05 6h T-cell immunoglobulin and mucin domain containing 4 
TJP1 0.43 8.70E-01 6h 3.04 1.51E-04 6h 4.69 4.45E-10 6h tight junction protein 1 
TLR5 0.25 1.00E+00 1h -2.14 3.09E-06 24h -1.47 1.10E-03 24h toll-like receptor 5 
TLR7 -3.07 1.21E-12 24h 1.73 5.45E-05 6h 2.07 6.31E-07 6h toll-like receptor 7 
TM4SF1 2.58 9.18E-03 6h 2.66 1.67E-03 6h 1.35 1.65E-01 6h transmembrane 4 L six family member 1 
TM4SF19 2.51 1.58E-06 24h 0.61 3.94E-01 24h -1.08 5.61E-02 6h transmembrane 4 L six family member 19 
TM6SF1 -1.43 2.06E-03 6h -2.61 6.08E-11 24h -2.77 6.87E-13 24h transmembrane 6 superfamily member 1 
TMC8 -1.38 3.57E-06 24h -1.92 1.09E-12 6h -2.30 5.60E-18 6h transmembrane channel-like 8 
TMEM132A 2.38 1.90E-04 24h 1.94 1.61E-03 24h 0.64 3.80E-01 24h transmembrane protein 132A 
TMEM132C -0.98 4.65E-01 24h -1.91 3.00E-02 24h -2.60 8.42E-04 6h transmembrane protein 132C 
TMEM132E 0.02 1.00E+00 1h -2.94 3.70E-05 6h -3.86 9.99E-08 24h transmembrane protein 132E 
TMEM144 -2.50 5.76E-07 6h -2.04 1.05E-05 6h -2.48 1.01E-07 6h transmembrane protein 144 
TMEM170B -1.80 1.97E-04 6h -2.44 7.73E-09 6h -2.39 1.46E-08 6h transmembrane protein 170B 
TMEM171 -1.61 7.62E-02 24h 2.08 1.24E-03 24h 1.78 5.48E-03 6h transmembrane protein 171 
TMEM217 1.15 1.89E-01 24h 3.68 4.17E-13 6h 4.31 5.74E-16 24h transmembrane protein 217 
TMEM255A 1.93 9.08E-03 6h 3.52 1.02E-09 24h 3.19 2.93E-08 24h transmembrane protein 255A 
TMEM37 -1.74 1.74E-01 24h -2.44 1.06E-02 24h 0.36 7.92E-01 6h transmembrane protein 37 
TMEM45B -0.43 7.77E-01 6h -2.14 9.53E-05 6h -2.32 1.72E-05 6h transmembrane protein 45B 
TMEM52B 0.71 1.00E+00 1h -2.05 2.87E-03 24h -2.61 5.65E-05 24h transmembrane protein 52B 
TMEM54 1.78 6.06E-01 1h 3.08 2.90E-05 6h 4.37 1.48E-09 24h transmembrane protein 54 
TMEM63C -1.40 6.12E-03 6h -1.08 1.58E-02 6h -1.42 1.38E-03 6h transmembrane protein 63C 
TMEM86A -1.43 1.23E-02 6h -2.53 6.31E-08 24h -2.96 7.27E-11 6h transmembrane protein 86A 
TMEM92 -1.15 1.00E+00 1h -1.59 3.28E-02 24h -2.58 2.08E-04 24h transmembrane protein 92 
TMIE -1.43 2.16E-02 24h -1.72 2.83E-03 24h -1.83 5.50E-04 6h transmembrane inner ear 
TNF 2.59 3.98E-02 1h 4.04 2.65E-07 6h 3.82 1.03E-06 6h tumor necrosis factor 
TNFAIP6 3.68 1.15E-07 6h 4.54 1.21E-12 6h 4.27 2.38E-11 6h tumor necrosis factor, alpha-induced protein 6 
TNFRSF10C -1.45 3.76E-02 6h -2.21 1.32E-04 24h -1.65 3.08E-03 24h tumor necrosis factor receptor superfamily, member 10c
TNFRSF11A -2.66 1.27E-10 6h -2.56 5.46E-11 6h -3.26 5.48E-17 6h tumor necrosis factor receptor superfamily, member 11a
TNFSF10 0.15 1.00E+00 1h 4.31 1.00E-24 6h 4.71 1.35E-29 6h tumor necrosis factor (ligand) superfamily, member 10 
TNFSF15 3.19 5.74E-08 6h 3.53 1.16E-10 6h 3.09 2.12E-08 6h tumor necrosis factor (ligand) superfamily, member 15 
TNFSF9 1.85 1.78E-03 24h 3.42 1.07E-12 6h 4.53 3.80E-22 6h tumor necrosis factor (ligand) superfamily, member 9 
TNIP3 6.17 4.33E-30 6h 6.34 1.02E-32 6h 7.88 1.16E-50 6h TNFAIP3 interacting protein 3 
TNNT1 0.09 1.00E+00 1h -2.14 1.18E-03 6h -2.71 1.65E-05 24h troponin T type 1 (skeletal, slow) 
TPBGL 0.52 7.52E-01 6h -1.76 1.95E-02 6h -2.67 2.60E-04 24h trophoblast glycoprotein-like 
TPCN1 0.16 1.00E+00 1h -2.31 4.42E-08 24h -2.49 1.83E-09 24h two pore segment channel 1 
TPM2 -1.77 1.94E-05 24h -1.67 2.30E-05 24h -2.29 9.53E-10 24h tropomyosin 2 (beta) 
TREM2 -2.68 1.09E-02 24h -2.94 1.19E-03 6h -3.13 4.42E-04 24h triggering receptor expressed on myeloid cells 2 
TRIM22 0.15 1.00E+00 1h 3.23 5.95E-22 6h 3.48 1.32E-25 6h tripartite motif containing 22 
TRPV4 0.29 1.00E+00 1h -2.26 3.83E-03 24h 0.42 1.00E+00 1h transient receptor potential cation channel, subfamily V, member 4 
TSPAN32 -1.57 9.39E-04 24h -2.04 1.07E-06 6h -2.43 2.94E-09 6h tetraspanin 32 
TSPAN7 2.47 6.30E-03 24h 0.99 1.00E+00 1h -0.59 1.00E+00 1h tetraspanin 7 
TTC16 -1.40 1.72E-02 24h -1.41 8.42E-03 24h -1.63 1.06E-03 24h tetratricopeptide repeat domain 16 
TXN 1.99 1.64E-03 24h 4.07 1.15E-14 24h 3.42 1.26E-10 24h thioredoxin 
UNC5B 0.35 1.00E+00 1h -2.61 7.33E-05 24h -2.54 5.86E-05 24h unc-5 homolog B (C. elegans) 
UNC5C 1.00 1.00E+00 1h 4.22 2.01E-08 6h 4.27 1.08E-08 6h unc-5 homolog C (C. elegans) 
UPB1 2.70 1.31E-07 6h 2.79 7.40E-09 24h 2.22 5.24E-06 24h ureidopropionase, beta 
USP18 0.41 1.00E+00 1h 6.26 1.94E-83 24h 6.28 9.82E-84 24h ubiquitin specific peptidase 18 
USP41 0.31 8.98E-01 24h 4.30 1.00E-08 24h 4.73 8.40E-11 24h ubiquitin specific peptidase 41 
VCAN 1.09 4.55E-01 24h -2.27 9.28E-03 6h -2.21 1.04E-02 6h versican 
VIPR1 -1.97 4.46E-07 24h -2.76 2.55E-14 24h -3.33 4.94E-21 24h vasoactive intestinal peptide receptor 1 
VNN3 2.41 3.50E-03 24h 1.53 5.50E-02 6h 2.09 5.06E-03 24h vanin 3 
VSIG1 -0.84 7.55E-02 24h -2.06 1.12E-08 24h -2.51 2.85E-13 6h V-set and immunoglobulin domain containing 1 
VSIG4 0.21 1.00E+00 1h -2.90 1.95E-03 24h -2.43 9.36E-03 24h V-set and immunoglobulin domain containing 4 
WARS 0.45 6.00E-01 6h 3.27 3.24E-20 6h 3.33 5.84E-21 6h tryptophanyl-tRNA synthetase 
WNK2 2.34 3.15E-06 24h 1.88 1.24E-04 6h 2.25 1.79E-06 24h WNK lysine deficient protein kinase 2 
WNT5A 3.62 9.74E-08 6h 3.40 1.26E-07 6h 1.34 6.75E-02 24h wingless-type MMTV integration site family, member 5A 
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WNT7A -1.70 2.24E-05 24h -3.14 4.21E-18 6h -4.23 4.97E-24 24h wingless-type MMTV integration site family, member 7A 
XAF1 0.13 1.00E+00 1h 3.97 1.65E-27 24h 4.18 1.10E-30 24h XIAP associated factor 1 
XIRP1 1.43 1.00E+00 1h 3.28 5.27E-05 6h 3.63 4.70E-06 6h xin actin-binding repeat containing 1 
YPEL4 -1.60 1.60E-06 6h -2.51 1.09E-16 6h -3.73 1.34E-32 6h yippee-like 4 (Drosophila) 
ZBP1 -0.69 4.95E-04 24h 3.31 1.54E-99 24h 3.00 1.86E-82 24h Z-DNA binding protein 1 
ZBTB32 0.28 8.03E-01 24h 3.37 6.88E-17 24h 2.77 1.04E-11 24h zinc finger and BTB domain containing 32 
ZC3H12C 2.30 3.67E-05 24h 2.55 5.67E-07 6h 2.65 1.68E-07 24h zinc finger CCCH-type containing 12C 
ZNF467 -1.98 2.13E-02 6h -2.07 3.92E-03 6h -1.74 1.71E-02 6h zinc finger protein 467 
ZNF503 -1.90 7.79E-04 6h -1.96 1.02E-04 6h -1.17 2.97E-02 6h zinc finger protein 503 
97
	 98	
 
References 
Ablasser, A., F. Bauernfeind, G. Hartmann, E. Latz, K.A. Fitzgerald, and V. Hornung. 
2009. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA 
polymerase III-transcribed RNA intermediate. Nat Immunol 10:1065-1072. 
Altare, F., A. Durandy, D. Lammas, J.F. Emile, S. Lamhamedi, F. Le Deist, P. Drysdale, 
E. Jouanguy, R. Doffinger, F. Bernaudin, O. Jeppsson, J.A. Gollob, E. Meinl, 
A.W. Segal, A. Fischer, D. Kumararatne, and J.-L. Casanova. 1998. Impairment 
of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 
280:1432-1435. 
Bindea, G., B. Mlecnik, H. Hackl, P. Charoentong, M. Tosolini, A. Kirilovsky, W.H. 
Fridman, F. Pages, Z. Trajanoski, and J. Galon. 2009. ClueGO: a Cytoscape 
plug-in to decipher functionally grouped gene ontology and pathway annotation 
networks. Bioinformatics 25:1091-1093. 
Bukhari, M., M.A. Aslam, A. Khan, Q. Iram, A. Akbar, A.G. Naz, S. Ahmad, M.M. 
Ahmad, U.A. Ashfaq, H. Aziz, and M. Ali. 2015. TLR8 gene polymorphism and 
association in bacterial load in southern Punjab of Pakistan: an association study 
with pulmonary tuberculosis. Int J Immunogenet 42:46-51. 
Cervantes, J.L., C.J. La Vake, B. Weinerman, S. Luu, C. O'Connell, P.H. Verardi, and 
J.C. Salazar. 2013. Human TLR8 is activated upon recognition of Borrelia 
burgdorferi RNA in the phagosome of human monocytes. J Leukoc Biol 94:1231-
1241. 
Chan, C.T., W. Deng, F. Li, M.S. DeMott, I.R. Babu, T.J. Begley, and P.C. Dedon. 2015. 
Highly Predictive Reprogramming of tRNA Modifications Is Linked to Selective 
Expression of Codon-Biased Genes. Chem Res Toxicol 28:978-988. 
Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B.R. Bloom. 1995. Effects of nitric oxide 
synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect  
Immun 63:736-740. 
Chan, P.P., and T.M. Lowe. 2009. GtRNAdb: a database of transfer RNA genes 
detected in genomic sequence. Nucleic Acids Res 37:D93-97. 
Collins, A.C., H. Cai, T. Li, L.H. Franco, X.D. Li, V.R. Nair, C.R. Scharn, C.E. Stamm, B. 
Levine, Z.J. Chen, and M.U. Shiloh. 2015. Cyclic GMP-AMP Synthase Is an 
Innate Immune DNA Sensor for Mycobacterium tuberculosis. Cell Host Microbe 
17:820-828. 
	 99	
Davila, S., M.L. Hibberd, D.R. Hari, H.E. Wong, E. Sahiratmadja, C. Bonnard, B. 
Alisjahbana, J.S. Szeszko, Y. Balabanova, F. Drobniewski, C.R. van, d. van, V, 
S. Nejentsev, T.H. Ottenhoff, and M. Seielstad. 2008. Genetic association and 
expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. 
PLoS Genet 4:e1000218. 
Daya, M., L. van der Merwe, P.D. van Helden, M. Moller, and E.G. Hoal. 2014. 
Investigating the Role of Gene-Gene Interactions in TB Susceptibility. PLoS One 
10:e0123970. 
Fabri, M., S. Stenger, D.M. Shin, J.M. Yuk, P.T. Liu, S. Realegeno, H.M. Lee, S.R. 
Krutzik, M. Schenk, P.A. Sieling, R. Teles, D. Montoya, S.S. Iyer, H. Bruns, D.M. 
Lewinsohn, B.W. Hollis, M. Hewison, J.S. Adams, A. Steinmeyer, U. Zugel, G.H. 
Cheng, E.K. Jo, B.R. Bloom, and R.L. Modlin. 2011. Vitamin D Is Required for 
IFN-gamma-Mediated Antimicrobial Activity of Human Macrophages. Sci. Transl. 
Med. 3:104ra102. 
Fan, J.B., and D.E. Zhang. 2013. ISG15 regulates IFN-gamma immunity in human 
mycobacterial disease. Cell Res 23:173-175. 
Fang, R., H. Hara, S. Sakai, E. Hernandez-Cuellar, M. Mitsuyama, I. Kawamura, and K. 
Tsuchiya. 2014. Type I interferon signaling regulates activation of the absent in 
melanoma 2 inflammasome during Streptococcus pneumoniae infection. Infect 
Immun 82:2310-2317. 
Feng, C.G., M. Kaviratne, A.G. Rothfuchs, A. Cheever, S. Hieny, H.A. Young, T.A. 
Wynn, and A. Sher. 2006. NK cell-derived IFN-gamma differentially regulates 
innate resistance and neutrophil response in T cell-deficient hosts infected with 
Mycobacterium tuberculosis. J. Immunol. 177:7086-7093. 
Flynn, J.L., J. Chan, K.J. Triebold, D.K. Dalton, T.A. Stewart, and B.R. Bloom. 1993. An 
essential role for interferon-gamma in resistance to Mycobacterium tuberculosis 
infection. J. Exp. Med. 178:2249-2254. 
Garcia, V.E., K. Uyemura, P.A. Sieling, M.T. Ochoa, C.T. Morita, H. Okamura, M. 
Kurimoto, T.H. Rea, and R.L. Modlin. 1999. IL-18 promotes type 1 cytokine 
production from NK cells and T cells in human intracellular infection. J Immunol 
162:6114-6121. 
Gautier, G., M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott, E.E. Bates, G. Trinchieri, 
C. Caux, and P. Garrone. 2005. A type I interferon autocrine-paracrine loop is 
involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic 
cells. J Exp Med 201:1435-1446. 
	 100	
Gorski, K.S., E.L. Waller, J. Bjornton-Severson, J.A. Hanten, C.L. Riter, W.C. Kieper, 
K.B. Gorden, J.S. Miller, J.P. Vasilakos, M.A. Tomai, and S.S. Alkan. 2006. 
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 
agonists. Int Immunol 18:1115-1126. 
Guarda, G., M. Braun, F. Staehli, A. Tardivel, C. Mattmann, I. Forster, M. Farlik, T. 
Decker, R.A. Du Pasquier, P. Romero, and J. Tschopp. 2011. Type I interferon 
inhibits interleukin-1 production and inflammasome activation. Immunity 34:213-
223. 
Hermann, P., M. Rubio, T. Nakajima, G. Delespesse, and M. Sarfati. 1998. IFN-alpha 
priming of human monocytes differentially regulates gram-positive and gram-
negative bacteria-induced IL-10 release and selectively enhances IL-12p70, 
CD80, and MHC class I expression. J Immunol 161:2011-2018. 
Hu, Z., J. Mellor, J. Wu, and C. DeLisi. 2004. VisANT: an online visualization and 
analysis tool for biological interaction data. BMC Bioinformatics 5:17. 
Jouanguy, E., S. Lamhamedi-Cherradi, D. Lammas, S.E. Dorman, M.C. Fondaneche, S. 
Dupuis, R. Doffinger, F. Altare, J. Girdlestone, J.F. Emile, H. Ducoulombier, D. 
Edgar, J. Clarke, V.A. Oxelius, M. Brai, V. Novelli, K. Heyne, A. Fischer, S.M. 
Holland, D.S. Kumararatne, R.D. Schreiber, and J.L. Casanova. 1999. A human 
IFNGR1 small deletion hotspot associated with dominant susceptibility to 
mycobacterial infection. Nat. Genet. 21:370-378. 
Junqueira-Kipnis, A.P., A. Kipnis, A. Jamieson, M.G. Juarrero, A. Diefenbach, D.H. 
Raulet, J. Turner, and I.M. Orme. 2003. NK cells respond to pulmonary infection 
with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol 
171:6039-6045. 
Kadowaki, N., S. Ho, S. Antonenko, R.W. Malefyt, R.A. Kastelein, F. Bazan, and Y.J. 
Liu. 2001. Subsets of human dendritic cell precursors express different toll-like 
receptors and respond to different microbial antigens. J. Exp. Med. 194:863-869. 
Klug-Micu, G.M., S. Stenger, A. Sommer, P.T. Liu, S.R. Krutzik, R.L. Modlin, and M. 
Fabri. 2013. CD40 ligand and interferon-gamma induce an antimicrobial 
response against Mycobacterium tuberculosis in human monocytes. Immunology 
139:121-128. 
Lai, Y.F., T.M. Lin, C.H. Wang, P.Y. Su, J.T. Wu, M.C. Lin, and H.L. Eng. 2016. 
Functional polymorphisms of the TLR7 and TLR8 genes contribute to 
Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 98:125-131. 
Lande, R., E. Giacomini, T. Grassi, M.E. Remoli, E. Iona, M. Miettinen, I. Julkunen, and 
E.M. Coccia. 2003. IFN-   Released by Mycobacterium tuberculosis-Infected 
	 101	
Human Dendritic Cells Induces the Expression of CXCL10: Selective 
Recruitment of NK and Activated T Cells. The Journal of Immunology 170:1174-
1182. 
Langfelder, P., and S. Horvath. 2008a. WGCNA: an R package for weighted correlation 
network analysis. BMC Bioinformatics 9:559. 
Langfelder, P., and S. Horvath. 2008b. WGCNA: an R package for weighted correlation 
network analysis. BMC Bioinformatics 9:559. 
Lee, H.R., S.Y. Yoon, S.B. Song, Y. Park, T.S. Kim, S. Kim, D.Y. Hur, H.K. Song, H. 
Park, and D. Cho. 2011. Interleukin-18-mediated interferon-gamma secretion is 
regulated by thymosin beta 4 in human NK cells. Immunobiology 216:1155-1162. 
Liu, J., X. Guan, T. Tamura, K. Ozato, and X. Ma. 2004. Synergistic activation of 
interleukin-12 p35 gene transcription by interferon regulatory factor-1 and 
interferon consensus sequence-binding protein. J Biol Chem 279:55609-55617. 
Love, M.I., W. Huber, and S. Anders. 2014. Moderated estimation of fold change and 
dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. 
Lu, H., G.N. Dietsch, M.A. Matthews, Y. Yang, S. Ghanekar, M. Inokuma, M. Suni, V.C. 
Maino, K.E. Henderson, J.J. Howbert, M.L. Disis, and R.M. Hershberg. 2012. 
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. 
Clin Cancer Res 18:499-509. 
Ma, F., B. Li, S.Y. Liu, S.S. Iyer, Y. Yu, A. Wu, and G. Cheng. 2015. Positive feedback 
regulation of type I IFN production by the IFN-inducible DNA sensor cGAS. J 
Immunol 194:1545-1554. 
MacMicking, J.D., R.J. North, R. LaCourse, J.S. Mudgett, S.K. Shah, and C.F. Nathan. 
1997. Identification of nitric oxide synthase as a protective locus against 
tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 94:5243-5248. 
Manca, C., L. Tsenova, S. Freeman, A.K. Barczak, M. Tovey, P.J. Murray, C. Barry, and 
G. Kaplan. 2005. Hypervirulent M. tuberculosis W/Beijing strains upregulate type 
I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J 
Interferon Cytokine Res 25:694-701. 
Manzanillo, P.S., M.U. Shiloh, D.A. Portnoy, and J.S. Cox. 2012. Mycobacterium 
tuberculosis activates the DNA-dependent cytosolic surveillance pathway within 
macrophages. Cell Host Microbe 11:469-480. 
Matikainen, S., A. Paananen, M. Miettinen, M. Kurimoto, T. Timonen, I. Julkunen, and 
T. Sareneva. 2001. IFN-alpha and IL-18 synergistically enhance IFN-gamma 
	 102	
production in human NK cells: differential regulation of Stat4 activation and IFN-
gamma gene expression by IFN-alpha and IL-12. Eur J Immunol 31:2236-2245. 
Newport, M.J., C.M. Huxley, S. Huston, C.M. Hawrylowicz, B.A. Oostra, R. Williamso, 
and M. Levin. 1996. A mutation in the interferon-(gamma)-receptor gene and 
susceptibility to mycobacterial infection. N. Engl. J. Med. 335:1941-1949. 
O'Garra, A., P.S. Redford, F.W. McNab, C.I. Bloom, R.J. Wilkinson, and M.P. Berry. 
2013. The immune response in tuberculosis. Annu Rev Immunol 31:475-527. 
Obregon-Henao, A., M.A. Duque-Correa, M. Rojas, L.F. Garcia, P.J. Brennan, B.L. 
Ortiz, and J.T. Belisle. 2012. Stable extracellular RNA fragments of 
Mycobacterium tuberculosis induce early apoptosis in human monocytes via a 
caspase-8 dependent mechanism. PLoS One 7:e29970. 
Orme, I.M., R.T. Robinson, and A.M. Cooper. 2015. The balance between protective 
and pathogenic immune responses in the TB-infected lung. Nat Immunol 16:57-
63. 
Portevin, D., L.E. Via, S. Eum, and D. Young. 2012. Natural killer cells are recruited 
during pulmonary tuberculosis and their ex vivo responses to mycobacteria vary 
between healthy human donors in association with KIR haplotype. Cell Microbiol 
14:1734-1744. 
Salie, M., M. Daya, L.A. Lucas, R.M. Warren, G.D. van der Spuy, P.D. van Helden, E.G. 
Hoal, and M. Moller. 2015. Association of toll-like receptors with susceptibility to 
tuberculosis suggests sex-specific effects of TLR8 polymorphisms. Infect Genet 
Evol 34:221-229. 
Schenk, M., S.R. Krutzik, P.A. Sieling, D.J. Lee, R.M. Teles, M.T. Ochoa, E. 
Komisopoulou, E.N. Sarno, T.H. Rea, T.G. Graeber, S. Kim, G. Cheng, and R.L. 
Modlin. 2012. NOD2 triggers an interleukin-32-dependent human dendritic cell 
program in leprosy. Nat Med 18:555-563. 
Schierloh, P., N. Yokobori, M. Aleman, R.M. Musella, M. Beigier-Bompadre, M.A. Saab, 
L. Alves, E. Abbate, S.S. de la Barrera, and M.C. Sasiain. 2005. Increased 
susceptibility to apoptosis of CD56dimCD16+ NK cells induces the enrichment of 
IFN-gamma-producing CD56bright cells in tuberculous pleurisy. J. Immunol. 
175:6852-6860. 
Schmidt, K.N., B. Leung, M. Kwong, K.A. Zarember, S. Satyal, T.A. Navas, F. Wang, 
and P.J. Godowski. 2004. APC-independent activation of NK cells by the Toll-like 
receptor 3 agonist double-stranded RNA. J. Immunol. 172:138-143. 
	 103	
Sha, W., H. Mitoma, S. Hanabuchi, M. Bao, L. Weng, N. Sugimoto, Y. Liu, Z. Zhang, J. 
Zhong, B. Sun, and Y.J. Liu. 2014. Human NLRP3 inflammasome senses 
multiple types of bacterial RNAs. Proc Natl Acad Sci U S A 111:16059-16064. 
Sun, Q., Q. Zhang, H.P. Xiao, and C. Bai. 2015. Toll-like receptor polymorphisms and 
tuberculosis susceptibility: A comprehensive meta-analysis. J Huazhong Univ Sci 
Technolog Med Sci 35:157-168. 
Teles, R.M., T.G. Graeber, S.R. Krutzik, D. Montoya, M. Schenk, D.J. Lee, E. 
Komisopoulou, K. Kelly-Scumpia, R. Chun, S.S. Iyer, E.N. Sarno, T.H. Rea, M. 
Hewison, J.S. Adams, S.J. Popper, D.A. Relman, S. Stenger, B.R. Bloom, G. 
Cheng, and R.L. Modlin. 2013. Type I interferon suppresses type II interferon-
triggered human anti-mycobacterial responses. Science 339:1448-1453. 
Ushio, S., M. Namba, T. Okura, K. Hattori, Y. Nukada, K. Akita, F. Tanabe, K. Konishi, 
M. Micallef, M. Fujii, K. Torigoe, T. Tanimoto, S. Fukuda, M. Ikeda, H. Okamura, 
and M. Kurimoto. 1996. Cloning of the cDNA for human IFN-gamma-inducing 
factor, expression in Escherichia coli, and studies on the biologic activities of the 
protein. J. Immunol. 156:4274-4279. 
Wang, Z., L. Xiang, J. Shao, and Z. Yuan. 2006. The 3' CCACCA sequence of 
tRNAAla(UGC) is the motif that is important in inducing Th1-like immune 
response, and this motif can be recognized by Toll-like receptor 3. Clin Vaccine 
Immunol 13:733-739. 
Wassermann, R., M.F. Gulen, C. Sala, S.G. Perin, Y. Lou, J. Rybniker, J.L. Schmid-
Burgk, T. Schmidt, V. Hornung, S.T. Cole, and A. Ablasser. 2015. 
Mycobacterium tuberculosis Differentially Activates cGAS- and Inflammasome-
Dependent Intracellular Immune Responses through ESX-1. Cell Host Microbe 
17:799-810. 
Watson, R.O., P.S. Manzanillo, and J.S. Cox. 2012. Extracellular M. tuberculosis DNA 
targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 
150:803-815. 
Wu, L., Y. Hu, D. Li, W. Jiang, and B. Xu. 2015. Screening toll-like receptor markers to 
predict latent tuberculosis infection and subsequent tuberculosis disease in a 
Chinese population. BMC Med. Genet. 16:19. 
Zhang, Z., B. Yuan, M. Bao, N. Lu, T. Kim, and Y.J. Liu. 2011. The helicase DDX41 
senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat 
Immunol 12:959-965. 
Zhou, R., H. Wei, R. Sun, and Z. Tian. 2007. Recognition of double-stranded RNA by 
TLR3 induces severe small intestinal injury in mice. J. Immunol. 178:4548-4556. 
